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A bstract
Ovarian cancer has the highest mortality rate of the gynaecological cancers. This is 
partly due to the lack of effective screening markers. In this study, oligonucleotide 
microarrays complementary to -12,000 genes were used to establish a gene 
expression microarray (GEM) profile for normal ovarian tissue, as compared to stage 
III ovarian serous adenocarcinoma and omental metastases from the same 
individuals. The GEM profiles of the primary and secondary tumours from the same 
individuals were essentially alike, reflecting the fact that these tumours had already 
metastasised and acquired the metastatic phenotype. A novel biomarker, 
mammaglobin-2 (MGB2), was identified which is highly expressed specific to ovarian 
cancer. MGB2, in combination with other putative markers identified here, could have 
potential for screening.
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C hapter  1
Introduction
Ovarian cancer is the fourth most common cancer in women, after breast, colorectal 
and lung cancers. The UK has one of the highest incidences of ovarian cancer in 
Europe, with around 6,800 new cases being diagnosed each year, and 4,000 deaths 
[Cancer Research UK, 2002]. In America, ovarian cancer accounts for 4 percent of 
all cancers among women and ranks fifth as a cause of their deaths from cancer. 
The American Cancer Society statistics for ovarian cancer predicted that there would 
be approximately 25,400 new cases and 14,300 deaths in 2003 [Jemal et al., 2003]. 
70% of women present at an advanced FIGO (International Federation of 
Gynaecology and Obstetrics) stage, and overall 60% of patients with ovarian cancer 
will die from their disease. The high mortality of ovarian cancer is due firstly to the 
fact that the disease is relatively asymptomatic in its early stages, and that the 
symptoms of late stage disease, such as abdominal discomfort, weight loss, 
diarrhoea or constipation, vaginal bleeding and shortness of breath, are non-specific 
complaints. Secondly, ovaries are inaccessible pelvic organs, and therefore effective 
screening methods for early stage disease have remained elusive. Finally, no pre- 
malignant phenotype has been identified which is known to proceed through a 
stepwise progression to cancer which is amenable for screening. Survival figures for 
epithelial ovarian cancer (EOC), when diagnosed in its earliest stages, give rates of 
greater than 90%. However, stage IV disease has a 5 year survival of around 15% 
with overall 5 year survival for all four stages of 25%. This has remained largely 
unchanged over the past 20 years, despite new chemotherapeutic agents.
The recent availability of gene expression microarrays has transformed the study of 
cancer biology and has enabled the simultaneous examination of thousands of 
genes in parallel. This promises to extend our knowledge of the molecular events in 
the evolution and progression of ovarian cancer, extend cancer classification and 
identify molecules for effective prevention, detection and treatment of this disease. 
This thesis concerns the use of gene expression microarrays to identify novel 
markers in ovarian cancer which may contribute to this knowledge.
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1.1 Classification of Ovarian Tumours
The classification of all ovarian tumours is based on the tissue of origin. This is best 
understood in terms of the embryology of the ovary. The development can be divided 
into four main stages. First, the primordial germ cells become detached from the 
endoderm of the yolk sac wall and migrate to the genital ridges, which are bilateral 
thickenings of coelomic epithelium. Second, the coelomic epithelium undergoes 
proliferation, along with the underlying mesenchyme. During the third stage, the 
ovary divides into a central medulla and a peripheral cortex. The fourth stage 
comprises development of the cortex and involution of the medulla. The histogenetic 
classification categorises ovarian neoplasms according to whether they originate 
from the coelomic epithelium, germ cells or mesenchyme.
1.1.1 Histogenetic Classification of Ovarian Neoplasms
The histological classification of ovarian tumours by the World Health Organisation 
(WHO) is based on histogenetic principles, that is, ovarian tumours are characterised 
according to whether they are derived from coelomic surface epithelial cells, germ 
cells, or mesenchyme (the stroma and the sex cord). Epithelial ovarian tumours, 
which constitute 85-90% of malignant ovarian tumours, are further classified into 
histological types as follows: serous, mucinous, endometrioid, clear cell, transitional 
cell tumours (Brenner tumours), carcinosarcoma, mixed epithelial tumour, 
undifferentiated carcinoma, and others. Carcinosarcoma of the ovary, also known as 
malignant mixed mesodermal tumour (MMMT) behaves in a different way to other 
epithelial ovarian cancers in that it has a later age of onset, worse response to 
platinum-based chemotherapy and overall poor prognosis [Brown et al., 2004]. Clear 
cell and endometrioid carcinomas are highly associated with endometriosis. In stage 
distribution, serous carcinoma is found predominantly is stage III or IV. In contrast, 
clear cell and endometrioid carcinomas tend to remain confined to the ovary. Clear 
cell and endometrioid carcinomas may be unique histological types compared with 
serous carcinomas with respect to stage distribution and association with 
endometriosis.
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Classification of Ovarian Tumours
Tumours Derived from Coelomic Epithelium
Serous tumour
Mucinous
Endometrioid
Clear cell
Brenner
Undifferentiated
Carcinosarcoma & mixed mesodermal
Tumours Derived from Germ Cells
Teratoma 
Dysgerminoma 
Embryonal carcinoma 
Endodermal sinus tumour 
Choriocarcinoma 
Gonadoblastoma
Tumours Derived from Gonadal Stroma
Granulosa-theca cell tumours 
Sertoli-Leydig tumours
It is clear from the above list that the ovary is the origin of a great number of tumour 
types. By far the majority (85-90%) of all malignant ovarian cancers are epithelial in 
origin, and are therefore referred to as epithelial ovarian cancers. The most common 
(-60%) of the epithelial tumours are the serous cystadenocarcinomas.
Serous cystadenocarcinoma 60%
Endometrioid carcinoma 20%
Mucinous cystadenocarcinoma 10%
Undifferentiated carcinoma 8%
Clear Cell carcinoma 2%
Table 1.1. Percentage of epithelial ovarian cancer by 
subtypes
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1.2 Epidemiology
Epithelial ovarian cancer (EOC) is a disease of perimenopausal and postmenopausal 
women. The mean age of diagnosis is between 50 and 70 years of age. 90% of all 
EOC’s are thought to be sporadic, and 10% are familial.
1.2.1 Hereditary Epithelial Ovarian Cancer
A family history of ovarian cancer accounts for the greatest of all known risk factors, 
other than age, for the disease [Parazzini et al., 1991], with about 10% of all EOC’s 
resulting from a hereditary predisposition [Claus et al., 1996]. This thesis is not 
concerned with hereditary ovarian cancer, so it is only briefly mentioned.
1.2.1.1 The Breast and Ovarian Cancer Syndrome
The breast and ovarian cancer syndrome is responsible for about 90% of all cases of 
hereditary ovarian cancer [Narod et al., 1995a]. Approximately 10% of these women 
are carriers of the breast/ovarian cancer susceptibility genes, BRCA1 and BRCA2 
[Risch et al., 2001]. The lifetime risk of EOC in the general population is about 1.4%, 
while that for gene carriers, such as Ashkenazi Jews ranges between 16-30% 
[Struewing et al., 1997;Claus et al., 1996;Whittemore et al., 1997]. Families who 
have a total of five or more breast or ovarian cancers in first or second degree 
relatives are thought to qualify, as are families where at least three relatives have 
early-onset (less than 60 years) breast or ovarian cancer [Narod et al., 1995b]. Both 
BRCA1 and BRCA2 are tumour suppressor genes and are transmitted in an 
autosomal dominant fashion.
The BRCA1 gene, located on chromosome 17q, is associated with an increased risk 
of both ovarian and breast cancers, with a lifetime risk of ovarian cancer of 20-40% 
[Whittemore et al., 1997;Ford et al., 1994]. BRCA1 mutations are responsible for 
5.7% of ovarian cancers in women under the age of 40 years in the general 
population, 4.6% between the ages of 40 and 50, and 1.1% above the age of 50 
[Ford et al., 1995]. Features suggestive of a BRCA1 mutation include a family history
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of: two or more cases of ovarian cancer, ovarian and breast cancer in the same 
woman, one or more cases of pre-menopausal breast cancer with a case of ovarian 
cancer diagnosed at any age, two or more cases of postmenopausal breast cancer 
and one or more cases of ovarian cancer diagnosed at any age or male breast 
cancer.
The BRCA2 gene on chromosome 13q is also associated with high rates of ovarian 
and breast cancer. The lifetime risk of breast cancer has been reported to be similar 
to that of BRCA1 (55-85%), while the lifetime risk of ovarian cancer is estimated to 
be 10-20% [Ford et al., 1998]. BRCA2 is also associated with up to 40% risk of male 
breast cancer [Couch et al., 1996], as well as an increased risk of pancreatic cancer 
[Hahn et al., 2003]. BRCA2 features are similar to those outlined for BRCA1, but also 
include a family history of pancreas cancer in addition to breast and/or ovarian 
cancer. The role of the BRCA1 and BRCA2 genes in sporadic ovarian cancer 
remains unclear, since somatic mutations in either gene are uncommon. However, 
recently mutations in EMSY were identified in 17% of high-grade ovarian cancers 
[Hughes-Davies et al., 2003]. EMSY maps to chromosome 11 q13.5, a region known 
to be involved in breast and ovarian cancers. EMSY encodes a protein, EMSY, which 
binds to, and silences the function of BRCA2. This implicates the BRCA2 pathway of 
tumour suppression in sporadic ovarian cancer.
1.2.1.2 Hereditary Nonpolyposis Colorectal Cancer Syndrome
Hereditary Non-Polyposis Colorectal Cancer (HNPCC), also known as Lynch II 
syndrome is a hereditary syndrome most commonly characterized by an increased 
risk of colorectal, endometrial and ovarian cancers. It is closely linked with mutations 
in the DNA mismatch repair genes MSH2, MLH1, PMS1, and PMS2 [Lynch and 
Smyrk, 1996]. The lifetime risk for colorectal cancer is 80%, for endometrial cancer 
approximately 40%, and for ovarian cancer is 10% [Aarnio et al., 1995]. Other 
associated cancers include stomach, small bowel, urinary tract, and biliary tract.
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1.2.1.3 Site-Specific Ovarian Cancer
It was previously thought that families with an excess of ovarian cancer but no 
incidences of breast cancer form a third distinct group. However, genetic linkage 
analyses have only demonstrated linkage to BRCA1 [Steichen-Gersdorf et al., 1994], 
suggesting that these families are a variant of the breast and ovarian cancer 
syndrome where early-onset breast cancer is rare or has not yet appeared. There is 
a fourth group, comprising very young (less than 30 years old) women who have 
invasive ovarian cancer, but one recent study demonstrated that this is unlikely to be 
due to genetic predisposition [Stratton et al., 1999].
1.2.2 Sporadic Ovarian Cancer
90% of EOC is sporadic. The precise aetiology is not known, but several 
environmental, dietary and hormonal causes are suggested. These are detailed here.
1.2.2.1 Country of Origin, Race and Age
Epithelial ovarian cancer is predominantly a cancer of the developed world. 
Approximately 190,000 new cases and 114,000 deaths occur worldwide annually.
Figure 1.1. Incidence of ovarian cancer worldwide. Figure taken from WHO, World Health Report.
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The highest rates are found in the countries of Northern and Western Europe, USA 
and Canada. The lowest rates are found in Africa and Asia (see Figures 1.1 and 1.2).
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Figure 1.2. Age-standardised incidence rates for ovarian cancer 
(per 100,000 females per year) in the European Union, 1995.
Figure taken from Ferlay et al, 1999. Cancer incidence, mortality and 
prevalence in the European Union.
Survival differs significantly throughout the world. (Figure 1.3). It is unclear why this is 
the case.
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Figure 1.3. Five-year relative survival rates after diagnosis of ovarian cancer.
Data adapted from World Health Organisation, World Health Report.
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Ovarian cancer is a disease of increasing age. This is demonstrated by incidence 
and mortality rates for the UK (Figures 1.4 and 1.5). The incidence remains low until 
the age of 40 years and rises dramatically thereafter, with a peak in the seventh 
decade.
Women who migrate from countries with a low risk for ovarian cancer such as Asia to 
high-risk areas such as North America, there is a gradual increased incidence of 
ovarian cancer in these women compared to the expected rates for native born 
women [Kliewer and Smith, 1995].
Number of mew cases diagnosed and age specific rates per 100,000 women, 
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Figure 1.4. Number of new cases of ovarian cancer diagnosed and age-specific rates 
per 100,000 women in the UK, 1999.
Figure taken from Cancer Research UK Statistics
Number of deaths and age specific mortality rates per 100.000 women, ovarian cancer. UK. 2001
600 70
700 60
600
.c 500
40
400
30
200
100
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44  45-49  50-54 55-59 60-64 65-69 70-74 75-79  80-84 85 -
age at death
Figure 1.5. Number of deaths from ovarian cancer and age-specific mortality rates per 
100,000 women in the UK, 1999. Figure taken from Cancer Research UK Statistics
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1.2.2.2 Aetiology of Sporadic Epithelial Ovarian Cancer
Epidemiological studies have consistently shown that the risk of ovarian cancer is 
reduced by factors which inhibit ovulation, such as pregnancy, breast feeding and the 
combined oral contraceptive pill. Two major theories emerged; that of incessant 
ovulation and gonadotrophin stimulation. The incessant ovulation hypothesis is 
based on repeated damage and repair of the ovarian surface epithelium leading to 
increased epithelial cell proliferation and an accumulation of genetic mutations, and 
ultimately to tumour formation. The gonadotrophin hypothesis postulates that the 
pituitary FSH/LH surges cause elevations in oestrogen and these high levels cause 
stimulation of the ovarian epithelium leading to neoplastic transformation. Although 
there is some evidence in favour of these hypotheses, there are major flaws 
principally with relation to the magnitude of their effect being disproportionate with 
the increased risk of ovarian cancer. One unifying theory which has been proposed is 
inflammation. Inflammatory agents such as asbestos, talc and endometriosis have 
been linked to ovarian cancer, and although have not been shown to be causal, may 
indirectly have a role through inflammatory mechanisms. Tubal ligation and 
hysterectomy have been shown to be protective for ovarian cancer, and again may 
act through preventing ascending genital tract infection. The process of inflammation 
as a unifying theory will be discussed in relation to aetiological risk factors for ovarian 
cancer.
1.2.2.2.1 Incessant Ovulation
The incessant ovulation theory was first put forward by Fathalla in 1971 [Fathalla, 
1971]. It is proposed that repeated cycles of ovulation-induced trauma and repair of 
the OSE at the site of ovulation leads to DNA damage which DNA repair 
mechanisms are unable to repair. This theory initially gained much support through 
studies showing that pregnancy, prolonged breast feeding and the oral contraceptive 
pill which suppress ovulation are strikingly protective against ovarian cancer 
[Whittemore et al., 1992]. Further evidence was obtained from laboratory studies 
showing abnormal p53 expression; p53 plays a central role in repair of DNA-damage 
apoptosis [Murdoch et al., 2001;Verschraegen et al., 2003]. However, the protection
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is disproportionate as 5 year oral contraceptive usage gives a 50% risk reduction 
whilst only reducing the lifetime number of ovulations by 10-20% [Vessey and 
Painter, 1995]. In addition, there is evidence that the suppression of ovulation by 
pregnancy, breast feeding or the OCP has a greater effect in terms of risk reduction 
compared to the same length of suppression due to a late menarche or early 
menopause [Whittemore et al., 1992]. Although it is true that the extremes of 
menstrual life may be anovulatory, this further gives doubt as to whether it is purely 
the prevention of ovulation which is at play, or whether there is another process to 
account for this effect.
1.2.2.2.2 Gonadotrophins
The gonadotrophin theory proposes stimulation of the ovarian epithelium within 
inclusion cysts by high levels of oestrogen caused by high FSH and LH levels leads 
to ovarian cancer [Cramer and Welch, 1983]. As pregnancy provides the greatest 
overall risk reduction [Tung et al., 2005] and is associated with low basal levels of 
gonadotrophins, it was suggested that this was the mechanism by which the 
protective effect was conferred. However, pregnancy is also associated with very 
high levels of oestrogen, so this theory cannot hold. Other evidence that refutes this 
theory is the lack of correlation of serum levels of gonadotrophins with risk of 
developing ovarian cancer [Helzlsouer et al., 1995].
1.2.2.2.3 Infertility
It would follow from the incessant ovulation theory that anovulatory infertility is 
protective against ovarian cancer due to a lack of ovulation. There has been an 
ongoing debate regarding the link between ovarian cancer and infertility since it was 
first suggested in 1974 [Joly et al., 1974]. One study compared anovulatory infertility 
with other causes of infertility and found an relative risk of 1.8 [Rossing et al., 1994]. 
More recent studies have shown that it is not the drugs used per se, rather that 
nulliparous women with unexplained infertility in whom assisted conception was 
unsuccessful, had an inherently higher risk [Venn et al., 1999;Doyle et al., 2002].
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1.2.2.2.4 Hormone Replacement Therapy
The use of hormone replacement therapy (HRT) has increased dramatically over the 
past 10 years. Several studies have investigated the possible links of HRT with 
cancer. Three studies [Lacey, Jr. et al., 2002;Riman et al., 2002;Purdie et al., 1999] 
suggest the risk of EOC with HRT use only applies to the use of unopposed 
oestrogens, with the risk increasing with the duration of use: odds ratio 1.8 (95% Cl 
1.1-3.0) between 10 and 19 years of use, increasing to an odds ratio of 3.2 (95% Cl 
1.7-5.7) after 20 years [Lacey, Jr. et al., 2002]. More recently, the women’s health 
initiative (WHI) trial [Anderson et al., 2003] reported on 16,600 postmenopausal 
women with an intact uterus taking either placebo or combined oestrogen and 
progesterone HRT. Women without a uterus were also recruited, and were given 
either placebo or unopposed oestrogen. The first trial was stopped early in 2002 
because an increased rate of breast cancers was found in HRT users, which 
outweighed the benefits of therapy. An increased rate of 58% for ovarian cancer was 
found, which was not significant. 27 ovarian cancers per 100,000 women were 
diagnosed in the placebo group compared with 42 per 100,000 in the treatment arm. 
There was no difference in tumour anatomy, stage or grade of disease between the 
two groups. The second trial is still ongoing and is expected to complete in 2005, and 
should provide information on the effect of unopposed oestrogen use on ovarian 
cancer.
Overall, HRT has not been found to increase the risk of ovarian cancer. However, 
one study has demonstrated an increased risk of endometrioid and clear cell 
epithelial ovarian cancers with the use of unopposed oestrogen [Garg et al., 
1998].Postmenopausal HRT use causes increased levels of oestrogen with 
concomitant decreased levels of gonadotrophins, so would further argue against the 
gonadotrophin hypothesis.
1.2.2.2.5 Talc and Asbestos
In the 1960’s it was noted that occupational exposure to asbestos was associated 
with the development of abdominal mesotheliomas, histologically similar to invasive
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epithelial ovarian cancer [KEAL, 1960;Newhouse et al., 1977]. Talc (hydrated 
magnesium trisilicate) is a compound chemically related to asbestos, so a link 
between talc and EOC was suggested. Scientific evidence exists to demonstrate that 
asbestos and talc particles can travel to the upper genital tract in the presence of 
patent fallopian tubes [Heller et al., 1996a;Heller et al., 1996b;Venter, 1981]. Women 
using talc for perineal dusting and on sanitary napkins have a relative risk of invasive 
epithelial ovarian cancer of up to 3.28 (p<0.001) compared to women not performing 
either practices [Cramer et al., 1982]. The role of talc as a causative agent, however, 
is not universally accepted, as evidence to the contrary has been given [Wehner, 
2002;Wong et al., 1999;Shen et al., 1998].
1.2.2.2.6 Tubal Ligation and Hysterectomy
Tubal ligation has been associated with a reduction in the risk of ovarian cancer with 
odds ratios of 0.2 to 0.9 [Green et al., 1997;Rosenblatt and Thomas, 1996]. The 
protective effect of hysterectomy without oophorectomy has shown similar risk 
reduction with odds ratios ranging between 0.03 and 0.8 [Loft et al., 1997]. This could 
be due to ovaries being inspected at the time of surgery and removed if they look 
abnormal. However, some studies have shown that the protective effect is sustained 
over 20-25 years [Cramer and Xu, 1995]. It has been suggested that this may be due 
to the prevention of inflammatory and potentially carcinogenic agents, such as talc, 
ascending the genital tract. Interestingly, one study showed a 50% decreased risk of 
ovarian cancer in women using talc but having had a sterilisation compared with a 
30% increased risk in those using talc but not having been sterilised [Whittemore et 
al., 1989]. The same study found no protective effect of hysterectomy in women with 
a previous tubal ligation. The magnitude of the protection form the effects of talc are 
greater than expected, which suggests that other agents may also ascend the genital 
tract and cause inflammation, such as sexually transmitted infections.
1.2.2.2.7 Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) is an inflammation of the ovaries, fallopian tubes 
and endometrium due to sexually transmitted infections which ascend the genital
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tract. An association between PID and ovarian cancer has been found, with the risk 
increasing proportionately with the number of infective episodes [Shu et al., 
1989;Risch and Howe, 1995]. These women were more likely to have had PID at an 
early age, be nulliparous and infertile. PID causes inflammation and damage to the 
fallopian tube epithelium, and thereby tubal infertility; in fact women with tubal 
infertility have been reported to have a 3 fold risk of ovarian cancer [Rossing et al., 
1994]. Therefore the association between PID and ovarian cancer lends further 
support for an inflammatory role in the causation of this disease.
1.2.2.2.8 Endometriosis
Endometriosis has been suggested to be a possible premalignant lesion of ovarian 
cancer, as a high proportion of endometrioid and clear cell cancers have associated 
endometriosis adjacent to malignant cells [Heaps et al., 1990]. In addition, 
endometriosis is associated with decreased fertility and general endocrine 
dysfunction, both of which could be important in ovarian carcinogenesis. 
Endometriosis is characterised by the presence of endometrium in places other than 
the lining of the uterus, most often the ovaries. This causes a local inflammatory 
reaction, with the presence of macrophages and inflammatory cytokines. This again 
suggests that inflammation may have a role in ovarian cancer.
1.2.2.2.9 The Unifying Role of Inflammation in Ovarian Cancer
The many risk factors detailed above have led to a number of different theories on 
the overall mechanism causing ovarian cancer. These include incessant ovulation, 
high gonadotrophin levels and direct hormonal effects. It has been proposed that 
inflammation may be the key mechanism which underlies the effects of the different 
exposures, and is discussed below.
The role of inflammation may be mediated by the production of toxic oxidants by the 
process of inflammation causing direct DNA damage. This damage may then lead to 
cancer. DNA mutations occur more frequently in rapidly dividing cells where errors in 
replication and repair are not corrected; chronic inflammation is associated with a
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high cell turnover, so DNA integrity may be affected.
There is evidence that inflammatory molecules are increased in ovarian cancer. 
Chemokines, cytokines, adhesion molecules and other components of the 
extracellular matrix may contribute to a tissue environment that supports tumour 
proliferation and invasion. Chemokines have been found in ovarian cancers and 
ascites [Negus et al., 1995], and are known to facilitate the migration of immune cells 
into the tumour environment. Prostaglandins which are also mediators of 
inflammation are found in elevated amounts in ovarian cancers compared to normal 
ovaries [Gubbay et al., 2005]. Non-steroidal anti-inflammatory medications which 
reduce prostaglandin levels and have been found to be associated with a reduced 
risk of epithelial cancers including ovarian, breast and colon cancers [Harris et al., 
2005]. This lends weight to the inflammation theory.
Ovulation itself may predispose to carcinogenesis. The process of follicle rupture and 
subsequent invagination of epithelial cells around the edge of the wound can lead to 
entrapment of inclusion cysts. These cysts have been shown to be present in high 
frequency in women with ovarian cancer in the contralateral unaffected ovary. They 
are also more common in the ovaries of women who have a high genetic 
predisposition to ovarian cancer. These women may have ovarian surface epithelia 
which are already predisposed to ovarian cancer and one feature of this 
predisposition is the presence of inclusion cysts. P53 mutations are a frequent 
finding in ovarian cancer and are thought to be due to spontaneous errors in DNA 
synthesis [Jones et al., 1991]. One study has shown that ovarian cancers which have 
a p53 mutation are associated with an increase in the number of lifetime ovulations 
[Schildkraut et al., 1997]. However, this has not been replicated by others [Webb et 
al., 1998]. The carcinogenic effect of ovulation may be mediated by inflammation. 
There is a significant elevation of inflammatory markers around the ovulatory follicles 
[Espey, 1994] which affects the surrounding epithelium causing cellular oxidative 
damage and thereby leading to mutagenesis.
In summary, ovulation, endometriosis, PID and talc can induce inflammation and 
increase the risk of ovarian cancer. Conversely, sterilisation and hysterectomy
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protect the ovaries from the effect of substances which cause inflammation and 
thereby reduce the risk. The process of inflammation causes DNA damage and 
repair, oxidative stress, an increase in inflammatory molecules, all of which may be 
carcinogenic. Inflammation may be a unifying theory to explain the epidemiological 
risk factors for ovarian cancer although more laboratory studies are required for 
confirmation.
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1.3 Pathology of Serous Cystadenocarcinomas
1.3.1 Histopathology
Each epithelial ovarian cancer subtype resembles its tissue of origin. Serous 
cystadenocarcinomas resemble cells of the fallopian tube, mucinous tumours 
resemble the cervical cells, endometrioid tumours the endometrium and clear cell 
tumours the transitional cell epithelium of the bladder.
Serous cystadenocarcinomas are the most commonly encountered histologic type, 
comprising just over 40% of all primary ovarian neoplasms. Approximately 30-50% 
are malignant and 35-50% of tumours are bilateral. They tend to be large tumours 
with multiple and cystic spaces containing friable papillary projections, and solid 
nodules of adenocarcinoma (Figure 1.6). The fluid within the cysts tends to be watery 
and thin or “serous" in nature. At a microscopic level, psammoma bodies are 
frequently seen; these are small, laminated calcospherites composed of 
microcrystals similar to calcium-phosphate apatite crystals of bone, and are 
produced intracellularly. They are believed to be a consequence of dystrophic 
calcification associated with cellular degeneration. Tumours containing psammoma 
bodies (Figure 1.7) have an above-average survival, possibly because of their diploid 
DNA content and low S-phase fraction [Kuhn et al., 1989].
Serous adenocarcinomas can be classified according to their grade, with grade I 
(well-differentiated) tumours being composed almost entirely of glands and papillae, 
grade III (poorly-differentiated) almost entirely of sheets of malignant cells, with grade 
II containing a mixture of the two. Grading of tumours is very important as this confer 
varying prognoses. Median survival times for patients with grades I, II and III tumours 
are 4.6, 2.3 and 1.5 years, respectively [Demopoulos et al., 1984].
For this thesis I only focused on serious carcinoma, because if I included all different 
histological subtypes, I would have had to collect enough samples from the each 
group and the overall project would have been too complicated to complete within 24 
months. I used serous ovarian adenocarcinomas for my study, although these may
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have in fact been fallopian tube cancers. This possible divergence stems from the 
fact that more than 95% of fallopian tube cancers are papillary serous 
adenocarcinomas and have the same microscopic appearance as the serous 
epithelial ovarian cancers. The diagnosis of a fallopian tube cancer requires that the 
major portion of the cancer is within the tube rather than on the ovary. This was the 
case with all cancers I used for my experiments.
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Figure 1.6. Macroscopic appearance of serous ovarian adenocarcinoma.
Most often, at advanced stages, the entire ovary is taken over by tumour 
and no normal ovarian tissue is recognisable.
Figure 1.7. Microscopic appearance.
There are sheets of cancer cells with focal calcification (psammoma bodies, arrow).
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1.3.2 Staging
Ovarian cancer stage is the most important prognostic factor and, in advanced stage 
patients, volume of residual disease. The International Federation of Gynecology and 
Obstetrics (FIGO) has standardised the staging of gynaecological cancers (see 
Figure 1.8). FIGO stage is such a powerful predictor of prognosis in ovarian cancer 
that most other putative prognostic factors are of little importance in comparison to 
stage. Staging takes both surgical and pathological findings into account, hence the 
term, "surgicopathologic stage".
FIGO stage I ovarian carcinomas have an excellent prognosis. These patients have 
a 5-year survival of over 90%, as do patients in stages IA and IB (Figure 1.8). Poor 
prognostic factors in stage I include grade 3 histology and IC substage, both of which 
are associated with poorer survival rates. Although it is possible that the IC substage 
based on malignant cells in ascites or peritoneal washings is the first evidence of true 
metastatic ability, these cells may merely be exfoliated.
Stage II ovarian cancer is a small and heterogeneous group, and makes up about 
10% of ovarian cancers. It is defined as extension or metastasis to extraovarian 
pelvic organs, most commonly the fallopian tubes and pelvic peritoneum.
Stage III is most commonly encountered at presentation (at least 50% of cases). 
Tumour spreads along peritoneal surfaces, in the peritoneal fluid along the paracolic 
gutters and to the right subdiaphragmatic space. Metastases spread to the 
retroperitoneal lymph nodes and less commonly to the inguinal lymph nodes. It is still 
unclear whether omental and peritoneal spread is due to direct contiguous spread, or 
whether it is due to lymphatic or vascular spread.
Stage IV includes metastatic spread to the liver parenchyma and accounts for 13% of 
cases. The liver and lungs are the most common metastatic sites. Brain metastases 
are only present in 0.1 % of patients at presentation.
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Carcinoma of the ovary: FIGO nomenclature (Rio de Janeiro 1988)
Stage I Growth limited to the ovaries
la Growth limited to one ovary; no ascites present containing malignant
cells. No tumour on the external surface; capsule intact 
lb Growth limited to both ovaries; no ascites present containing malignant
cells No tumour on the external surfaces; capsules intact 
Ic * Tumour either Stage la or lb, but with tumour on surface of one or both
ovaries, or with capsule ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings
Stage II Growth involving one or both ovaries with pelvic extension
I la Extension and/or metastases to the uterus and/or tubes
lib Extension to other pelvic tissues
lie * Tumour either Stage lla or lib, but with tumour on surface of one or 
both ovaries; or with capsule(s) ruptured; or with ascites present 
containing malignant cells or with positive peritoneal washings
Stage III Tumour involving one or both ovaries with histologically confirmed
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
inguinal nodes.
Superficial liver metastases equals Stage III. Tumour is limited to the 
true pelvis, but with histologically proven malignant extension to small 
bowel or omentum
Ilia Tumour grossly limited to the true pelvis, with negative nodes, but with 
histologically confirmed microscopic seeding of abdominal peritoneal 
surfaces, or histologically proven extension to small bowel or 
mesentery
lllb Tumour of one or both ovaries with histologically confirmed implants, 
peritoneal metastasis of abdominal peritoneal surfaces, none 
exceeding 2 cm in diameter; nodes are negative 
I lie Peritoneal metastasis beyond the pelvis > 2 cm in diameter and/or 
positive retroperitoneal or inguinal nodes
Stage IV Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to 
Stage IV.
Parenchymal liver metastasis equals Stage IV
* In order to evaluate the impact on prognosis of the different criteria for allotting 
cases to Stage Ic or lie, it would be of value to know if rupture of the capsule was 
spontaneous, or caused by the surgeon; and if the source of malignant cells detected 
was peritoneal washings, or ascites.
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Figure 1.8. Staging of ovarian cancer: primary tumour and metastases (FIGO and TNM)
(from FIGO, www.FIGO.org).
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1.4 Molecular Biology of Sporadic Epithelial Ovarian 
Cancer
Epithelial ovarian cancer is thought to arise from the epithelial cells that line the 
surface of the ovary or from cells that line inclusion cysts immediately beneath the 
ovarian surface. By the time the disease is diagnosed, multiple tumour nodules are 
found studding the peritoneal surfaces. Molecular techniques have shown that more 
than 90% of EOC’s are clonal diseases that originate from the progeny of single 
cells. Where ovarian tumours have been compared to their corresponding peritoneal 
metastases, both show inactivation of the same X chromosome, areas of loss of 
heterozygosity (LOH) on the same chromosomes, and, when present, have the same 
base mutated in the p53 tumour suppressor gene indicating monoclonality [Jacobs et 
al., 1992;Mok et al., 1992;Li et al., 1993].
Over the last decade a number of genetic abnormalities have been detected in 
epithelial ovarian cancers.
1.4.1 Introduction
Cancer arises as a result of cumulative genetic changes in somatic cells and their 
progeny. The progression of a cancer cell from normal, pre-cancer, cancer, local 
invasion and finally to metastasis is a function of a clonal expansion of cells that have 
acquired a selective growth advantage which allows them to outnumber neighbouring 
cells. The cells in the neoplastic clone undergo changes in gene activity as a 
consequence of genetic and epigenetic changes. Ultimately, a cell population 
establishes which can grow regardless of normal controls of proliferation and 
surrounding tissues. Hanahan and Weinberg [Hanahan and Weinberg, 2000] have 
identified six hallmark features which best define the cancer cell phenotype: self- 
sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. These traits are found 
in most and perhaps all types of human cancers.
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The accumulation of genetic changes in cells during cancer development and 
progression have been most comprehensively described for colorectal cancer 
[Kinzler and Vogelstein, 1996] where the initial event is inactivation of the tumour 
suppressor gene APC, which allows a normal mucosal cell in the colonic epithelium 
to become an adenomatous polyp. Subsequently, mutations in oncogenes (e.g. C- 
myc or K-ras) or in tumour suppressor genes (e.g. p53 or DCC) lead to the 
progression from adenoma to carcinoma. Mismatch-repair genes recognise and 
correct mismatches which occur during DNA replication. In tumours where 
inactivation of the mismatch-repair genes has occurred, the rate at which DNA 
mutations occur is accelerated by the genetic instability. The APC gene has been 
described as the “gatekeeper” of the colonic epithelium, and in colon cancer, there is 
good evidence to suggest that disruption of the APC pathway is necessary for the 
initiation of the cancer. However, for epithelial ovarian cancer, as for most other 
cancers, such detailed knowledge of the early genetic events is lacking. The 
following details what is known about the molecular genetics of ovarian cancer.
1.4.2 Oncogenes and Tumour Suppressor Genes
Several factors are involved in the evolution of a cancer. These include alterations or 
mutations in specific oncogenes, and are divided into two categories: those that 
activate proto-oncogenes which promote cellular proliferation or inhibit cell death, 
and those that inactivate tumour suppressor genes which promote cell proliferation or 
promote cell death. These are discussed below.
1.4.2.1 Oncogenes
Oncogenes result from gain-of-function mutations in their normal cellular counterpart, 
proto-oncogenes, the normal function of which is to drive cellular proliferation. The 
most common mechanisms for mutational activation of proto-oncogenes are (i) gene 
amplification, leading to over-expression of an otherwise normal protein product, (ii) 
point mutation, leading to constitutive activation of a mutant form of the protein 
product and (iii) chromosomal translocation, which results in juxtaposition of the 
oncogene with the promoter region of a constitutively expressed gene, thereby
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resulting in over-expression of the oncogene-encoded protein.
The Her-2/neu (c-erbB-2) is one of the most extensively investigated proto­
oncogenes. It encodes a 185-kDa transmembrane glycoprotein with intrinsic tyrosine 
kinase activity, located on chromosome 17q21. It belongs to a family of growth factor 
receptors, including the epidermal growth factor receptor (EGFR or HER-1) and 
HER-3 and HER-4 [Carraway, III and Cantley, 1994]. HER-2 amplifies the signal 
provided by other HER receptors and so plays a central role in HER signalling. Over­
expression of HER-2 oncogene has been found in 20-30% of ovarian cancers 
[Hellstrom et al., 2001 ;McKenzie et al., 1993;Berchuck, 1995] and is associated with 
a poor prognosis [Yu et al., 1993;McKenzie et al., 1993;Cirisano and Karlan, 
1996;Rubin et al., 1993]. A poor prognosis could be related to a more aggressive 
phenotype due to ligand activation of the over-expressed receptor. Heregulin can 
inhibit clonogenic growth of ovarian cells that over-express HER-2 [Xu et al., 1999], 
but increases the ability of the same cells to invade matrigel membranes and to 
express proteases [Xu et al., 1997]. Therefore the poor prognosis associated with 
HER-2 over-expression may be due to increased invasiveness rather than to 
increased proliferation.
The G1 cyclin proteins regulate the progression of a cell through the G1-S phase of 
the cell cycle. The sequential activation of cyclin D1 followed by cyclin E leads to the 
inactivation of pRB1 (retinoblastoma protein) by phosphorylation, and allows the cell 
to enter the S phase of the cycle.
Up to 70% of ovarian tumours, mainly the late stage serous subtype over-express 
cyclin D1, and this confers a poor prognosis. The importance of cyclin E is less clear. 
12-18% of ovarian tumours, especially clear cell tumours [Session et al., 1999] have 
been reported to over-express cyclin E, although no information was given regarding 
prognosis.
Myc is a member of the helix-loop-helix/leucine zipper superfamily of genes. It is 
located on chromosome 8q24 and encodes a DNA-binding protein which, on 
heterodimerisation with the MAX protein, binds to target DNA sequences and
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induces transcription of several genes [Dang et al., 1999]. Myc plays a role in many 
cellular mechanisms including cell cycle control, differentiation, adhesion and 
apoptosis [Dang et al., 1999]. Studies have shown myc amplification in 28-50% of 
EOC’s [Baker et al., 1990;Bauknecht et al., 1993;Katsaros et al., 1995]. The clinical 
relevance, is, however, not clear [Bauknecht et al., 1993].
Ras mutations occur in less than 20% of serous ovarian cancers [Enomoto et al., 
1990]. However, physiologic activation of Ras has been found in a majority of ovarian 
cancer cell lines [Patton et al., 1998]. Activation of Ras may relate to the activity of 
receptor tyrosine kinases or to cross-talk from phosphatidylinositol 3-kinase (PI3- 
kinase).
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Figure 1.9. The phases of the cell cycle
The putative PIK3CA oncogene codes for the p110a catalytic subunit of PI3-kinase. 
It is located on chromosome 3q26; this region is increased in copy number in up to 
40% of ovarian cancer [Iwabuchi et al., 1995]. Signalling by PI3-kinase has been 
shown to result in proliferation [Klippel et al., 1998], glucose transport and catabolism 
[Frevert and Kahn, 1997], cell adhesion [Khwaja et al., 1997], apoptosis [Kennedy et 
al., 1997], Ras signalling [Downward, 1998] and oncogenic transformation [Jimenez 
et al., 1998;Meili et al., 1998]. The increased copy number of PIK3CA is associated 
with increased PIK3CA transcription, p110a protein expression and PI3-kinase 
activity. As PI3-kinase signalling is associated with cancer-related functions, this 
implicates PIK3CA as an oncogene [Shayesteh et al., 1999]. In addition, treatment 
with PI3-kinase inhibitor decreases proliferation and increases apoptosis in ovarian
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cancer tissue [Shayesteh et al., 1999].
In addition, downstream effectors of PI3-kinase, AKT1 and AKT2, have been found 
to be amplified in ovarian cancer. AKT2 is a gene on chromosome 19q which 
encodes a serine-threonine protein kinase. AKT2 has been shown to be amplified 
and over-expressed in two of eight cancer cell lines and two of 15 primary epithelial 
ovarian cancers [Cheng et al., 1992]. This study was confirmed by a larger series of 
132 primary ovarian cancers where 14% had AKT2 amplification or over-expression. 
This subset consisted of high grade, late stage tumours which were associated with 
worse survival [Bellacosa et al., 1995].
Gene Function Approximate frequency
Her-2/neu Tyrosine kinase 20%
Cyclin D1 Cell cycle 70%
Cyclin E Cell cycle 12-18%
Myc Transcription 28-50%
Ras G protein <20%
PIK3CA Serine/threonine kinase 40%
Table 1.2. Putative Oncogenes in Epithelial Ovarian Cancer
1.4.2.2 Tumour Suppressor Genes
Tumour suppressor genes encode proteins that are normally involved in inhibiting 
proliferation, and inactivation of these genes plays a role in the development of most 
cancers. Knudson’s “two-hit” model established the paradigm that both alleles must 
be inactivated in order to exert a phenotypic effect on tumorigenesis [Knudson,
1997]. The location and type of inactivating mutations may vary between cancers. 
Frequently, mutations in tumour suppressor genes alter the base sequence so that 
the encoded protein product is truncated because of the generation of a premature 
stop codon. Truncated protein products may result from several types of mutational 
events including nonsense mutations, in which a single base substitution changes a 
sequence from a specific amino acid to a stop codon (e.g., AAG to TAG). In addition, 
microdeletions or insertions of one or several nucleotides that disrupt the reading 
frame of the DNA (frameshifts) also lead to the generation of stop codons 
downstream in the gene. In some cases, missense mutations occur that change only 
a single amino acid in the encoded protein. A mutation in one allele, whether
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germline or somatic, is revealed after somatic inactivation of the homologous wild- 
type allele. In theory, the same spectrum of mutational events could contribute to 
inactivation of the second allele, but what is typically observed in tumours is 
homozygosity or hemizygosity for the first mutation, indicating “loss” of the wild-type 
allele. The loss of the heterozygosity (LOH) has become recognised as the hallmark 
of tumour suppressor gene inactivation (see later).
The p53 tumour suppressor gene maps to chromosome 17p13.1 and encodes a 
nuclear phosphoprotein. P53 is considered the guardian of the genome because of 
its role in activating genes involved in growth arrest or apoptosis following DNA 
damage [Lane, 1992]. Alteration of the p53 gene is the most common molecular 
event in ovarian cancer [Casey et al., 1996;Hartmann et al., 1994;Berchuck et al., 
1994]. In a normal cell, p53 regulates transcription of other genes involved in cell 
cycle arrest, such as p21. P53 is usually inactivated according to Knudson’s “two-hit” 
model. This leads in the majority of cases to missense mutations that change a 
single amino acid in the DNA binding domain of the p53 gene, and on to over­
expression of non-functional p53 protein. The rate of p53 mutation varies with the 
stage of disease; 10-20% of stage I/ll cancers have the mutation, compared to 40- 
60% at advanced stages (lll/IV). The increased rate of p53 over-expression in late 
stage tumours may signify that this is a late event in ovarian carcinogenesis, and 
where p53 is over-expressed it is associated with a worse prognosis [Marks et al., 
1991;Reles et al., 2001]. However, the evidence is conflicting with some studies not 
confirming this result.
The RB1 (retinoblastoma) protein (pRb) acts as a critical cell cycle regulator. In its 
hypophosphorylated, active form, pRb binds to the E2F transcription factor and 
prevents the cell from entering S phase [Gillett and Barnes, 1998]. However, 
following phosphorylation by cyclin D1 and cyclin-dependent kinases (CDKs) and the 
subsequent release of E2F, the inhibitory effect of pRb is removed allowing 
progression from the G1 to S phase of the cell cycle. 30-52% of ovarian tumours 
demonstrate LOH at the RB1 locus, but express wild-type protein [Dodson et al., 
1994;Kim et al., 1994;Li et al., 1991]. These data suggest that either RB1 is 
inactivated without affecting protein levels, or that a second suppressor gene lies
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close to the RB1 gene. A definitive role for RB1 in ovarian cancer remains to be 
determined.
The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the 
cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to 
uncontrolled cell growth. Defects of the 'Rb/cyclin D1/p16 pathway' have been shown 
to play a critical role in the development of virtually all human malignancies. A 
significant positive association has been reported between p16 expression and 
clinical outcome for epithelial ovarian cancer patients. P16 acts by inhibiting binding 
between CDK4 and CDK6 and the D cyclins. This results in hypophosphorylation of 
pRb and causes cell cycle arrest at G1 phase. Homozygous deletion of p16 have 
been reported in 12-18% of ovarian tumours [Kudoh et al., 2002;lchikawa et al., 
1996]. There is evidence that p16 inactivation in primary serous papillary tumours 
occurs by methylation [Niederacher et al., 1999]. However, other studies have failed 
to find any methylation in these cancers [Ichikawa et al., 1996;Ryan et al., 1998]. 
These data suggest that the CDKN2A gene is involved in the tumorigenesis of 
ovarian cancer, but the exact mechanism of CDKN2A gene inactivation in serous 
papillary ovarian cancer remains unclear.
PTEN (phosphatase and tensin homolog deleted on chromosome ten), a tumour 
suppressor gene located on chromosome 10q23, is also known as MMAC1 (mutated 
in multiple advanced cancers) and TEPI (TGFIJ-regulated and epithelial cell-enriched 
phosphatase). PTEN encodes a protein that functions as a dual-specificity 
phosphatase in vitro [Myers et al., 1997], thereby recognising and dephosphorylating 
tyrosine and serine/threonine residues. PTEN is involved in the PI3-kinase-mediated 
growth signalling pathway [Maehama and Dixon, 1998], anoikis [Di Cristofano and 
Pandolfi, 2000], inhibition of cell adhesion, integrin-mediated cell migration and 
tumour invasion [Tamura et al., 1999a;Tamura et al., 1999b;Gu et al., 1999]. LOH at 
the PTEN locus has been reported in 28% of serous and 43% of endometrioid 
ovarian cancers [Obata and Hoshiai, 2000;Kurose et al., 2001]. These data suggest 
that PTEN may play a role in carcinogenesis of a subset of ovarian tumours.
The ARHI (ras homologue gene family, member I) gene, previously known as
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N0EY2, has a 229-amino acid sequence and shares 54% amino acid homology with 
HRAS and 56 to 62% homology with ras-related proteins. PCR analysis of a genomic 
library and FISH [Yu et al., 1999] mapped the ARHI gene to 1p31, a region that is 
deleted in approximately 40% of breast [Loupart et al., 1995;Hoggard et al., 1995] 
and ovarian cancers [Yu et al., 1999] due to LOH.
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Figure 1.10. Role of oncogenes and tumour suppressor genes in signal transduction pathways 
and the cell cycle in tumour cells.
SPARC (secreted protein acidic and rich in cysteine) is an extracellular Ca(2+)- 
binding phosphorylated, acidic, matricellular glycoprotein of 43 kD, located on 
chromosome 5q31.3-q32 that associates with cell populations undergoing migration, 
morphogenesis, and differentiation. Studies on endothelial cells have established 
that its principal functions in vitro are counteradhesion and anti proliferation. The 
mechanism(s) underlying these antitumour effects is unknown. Brown et al 
demonstrated up-regulation of SPARC in reactive stroma associated with invasive 
ovarian cancer particularly at the tumour-stromal interface of the invading tumours, 
demonstrating the significance of the stroma to growth of cancers [Brown et al.,
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1999]. Yiu and colleagues showed that SPARC expression in ovarian cancer cells is 
inversely correlated with the degree of malignancy. They treated human ovarian 
surface epithelial cells and ovarian cancer cells with SPARC, and revealed that 
SPARC inhibits the proliferation of both normal and cancer cells, but induces 
apoptosis only in cancer cells. This shows that down-regulation of SPARC is 
essential for ovarian carcinogenesis as cancer cells become sensitized to the 
apoptotic activity of SPARC during malignant transformation. This study showed the 
first direct evidence that putative SPARC receptors are present on human ovarian 
epithelial cells, with their levels being higher than in cancer cells. It is likely that 
binding of SPARC to its receptor triggers tissue-specific signalling pathways that 
mediate its tumour suppressing functions. Decrease in ligand-receptor interaction by 
the down-regulation of SPARC and/or its receptor is an essential step for ovarian 
carcinogenesis [Yiu et al., 2001].
BRCA1 mutations are the most common cause of hereditary ovarian cancers. A 
recent study, in which complete sequencing of the gene was performed 103 ovarian 
cancers, somatic mutations were found in at least 7 cases [Berchuck et al., 1998]. In 
contrast to women whose median age at diagnosis is typically in the mid-forties, the 
median age of women with somatic mutations was about 60 years. Similar to ovarian 
cancers with germline BRCA1 mutations, all of the ovarian cancers with somatic 
BRCA1 were serous. In addition, loss of the wild-type BRCA1 allele invariably 
accompanied somatic BRCA1 mutations. These data support the hypothesis that 
loss of BRCA1 function occurs by way of the classic tumour suppressor paradigm, 
with mutation of one copy and deletion of the other.
Gene Chromosomallocation Function
P53 17p13 DNA stability 
Apoptosis
Rb1 Cell cycle regulator
CDKN2A 9p21 Cell cycle arrest
PTEN 10q23 Phosphatase
ARHI 1p31 Induces p21
(NOEY2) Inhibits cyclin D1
SPARC 5q31 Counteradhesion and 
antiproliferation
Doc2 5p13 Binds GRB2
LOT-1 6q25 Zinc finger
OVCA1 17p13 Unknown
Table 1.3.Putative Tumour Suppressor Genes in Epithelial Ovarian Cancer
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1.4.3 Cytogenetic Alterations
There are genetic changes at the chromosomal as well as the molecular level. 
Comparative genomic hybridisation (CGH) studies have demonstrated that most 
ovarian cancers have chromosomal gains, losses and complex translocations often 
of large segments of chromosomes. Gains on chromosomes 3 and 8, and losses on 
chromosomes 16 and 17 are the most common karyotypic findings in ovarian cancer 
[Iwabuchi et al., 1995]. Chromosome regions frequently affected with allelic 
imbalance include 1p [Chenevix-Trench et al., 1992], 2q [Saretzki et al., 1997], 3p 
[Lounis et al., 1998], 5q [Tavassoli et al., 1996], 6q25 [Colitti et al., 1998], 7q31 
[Zenklusen et al., 1995], 9p [Devlin et al., 1996], 11 p15 [Lu et al., 1997], 11 q 
[Launonen et al., 1998], 12p12 [Hatta et al., 1997], 13q [Yang-Feng et al., 1992], 
17q12 [Foulkes et al., 1993], 18q [Saretzki et al., 1997], 19q [Bicher et al., 1997], 22q 
[Englefield et al., 1994], and Xq [Choi et al., 1997]. There are differences between 
serous adenocarcinomas and the other histological subtypes. Serous tumours mostly 
have gains at 1q and 11q, whereas endometrioid tumours have gains at 1q and 10q, 
and mucinous have gains at 17q. Once the areas of chromosomal abnormality are 
pinpointed, molecular techniques such as LOH studies using microsatellite markers 
can be applied to narrow the target to the gene-locus level. These regions of 
recurrent abnormality are thought to encode genes involved in ovarian 
carcinogenesis when differentially expressed as a result of abnormal copy number or 
mutation. Certain oncogenes and tumour suppressor genes have been identified in 
several regions of allelic imbalance, and specific karyotypic abnormalities have been 
associated with clinical outcome [Saretzki et al., 1997;Launonen et al., 1998;Schwab 
and Amler, 1990], although it is unclear whether the extent of these genetic 
alterations reflects the inactivation of multiple tumour suppressor genes or whether it 
is the result of generalised instability of the genome. Many studies have consistently 
shown that poorly differentiated, late stage tumours have more genetic alterations 
than well differentiated, early stage or LMP tumours [Iwabuchi et al., 1995;Dodson et 
al., 1993]. This could be due to an accumulation of genetic changes during the 
evolution of a tumour, or it could be that late stage, high-grade cancers are more 
aggressive even early in their development due to specific mutations or increased 
genomic instability. If the latter theory is correct, then this could have significant
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implications for screening, as cancers which are inherently more aggressive are 
more likely to metastasise confer a worse prognosis.
1.4.4 Peptide Growth Factors
Growth factors are produced by many different cell types and exert their effects via 
autocrine and paracrine mechanisms. They function as stimulators or inhibitors of the 
division, differentiation and migration of cells and are involved in carcinogenesis, in 
which they influence a variety of functions including cell proliferation, cell invasion, 
metastasis formation, angiogenesis, local immune system functions and extracellular 
matrix synthesis.
The EGF-related peptides have been the most extensively studied in ovarian cancer. 
EGF, transforming growth factor (TGF)-a and amphiregulin bind to, and activate, the 
EGF receptor (EGFR). All three factors have been identified in ovarian tumours and 
cultured ovarian cancer cells. Studies have shown TGF-a to be present in 50-100%, 
EGF in 28-71% and amphiregulin in 18% of ovarian cancers [Kommoss et al., 
1990;Morishige et al., 1991;Owens et al., 1991b;Kohler et al., 1992;Stromberg et al., 
1994]. TGF-a has been detected in the sera of 62% of women with ovarian cancers 
compared with 28% with benign ovarian tumours and 11% of normal female controls 
[Chien et al., 1997]. Similarly, TGF-a has been detected in the urine of 79% of 
ovarian cancer patients compared with 17% of patients with benign tumours and 
23% of controls [Feldkamper et al., 1994].
The EGFR, a glycosylated membrane-spanning protein, has been found to be 
present in 33-75% of primary ovarian tumours by ligand binding [Bauknecht et al., 
1988;Battaglia et al., 1989;Morishige et al., 1991;Owens et al., 1991a] and by 
immunohistochemistry [Berchuck et al., 1991;Henzen-Logmans et al., 1992;Owens 
et al., 1992]. Levels of EGFR are higher in malignant than benign tumours or normal 
ovary, suggesting a possible role in malignant progression, and are related to poor 
prognosis [Bauknecht et al., 1988;Battaglia et al., 1989;Berchuck et al., 1991].
The TGF-p family are involved in cell growth regulation, angiogenesis and tissue
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remodelling. TGF-p peptides have an inhibitory rather than stimulatory role. They 
have been shown to inhibit the growth of both ovarian cancer cells (by 95%), 
immortalised ovarian cancer cell lines [Berchuck et al., 1990;Marth et al., 
1992;Bartlett et al., 1992;Jozan et al., 1992] and normal ovarian epithelial cells grown 
in culture [Hurteau et al., 1994]. It has been suggested that TGF-p is an important 
regulator of normal ovarian epithelium and autocrine inhibition may be lost in many 
cancer cell lines. Some ovarian cancers that are growth-inhibited by TGF-p are also 
more likely to undergo apoptosis [Havrilesky et al., 1995].
Inhibin, another member of the TGF- p family, is increased in the sera of patients 
with EOC and is associated with increased survival [Blaakaer et al., 1993;Cooke et 
al., 1995].
The insulin-like growth factors (IGF), IGF-I and IGF-II are important mitogenic growth 
factors which show close structural homology to insulin [Barreca and Minuto, 1989]. 
The IGFs, IGF receptors (insulin, type I and type II receptors) and IGF binding 
proteins (IGFBPs) have been identified in many ovarian tumours [Beck et al., 
1994;van Dam et al., 1994;Weigang et al., 1994] and ovarian cancer cell lines 
[Resnicoff et al., 1993;Hofmann et al., 1994] and have a stimulatory effect. As both 
IGF-I and its receptor are co-expressed, and autocrine mechanism can be 
postulated. IGFBP-2 levels have been shown to be high in sera of ovarian cancer 
patients [Flyvbjerg et al., 1997] and in malignant ovarian cyst fluid [Karasik et al., 
1994] and correlate with aggressiveness of the tumour.
Platelet-derived growth factor (PDGF) expression is elevated in ovarian cancers and 
undetectable in normal ovaries and benign tumours [Henriksen et al., 1993;Versnel 
et al., 1994]. Tumours expressing the PDGF receptor are associated with shorter 
overall survival [Henriksen et al., 1993]. The concomitant expression of both PDGF 
and its receptor is related to disease progression, suggesting autocrine growth 
regulation.
Basic fibroblast growth factor (bFGF) and its receptor are both expressed in ovarian 
cancer cells, again suggesting an autocrine mechanism, and function in a stimulatory
45
manner [Crickard et al., 1994]. FGFs stimulate both mitogenesis and angiogenesis.
In summary, ovarian cancers produce and respond to many peptide growth factors 
such as epidermal growth factor, transforming growth factor-a, insulin-like growth 
factors, platelet-derived growth factor and basic fibroblast growth factor. The 
concomitant over-expression of both growth factor and receptor suggests an 
autocrine stimulatory mechanism. However, as normal ovarian epithelial cells also 
produce and respond to the same peptide growth factors found in ovarian cancer 
cells, it is unclear whether these growth factors play a role in the development of 
tumours or merely maintain cell growth once tumours are established.
1.4.5 Metastasis Suppressor Genes
1.4.5.1 E-Cadherin (CDH1)
E-cadherin is a transmembrane glycoprotein, which, through its attachment to the 
actin cytoskeleton via a, ft and y-catenin, functions as a cell adhesion molecule. Loss 
of functional E-cadherin or catenin is associated with ability of cancer cells to detach 
from the primary tumour, thereby facilitating metastasis progression. E-cadherin 
(CDH1) mutations are rare in ovarian cancer [Risinger et al., 1994]. CDH1 protein 
expression is reduced in poorly differentiated ovarian tumours and ovarian cancer 
metastases compared with primary tumours, implying that loss of CDH1 correlates 
with acquired invasive and metastatic potential [Davies et al., 1998]. The CDH1 
pathway may potentially be disrupted via mutations in the catenin genes, and 
missense mutations of ft-catenin have been reported in endometrioid ovarian 
tumours but rarely in other histological subtypes [Gamallo et al., 1999;Wright et al., 
1999]. Reduction or absence of either ft- or a-catenin expression in ovarian tumours 
is associated with increased metastatic potential and poor prognosis [Davies et al., 
1998].
1.4.5.2 Nm23 (NME1 & 2)
The nm23-H1 (NME1) and nm23-H2 (NME2) genes are located on chromosome
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17q21.3 and encode nucleoside diphosphate kinase A and B respectively. These 
proteins catalyse the phosphorylation of nucleoside diphosphates using ATP, 
resulting in the production of the corresponding nucleoside triphosphates [Lombardi 
et al., 2000]. Reduced expression of NME1 and NME2 is associated with a highly 
metastatic phenotype in ovarian tumours and cell lines [Simone et al., 2001 ;Tas et 
al., 2002;Galani et al., 2002]. NME1 may also be important in the progression of 
ovarian tumours as reduced NME1 expression is associated with late stage disease 
lymph node involvement and distant metastasis [Mandai et al., 1994].
1.4.6 Cell Survival and Cell Death Pathways
1.4.6.1 Senescence
Normal somatic cells can undergo division only a finite number of times, and after a 
certain number of doublings, undergo senescence. This is characterised by arrest of 
proliferation without loss of biochemical function or viability. The maximum number of 
doublings has often been referred to as the “Hayflick limit”, that is, there is a counting 
mechanism or “molecular clock” which can trigger senescence at the appropriate 
time. Cellular senescence is due to the shortening of repetitive DNA sequences 
(TTAGGG) called telomeres that cap the ends of each chromosome. Telomeres 
stabilise chromosomes and prevent recombination during mitosis. Chromosomes 
have long telomeric sequences at birth, which then become progressively shorter 
each time the cell divides. Cancer cells must bypass senescence in order to gain the 
ability to replicate an unlimited number of times, and undergo immortalisation, and 
essential step in malignant transformation of normal cells. They accomplish this by 
inducing the expression of telomerase which acts to lengthen the telomeres [Shay, 
1998]. Telomerase is a ribonudeoprotein whose RNA acts as a template for telomere 
extension and the protein catalyses the synthesis of new telomeric repeats.
The expression of telomerase is limited to those cells actively dividing, so it has been 
suggested that telomerase would be a useful diagnostic marker in patients with 
cancer. Researchers have demonstrated that telomerase activity is detectable in 
most ovarian cancers [Duggan et al., 1998;Wan et al., 1997]. It has been suggested
47
that persistence of telomerase activity in peritoneal washings after primary therapy 
for advanced ovarian cancer may predict the presence of microscopic residual 
disease in some cases even when the cytological washings and biopsies are 
negative. More studies are required before this is demonstrated as a feasible clinical 
tool.
1.4.6.2 Apoptosis
Apoptosis plays a vital role in a variety of human diseases, including cancer. It is an 
active, energy-dependent process that involves endonuclease and protease 
cleavage of DNA and proteins. Morphologically it is characterised by cytoplasmic 
shrinkage, active membrane blebbing, chromatin condensation and fragmentation 
into membrane-enclosed vesicles [Kerr et al., 1972;Wyllie et al., 1980]. This is 
different to necrosis which is characterised by loss of osmoregulation and cellular 
fragmentation. Because the balance between cell proliferation and cell death controls 
the size of a cell population, tumour growth can result from either increased 
proliferation or decreased apoptosis. Suppression of apoptosis can lead to cells 
becoming malignant by allowing the accumulation of genetic mutations, growth 
factor-independent tumour cell growth, and escape from cell-cycle checkpoints which 
would normally induce apoptosis.
An important role of apoptosis is to eliminate cells which have undergone mutation, 
thereby preventing malignant transformation. When cells are exposed to mutagens 
such as radiation, the cell cycle is arrested so that DNA repair may take place. If the 
DNA cannot be repaired, then apoptosis has to occur to remove any abnormal cells 
before they become malignant. The p53 tumour suppressor gene plays a critical part 
in regulation of cell cycle arrest and apoptosis. Other genes involved in this process 
include bcl-2, which was first identified at a translocation breakpoint in B-cell 
lymphomas. Bcl-2 expression inhibits apoptosis although paradoxically, the 
continued expression of bcl-2 in ovarian cancers is associated with a good prognosis 
[Herod et al., 1996;Henriksen et al., 1995]. The bcl-XL expression (a structural and 
functional homologue of bcl-2) also inhibits apoptosis in ovarian cancer cells in 
response to chemotherapy [Liu et al., 1998]. Other related genes such as bax and
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bcl-XS are pro-apoptotic. Studies have found high bax expression in primary ovarian 
cancers, and this was associated with a good response to chemotherapy [Tai et al., 
1998].
1.4.6.3 Proliferation
Increased proliferation is a hallmark of cancer cells. Proliferation can be measured by 
assessing the DNA content of cells or by immunohistochemical staining Ki67 or 
proliferative cell nuclear antigen (PCNA), which are proteins expressed by 
proliferating cells. Ki67 is expressed in G1, S and G2 phases of the cell cycle but not 
in GO cells. Ki67 correlates with poor survival in ovarian cancer [Anttila et al., 1998].
1.4.6.4 DNA Index
Aneuploidy is present in most malignant tumours and in many early stage 
carcinomas. It is defined as cells with chromosome numbers greater or smaller than 
the normal diploid complement. A variety of methods have been used to demonstrate 
aneuploidy including karyotyping [Wang et al., 2000], flow cytometry [Eissa et al.,
1998], image analysis [Guidozzi et al., 1996] and fluorescence in situ hybridisation 
(FISH) [Mark et al., 1999]. Many groups have investigated the value of ploidy in 
ovarian cancer. Advanced stage (I I I/I V), poorly differentiated tumours are aneuploid 
in 65-90% of cases and aneuploid tumours have an aggressive clinical course and a 
poor outcome [Ozalp et al., 2001 ;But and Gorisek, 2000]. Aneuploidy is present early 
during tumour progression [Skirnisdottir et al., 2001] and it appears that the altered 
DNA content, and its underlying cause, may play a role in both the development and 
progression of ovarian tumours. Therefore although the DNA index may not be 
predictive in patients with advanced stage ovarian carcinoma, it may help predict the 
risk of recurrence in patients with early-stage disease as these tumours are less 
commonly aneuploid [Schueler et al., 1996].
1.5 Invasion and Metastasis of Ovarian Cancer
The spread of cancer, either by local invasion or metastasis through the bloodstream 
or lymphatics is the hallmark of malignancy [Liotta, 1992]. Cells leave the primary 
tumour and enter either the lymphatic or vascular network before spreading to other 
organs. Ovarian cancer spread occurs at two levels: (i) in the abdominal cavity and 
(ii) in the retroperitoneal space. The first method, spread into the abdominal cavity 
involves individual cancer cells shedding from the ovary and entering the peritoneal 
fluid. These carcinoma cells then attach to the layer of mesothelial cells that line the 
inner surface of the peritoneal cavity. Once ovarian carcinoma cells adhere to 
mesothelial cells, they migrate through the layer of mesothelial cells, invade the local 
organs and can spread to distant sites. This process of cancer cell adhesion, 
migration and invasion can eventually lead to death of the patient. The second 
method, spread into the retroperitoneal space, involves spread through lymphatic 
channels leaving from the hilus of the ovary and on to inguinal, iliac, obturator and 
para-aortic lymph nodes. Spread to lymph nodes is not a late event as in apparently 
stage I tumours, nodal metastases have been reported in between 14 to 24% of 
cases [Burghardt et al., 1991]. The incidence of nodal metastasis increases with 
stage, involving 50% of stage II and 70% of stage III tumours. Ascites often co-exists 
with ovarian cancer at the time of presentation. Peritoneal fluid is constantly formed 
as a transudate from small blood vessels, and is resorbed by subdiaphragmatic 
lymphatics. Ascites develops when the balance of equilibrium is towards formation 
over resorption. In ovarian cancer patients, ascites forms when lymphatic channels 
are blocked by tumour, or due to increased vascular permeability.
At the molecular level, cells of the primary tumour acquire genetic mutations which 
confer the ability to survive. A cell population evolves that disregards the normal 
controls of proliferation and territory. Hanahan and Weinberg [Hanahan and 
Weinberg, 2000] described “six hallmarks of cancer”: disregard of signals to stop 
proliferating and of signals to differentiate; capacity for sustained proliferation; 
evasion of apoptosis; invasion and angiogenesis (Figure 1.11). The primary tumour 
cannot grow beyond 1-2mm in size without acquiring a blood supply (the “angiogenic 
switch”) [Folkman, 1971]. Angiogenesis is the growth of new capillary blood vessels,
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and important mediators of this process are vascular endothelial growth factor 
(VEGF) and its mitogenic receptor VEGFR-2, which is localised on endothelial cells, 
and basic fibroblast growth factor (bFGF), produced by both the tumour and by 
infiltrating cells. High VEGF expression in carcinoma cells is an independent 
prognostic factor for poor prognosis in both advanced [Hartenbach et al., 1997] and 
early stage [Paley et al., 1997] disease. Angiogenesis is also assisted by 
extracellular matrix (ECM) breakdown and it appears that matrix metalloproteinases 
(MMPs) are expressed early in tumour growth. The neovasculature of the tumour is 
more permeable than normal vessels due to fenestrated basement membranes and 
fewer cell junctions, which assist the metastatic process.
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Figure 1.11. The six hallmarks of cancer.
Figure taken from Hanahan & Weinberg, (2000).
The next stage of the metastatic process involves movement through the tumour 
basement membrane and breakdown of the ECM, which is composed of collagens, 
fibronectin, glycosaminoglycans and laminins. The ECM provides structural support 
for cells, ligands for cellular receptors such as integrins and produces inactive forms 
of growth factors and proteases. Of these proteases, MMPs are produced by both
51
stromal and endothelial cells in response to factors released by tumour cells, but they 
are also produced by tumour cells themselves. They are regulated in balance with 
tissue inhibitors of metalloproteinases (TIMPs). Two metalloproteinases, MMP-2 and 
MMP-9 (72kDa and 92kDa type IV collagenases or gelatinase A and B, respectively), 
play a role in ovarian cancer. They are able to degrade type IV collagen, which is a 
major component of the basement membrane [Nelson et al., 2000]. Secretion of 
MMP-2 and MMP-9 has been observed in several ovarian cancer cell lines and 
detected in ascitic fluid from patients with advanced ovarian cancer. The 
invasiveness of ovarian cancer cell lines correlates with MMP-2 and MMP-9 
expression in vitro [Moser et al., 1994;Young et al., 1996;Afzal et al., 1996]. MMPs 
probably act in two ways in ovarian cancer; they enable ovarian cancer cells to 
detach from the epithelial surface and migrate into the peritoneal cavity and also to 
invade through the basement membrane into the ovarian stroma, then to adjacent 
tissues.
A second group comprises the serine proteases including urokinase-type 
plasminogen activator (u-PA) which must bind to its membrane receptor (uPAR) to 
facilitate cell invasion and metastasis. The enzymatic activity of uPA is regulated by 
the plasminogen activator-inhibitors PAI1 and PAI2. High levels of uPAH (urokinase- 
type plasminogen activator inhibitor) in ascitic fluid of ovarian cancer patients 
correlate with a good prognosis [Chambers et al., 1995], but high uPA [Konecny et 
al., 2001] and PAH and/or uPA [Kuhn et al., 1999] expression correlate with a poor 
prognosis in advanced stage ovarian cancer in some, but not all studies [van der 
Burg et al., 1996]. A third degradative protein is heparanase, an endoglycosidase for 
heparan sulphate (HS) in glycosaminoglycans, which regulates bFGF and Pas 
released by HS. The proteases and heparanase act in concert to degrade the ECM 
and enable breakthrough of ovarian cancer cells from the tumour bulk, and also 
facilitate the release of cytokines and growth factors that induce proliferation and 
migration of endothelial, mesenchymal and tumour cells. The local stromal 
environment plays a pivotal role in ovarian tumorigenesis, with interactions between 
the different cell types within the tumour and the microenvironment paralleling 
neoplastic change (Figure 1.12).
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Invasion is characterised by cellular movement. Ovarian cancer cells move either by 
passive translocation in response to mechanical pressure or by active migration. In 
many ovarian epithelial tumours, E-cadherin (the adherens junction component) is 
lost, leading to reduced cell-cell adhesion, enabling cells to detach and spread to the 
peritoneum [Fujioka et al., 2001]. Low E-cadherin levels are strong markers of poor 
prognosis [Herrera et al., 2002].
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Figure 1.12. The interplay between epithelial tumour cells and the stroma.
Figure taken from Liotta & Kohn, (2001).
The next stage of dissemination of malignant cells from the primary tumour to 
adjacent tissue or to distant organs via lymphatics or the bloodstream is the hallmark 
of metastasis. Metastasis is the leading cause of death in patients in most epithelial 
malignancies. Haematogenous spread regulated by VEGF controlling angiogenesis 
is well characterised. However, this is not the main route of spread for ovarian 
cancer, and it is possible that lymphangiogenesis plays an even more important role. 
VEGF is known to signal through two tyrosine kinase receptors, VEGFR-1 and 
VEGFR-2, which are expressed primarily but not exclusively on vascular endothelial 
cells. The field of lymphangiogenesis research gained momentum with the discovery 
of a third VEGF receptor, VEGFR-3, which was found to be predominantly expressed
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on lymphatic vessels during development [Kaipainen et al., 1995]. VEGF was not 
found to bind to VEGFR-3, but instead two novel ligands, VEGF-C and VEGF-D were 
found to bind VEGFR-3 [Joukov et al., 1996;Achen et al., 1998]. Researchers have 
shown that VEGFR-3 and its ligands VEGF-C and VEGF-D have an important role in 
tumour-induced lymphangiogenesis and lymphatic metastasis in mouse models 
[Makinen et al., 2001;Stacker et al., 2001]. VEGF-C gene expression in ovarian 
cancer cell lines has been directly correlated with invasion [Ueda et al., 2001], 
suggesting cancers expressing VEGF-C have greater metastatic potential due to 
their ability to stimulate formation of lymphatic endothelia which leads to lymphatic 
tumour cell spread. In addition, increased expression of VEGF-C, VEGF-D and 
VEGFR-3 has been demonstrated in ovarian cancers, and was significantly 
associated with lymph node and peritoneal metastases [Yokoyama et al., 2003]. 
Figure 1.13 shows the VEGF family members and their receptors.
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Figure 1.13. Members and receptors of the VEGF family.
Adapted from Cross et al, (2003).
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1.6 Microarrays
1.6.1 Introduction
The completion of the human genome project will vastly increase our knowledge of 
the genomic sequences of humans and the genes that they encode. Traditional 
techniques for detecting and quantitating gene expression levels include northern 
blots [Alwine et al., 1977], S1 nuclease protection [Berk and Sharp, 1977], differential 
display [Liang and Pardee, 1992], sequencing of cDNA libraries [Adams et al., 
1991;Okubo et al., 1992] and serial analysis of gene expression (SAGE) [Velculescu 
et al., 1995]. These are both laborious and time consuming. With the advent of 
microarray technology, the study of gene function has been revolutionised. The 
expression pattern of thousands of genes can be screened in parallel to give a gene- 
expression or molecular profile of a certain cell or tissue. Microarray technology has 
been advancing rapidly in the past few years, and improvements have been made at 
every step, including array production, probe manufacture, hybridisation, scanning, 
data analysis and data mining.
A major challenge in the postgenomic age is the development of systematic 
approaches for identifying the biological function of all genes. Microarray technology 
provides a major advance toward this goal. It provides a strategy to monitor gene 
expression for tens of thousands of genes in parallel. Because the relative 
abundance of gene expression often reflects specific cellular processes, a sufficiently 
large and diverse set of gene expression profiles from different tissue samples are 
providing insight into gene functions.
Two main DNA microarray technologies have been developed to investigate gene 
expression analysis. These are oligonucleotide-based microarrays and cDNA 
microarrays. These are discussed and compared with emphasis on oligonucleotide 
arrays.
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1.6.2 Comparison Between Oligonucleotide and cDNA Arrays
The basic principle of both types of microarrays is the precise positioning of DNA 
fragments (probes) at high density on a solid support so that they can function as 
molecular detectors. The probe refers to the DNA arrayed since it is equivalent to the 
probe used in a northern blot analysis. Every strand of nucleic acid has the capacity 
to recognise complementary sequences through base pairing. Nucleic acid arrays 
work on the principle that labelled RNA or DNA molecules in solution (target) 
hybridise to DNA molecules attached at specific locations on a surface. This process 
of hybridisation can be highly parallel; every RNA/DNA sequence can be investigated 
simultaneously.
1.6.2.1 Probes
Probes for cDNA arrays are usually PCR products representing specific genes, with 
sequences generated from databases such as GenBank or UniGene, and partially 
sequenced cDNAs (or ESTs) from any cDNA library of interest. The probes are 
robotically printed on to glass slides or nylon membranes as spots at defined 
locations, and are referred to as probe cells. The spots are 100-300pm in size, are 
spaced the same distance apart and contain one single length (up to 1,000 base 
pairs) of double-stranded DNA. Using this technique, glass substrates the size of a 
microscope slide can accommodate approximately 30,000 cDNAs.
Oligonucleotide arrays differ from spotted cDNA arrays in that they utilise short 20- 
25-mer oligonucleotide lengths based on DNA sequences generated from a given 
gene. These can either be synthesised in situ directly on to silicon wafers by 
photolithography (high-density oligonucleotide arrays from Affymetrix, 
http://www.affymetrix.com) or presynthesised then printed on to glass slides. In the 
case of photolithographically synthesised arrays, -107 copies of each selected 
oligonucleotide are synthesised base by base in hundreds of thousands of different 
24pm x 24pm areas on a 1.28 x 1.28 cm glass surface. Because oligonucleotide 
arrays are designed and synthesised based only on information of the DNA 
sequence, physical intermediates such as PCR products and cDNAs are not needed.
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The 25mer oligonucleotides are designed so that they are as unique, sensitive and 
sequence-specific as possible, and as dissimilar to other gene family members, other 
genes and other RNAs which may be present in the sample (e.g. rRNAs, tRNAs and 
mRNA). The arrays are designed in silico (designed by computer programs that 
select the best probes without cross hybridisation to other targets) negating the need 
to prepare, verify, quantitate and catalogue a long list of PCR products and cDNAs. 
In addition, because probes can be designed to represent the most unique part of a 
particular transcript, it is possible to detect closely related genes and splice variants. 
For both types of array, the probes are designed from sequences near the 3’ end of 
the gene (near the poly-A tail in eukaryotic mRNA) in order to decrease problems 
with RNA degradation.
An important feature of oligonucleotide arrays is probe redundancy, where the same 
gene has many oligonucleotides with different sequences designed to hybridise to it. 
This greatly improves the signal-to-noise ratio, improves the accuracy of RNA 
quantitation, prevents effects due to cross-hybridisation and greatly reduces the false 
positive and miscall rates. Another level of probe redundancy is the use of mismatch 
(MM) control probes which are identical to the perfect match (PM) probes except for 
one base pair. This increases specificity by removing background and cross­
hybridisation signals, and enables the array to discriminate between “real” signals 
and those due to non-specific or semi-specific hybridisation. Redundant PM/MM 
probe sets can differentiate whether the intended RNA molecule is generating a 
hybridisation signal; a single spot intensity generated by cDNA arrays is not as 
discriminative.
1.6.2.2 Target Preparation
Oligonucleotide arrays differ to cDNA arrays in the preparation of the target (sample 
of interest). For both types, RNA extracted from cells or tissue, transcribed into DNA, 
labelled, hybridised to the DNA probes on the microarray surface then detected by 
either phosphor-imaging or fluorescence scanning. Oligonucleotide arrays use 
double-stranded cDNA to serve as template for a reverse transcription reaction in 
which labelled nucleotides are incorporated into cRNA. The most commonly used
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label is nonfluorescent biotin which is subsequently labelled by staining with a 
fluorescent streptavidin conjugate. These arrays are very robust and produce highly 
reproducible data, so that signals from separate arrays can be compared with one 
another. In the case of cDNA spotted arrays, however, the process of gridding is not 
accurate enough to allow comparison between separate arrays. Therefore the target 
preparation process involves labelling of two distinct RNA populations by two 
separate fluorescent dyes (the most commonly used are Cy3 and Cy5), mixing and 
hybridisation to the same array.
1.6.2.3 Scanning
After the targets are labelled and hybridised (usually for approximately 16 hours), the 
arrays are scanned. For the oligonucleotide arrays, the light emitted from each probe 
cell is proportional to the bound target at each location, therefore the presence or 
absence of a particular transcript above background and noise levels can be 
assessed. In the case of cDNA arrays, two fluorescent dyes are used, causing 
competitive binding, so the ratio of fluorescence intensities between the two dyes in 
one spot gives information on the extent of up- or down-regulation of a gene.
1.6.3 Data Analysis
Microarray experiments generate vast amounts of data. This is usually in the form of 
long lists of spot intensities and intensity ratios, generated either by comparing 
several samples to a control (oligonucleotide arrays) or by pairwise comparison of 
two samples (cDNA arrays). The aim is then to convert these data into meaningful 
information.
1.6.3.1 Normalisation
The intensity information from the values of each of the probes in a probeset is 
combined together to get an expression measure (MAS 5.0 statistical algorithm from 
Affymetrix 2001). Normalisation is needed when dealing with experiments from more 
than one array. There are two main types of variation, interesting variation and
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obscuring variation. An example of interesting variation is the differences in gene 
expression between normal and malignant tissues. Obscuring variation is that 
introduced by performing the experiments themselves e.g. unequal quantities of 
starting RNA, differences in sample preparation (e.g. labelling) and array processing 
(scanning) and differences in hybridisation efficiency.
Affymetrix normalisation is performed on expression summary values. This approach 
does not work well in the case of non-linear relationships between arrays. Other 
approaches include using non-linear smooth curves [Li and Hung, 2001] and 
transforming the data so that the distribution of probe intensities is the same across a 
set of arrays; both parametric and non-parametric methods can be used to achieve 
this. These approaches depend on the choice of a baseline array.
1.6.3.2 Clustering
Analysing microarray data involves classifying individual genes into a set of 
categories. Some methods classify genes into predefined categories (supervised 
clustering), whereas other methods use categories that are discovered during the 
analysis (unsupervised clustering). Both supervised and unsupervised clustering 
methods assign a category to gene (using expression measurements across array 
experiments), the categories being biological functions of genes or diagnoses 
associated with pathologic specimens.
1.6.3.2.1 Unsupervised Clustering
Unsupervised clustering techniques for analyzing microarrays include hierarchical 
clustering, k-means clustering and self-organising maps. They are useful for initial 
data exploration, and have been validated under certain circumstances by their 
successful "rediscovery" of known classes of genes [Alizadeh et al., 2000;Eisen et 
al., 1998;Wen et al., 1998]. A disadvantage, however is that because prior biological 
knowledge is not incorporated, all measurements within the expression profile 
contribute equally to the analysis. This means that measurements that have little or 
nothing to do with distinguishing the groups of interest can confound the placement
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of a sample into the correct category.
Hierarchical Clustering
Average-linkage hierarchical clustering was the first method to be used for ordering 
microarray data [Eisen et al., 1998]. This approach finds the pair of genes with the 
most similar expression profiles, and iteratively builds a hierarchy by pairing genes 
(or existing clusters) that are most similar. The resulting hierarchy is shown using 
dendrograms. Genes which have similar functions are often co-expressed and so 
cluster together. In this way, the functions of yet uncharacterised genes can be 
assigned based on the functions of genes with which they cluster. This can be 
extended to samples from similar origins, which will cluster together due to their 
expressing similar sets of genes [Perou et al., 1999].
K-means Clustering
K-means clustering requires a parameter, k, which represents the expected number 
of clusters [Tavazoie et al., 1999]. First, cluster centres are chosen at random. Using 
the distance metric, each profile is assigned iteratively to the cluster whose centre it 
is nearest to; then the cluster centre is recalculated depending on the profiles within 
the cluster.
Self-Organising Maps (SOMs)
Self-organising maps are topological neural networks [Tamayo et al., 1999]. Clusters 
are already organised into a “map” where clusters which are similar are topologically 
close together. The number and topology of the clusters are already specified. The 
clustering is similar to the k-means method except that the cluster centres are 
recalculated at each iteration based on the profiles within each cluster as well as the 
profiles in separate clusters.
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1.6.3.2.2 Supervised Clustering
Supervised clustering techniques such as support vector machine (SVM) incorporate 
previous biological knowledge. For example, a supervised approach might be used 
to predict whether a gene is involved in ovarian carcinogenesis by comparing its 
expression profile to the profiles of both genes known to be involved and genes 
known not to be involved in ovarian carcinogenesis. Recent reports have 
demonstrated the ability of supervised classification to assign functions to genes 
[Brown et al., 2000] and to type leukaemia (myeloid vs. lymphoid) [Golub et al., 
1999], based on microarray data.
The main disadvantage of supervised methods is that they are hypothesis driven. If a 
hypothesis is based on prior knowledge, supervised methods will help to accept or 
reject it. They cannot reveal the unexpected and do not form new hypotheses or data 
classifications. For example, if tumours fall into two unanticipated classes on the 
basis of their expression profiles, a supervised method will not be able to discover 
this. Another disadvantage is the possibility of misclassification of samples; 
supervised methods will not discover, in general, samples that were mistakenly 
labelled and used in, say, the training set.
1.6.3.3 Verification of Results
As microarray technology is still in its infancy, the techniques are continually being 
improved. Problems may arise such as probes not detecting the correct transcript 
species as a result of cross-hybridisation or adverse secondary structure. Verification 
of a subset of results by well-established techniques such as quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) or northern hybridisation is 
important. QRT-PCR or Northern blotting is still considered standard to verify array 
data especially where only a few replicates are used. Comparative array analysis 
with other datasets available in the public domain is also helpful to verify array 
results.
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1.6.4 The Application of Microarrays to Cancer Pathways
Gene expression profiling of cancers has expanded greatly in the past few years, 
and is becoming the most comprehensive approach for characterising human 
cancers at a molecular level. Gene expression profiling provides a global overview of 
the mechanisms and pathways involving numerous genes operating at a cellular 
level in many cancers, such as breast, colon, lung, stomach, ovary and head and 
neck. A vast amount of data has been generated, with some of these genes already 
known to be involved in the carcinogenic process, and many whose functions are still 
presently unknown. Similarly, the patterns of expression of genes with a known 
function can reveal information on novel phenotypic features of cells and tissues 
being studied.
1.6.4.1 Cancer Classification
Accurate classification of cancers is vital since correct treatment hinges on detailed 
knowledge of the primary tumour and presence or absence of metastatic spread. 
Until now, diagnosis has been determined histologically by appearance alone. The 
problem with this approach is that tumours, including tumour subtypes with similar 
histopathological appearance can have vastly divergent clinical outcomes and 
responses to treatment. Classification of tumours using gene expression profiles is 
providing a new dimension.
Golub and colleagues were the first to report that the expression patterns of diverse 
classes of genes contained information that could be used to classify tumours, 
specifically leukaemias [Golub et al., 1999]. They suggested a class discovery and a 
class prediction model. Class discovery defines previously unrecognised tumour 
subtypes, and class prediction refers to the assignment of tumours into defined 
categories according to their current state or future outcomes. 38 leukaemia cases 
were taken and analysed by self-organising maps (SOMs) using high-density 
oligonucleotides microarray containing almost 7,000 genes. A distinct molecular 
difference was shown between acute myeloid leukaemia (AML) and acute 
lymphoblastic leukaemia (ALL) based on the gene expression profiles. For class
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prediction, tumours were assigned one of the two groups based on the class 
discovery. For example, one tumour had initially been diagnosed histopathologically 
as AML, but showed atypical morphology. Gene expression profiling demonstrated 
high expression of genes suggesting this was a tumour of mesenchymal origin. 
Subsequent cytogenetic re-analysis confirmed this to be a rhabdomyosarcoma, and 
treatment was changed accordingly. The authors stress that this method is an aid 
rather than a replacement to classic histopathological diagnoses.
A study by Alizadeh and colleagues [Alizadeh et al., 2000] investigated diffuse large 
B-cell lymphoma (DLBCL), an aggressive malignancy of mature B lymphocytes and 
the most common subtype of non-Hodgkin’s lymphoma. Classification of this disease 
based on morphology has been largely unsuccessful, due to lack of agreement on 
histological appearance of possible subtypes. The clinical course is variable: 
although 40% of patients respond well to therapy, 60% do not, and ultimately 
succumb to their disease. Hierarchical clustering identified two molecularly distinct 
groups of DLBCL: the gene expression pattern of one group was indicative of B-cell 
differentiation pattern in germinal centres of lymph nodes, and the other group 
expressed genes induced during in vitro activation of peripheral B cells. Patients with 
the germinal centre B-like DLBCL had a significantly better overall survival rate. This 
study demonstrates that tumours can be classified into previously unrecognised but 
clinically significant subgroups.
Breast cancers are a heterogeneous group of tumours, with several different 
subtypes, with correspondingly variable prognoses. Perou et al [Perou et al., 1999] 
defined a further subtype of oestrogen-receptor negative group with basaloid 
features. Although histopathologists recognise the basaloid breast cancer subset, it 
has never been treated as a distinct clinical entity in clinical practice. This study, 
along with others [Jones et al., 2000;Jones et al., 2001;Tsuda et al., 2000] 
demonstrate that this group of tumours has a different gene expression profile and a 
metastatic pattern similar to ductal carcinomas in general. Microarrays can define the 
gene expression profile of this subset of ductal tumours, and other groups will most 
likely be discovered in the process.
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Ross et al. [Ross et al., 2000] used cDNA microarrays to determine the expression of 
8,000 genes within the 60 cell lines used in the National Cancer Institute screen for 
anticancer drugs. Hierarchical clustering analysis grouped cells of the same tissue 
origin together. Cell lines derived from leukaemia, melanoma, the central nervous 
system, colon, kidney and ovarian tissue clustered in distinct groups. However, 
breast cancer cell lines clustered in many different branches, suggesting a 
heterogeneous pattern of gene expression. Specifically, the profile obtained for two 
related breast carcinoma cell lines, MDA MB435 and MDA-N, which were derived 
independently from the same patient, was similar to that from melanoma cell lines. 
This suggested either that some breast cancers may have expression profiles 
exhibiting neuroendocrine features or that the cell lines are actually derived from a 
melanoma.
Cancers from divergent tissue types can also be classified into groups according to 
their gene expression profile. Taking gene expression profiles of 90 normal tissue 
samples, and 218 tumour samples containing 14 different tumour types, 
Ramaswamy et al showed that these cancers can be classified with an accuracy 
approaching 78% [Ramaswamy et al., 2001]. This group also showed that well 
differentiated tumours differ from poorly differentiated cancers, and very highly 
related tumour types are harder to classify. Another similar study looking at GEM 
profiles of 175 carcinomas from different tumour types used supervised machine 
learning algorithms to first filter genes not involved in tumour classification, then 
ranked the remaining genes according to their contribution to predict tumour types to 
classify these tumours [Su et al., 2001]. This approach allowed the prediction of 
tumour origin of 90% of the tumours studied.
1.6.4.2 Identification of Metastatic Markers
The pathways involved in invasion and progression of disease are poorly 
understood. Identification of genes responsible for metastasis can lead to the 
development of drugs aimed at preventing the expression of these genes and thus 
individualising patient treatment. The following microarray studies have shed some 
light on the identification of potential key regulators of human cancer.
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A gene involved in the metastasis of melanoma, RhoC has been identified [Clark et 
al., 2000]. Highly metastatic melanoma cell lines were compared with non-metastatic 
lines. GEM profiling revealed a cluster of genes, including RhoC which were over­
expressed in metastasis. Functional studies demonstrated that RhoC over­
expression facilitated metastasis whereas dominant-negative RhoC inhibited 
metastasis in animal models. The authors concluded that RhoC may regulate 
invasion by triggering cytoskeletal organisation in response to signals stimulating cell 
motility. Drugs targeted towards RhoC could be used to reduce the spread of primary 
melanoma.
Prostate cancer is one of the most common cancers in men. It is histopathologically 
heterogeneous with a clinically diverse outcome, and is almost incurable once 
metastasised. Dhanasekharan et al have described a molecular signature for 
prostate cancer progression by comparing the gene expression profiles of normal 
prostate, primary prostate cancers and metastatic prostate samples [Dhanasekaran 
et al., 2001]. 55 genes were found to be over-expressed in metastatic specimens, of 
which the Polycomb protein enhancer of zeste homologue 2 (EZH2) was the most 
significantly up-regulated. In a follow-up study by the same group of researchers, 
EZH2 was further investigated and confirmed to be more highly expressed in 
metastatic prostate tissue than benign tissue [Varambally et al., 2002]. When 
expression of EZH2 was inhibited using small interfering RNA (siRNA), cellular 
growth of prostate cancer cells was significantly reduced. High EZH2 expression was 
correlated with poor prognosis. This suggests that EZH2 is a good marker for 
prostate cancer invasion and metastasis by its role in regulating cell growth. Drug 
treatment targeted against EZH2 may prevent metastatic spread of prostate cancer.
Breast cancer is one of the commonest cancers in women. The presence of lymph 
node metastases at the time of primary surgery is currently used to determine 
whether patients require adjuvant treatment in the form of cytotoxic or radiation 
therapy. These are associated with significant side-effects, and identifying in situ 
disease which is likely to metastasise is invaluable in improving quality of life for 
patients. Van’t Veer and colleagues performed microarray studies on 78 breast 
cancers from patients with no lymph node metastases who had not received adjuvant
65
therapy ['t Veer et al., 2002]. These patients were followed up and a gene expression 
profile was generated to differentiate between tumours which went on to metastasise 
and those which did not. A “poor prognosis signature” comprising 70 differentially 
expressed genes was generated. This prognosis signature was then tested on 
another group of newly diagnosed breast cancer patients and accurately predicted 
disease outcome. The authors concluded that the signature for poor prognosis is 
already present in primary tumours, and this can be used at the time of initial surgery 
to predict survival. Such studies in the future may help to identify women with early 
breast cancer who will benefit from adjuvant chemotherapy after initial local 
treatment. However, there is currently a debate regarding the validity of the analysis 
used by V’ant Veer and colleagues to identify this high risk group.
Cancers in children can be devastating. Medulloblastoma is one such tumour; it is a 
highly metastatic cancer of the brain which is often difficult to distinguish 
histopathologically from other tumours. It is a lethal cancer due to its propensity for 
spread, and there is a need for reliable molecular markers that can distinguish this 
cancer from the non-metastatic types. MacDonald and colleagues used gene 
expression profiling to identify genes differentially expressed between the metastatic 
and non-metastatic medulloblastomas [MacDonald et al., 2001]. They found that 
platelet-derived growth factor receptor a (PDGFRa) and members of the Ras/MAPK 
(mitogen activated protein kinase) downstream pathway were slightly over-expressed 
in the metastatic tumours both at the RNA and protein levels. Functional studies 
demonstrated reduction of cell adhesion and migration in a medulloblastoma cell line 
in response to inhibitors of PDGFRa and the Ras/MAPK pathway. These findings 
suggest that PDGFRa and the Ras/MAPK pathway are involved in metastatic spread 
and that inhibitors of this pathway can be exploited for the treatment of 
medulloblastoma.
Potentially more effective drugs can be designed by using large-scale studies 
correlating gene expression profiles with drug responses [Scherf et al., 
2000;Zembutsu et al., 2002]. Gene expression profiling can be used to monitor, 
validate and improve cancer drugs. Studies have been performed aimed at 
monitoring the metabolism and toxicology of anticancer therapies [Zhou et al.,
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2002;Gerhold et al., 2001]. Other studies have identified the cellular targets of drugs 
and delineated the molecular mechanisms of drug action [Dimitroulakos et al., 
2002;Chang et al., 2002]. These data should contribute to new drug design which is 
individually tailored to patients with minimum of adverse drug events.
1.6.4.3 Gene expression profiling of ovarian tumours
A series of studies have been performed investigating the gene expression profiles in 
ovarian cancers. These have been for the purpose of gaining insight into the 
progression pathway of ovarian carcinogenesis [Tapper et al., 2001;Matei et al., 
2002;Jazaeri et al., 2003;Shridhar et al., 2001] and also for discovering gene 
products that can act as ovarian cancer specific markers and used for screening.
1.6.5 The Use of Microarrays in Ovarian Cancer
1.6.5.1 Understanding Ovarian Carcinogenesis
The molecular pathways crucial for initiation and progression of EOC remain largely 
unknown. Prognosis for EOC differs according to histological subtype, grade and 
stage of disease. Gene expression profiling may contribute to our knowledge and so 
improve patient outcome after treatment. Tapper and colleagues have attempted to 
define genes involved in ovarian cancer progression [Tapper et al., 2001]. They 
compared gene expression profiles from benign, local highly differentiated and 
advanced ovarian serous adenocarcinomas. The most significantly up-regulated 
gene between local, well-differentiated and benign tumours was cell division cycle 42 
(cdc42) homologue, and that between local and advanced tumours was collagen 
type III alpha 1 (COL3A1) also known as type III or fetal collagen. Whilst this is a very 
good attempt at defining genes along the progression pathway, it assumes that 
benign tumours are a pre-malignant lesion, which is not the generally accepted view.
Ovarian cancer stage is one of the most important independent prognostic indicators; 
Shridhar et al compared GEM profiles of five stage I, two stage II and seven stage III 
ovarian cancers with normal ovary [Shridhar et al., 2001]. Hierarchical clustering
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showed a clear distinction between normal and malignant tissues, although the 
tumour stages did not cluster together, and the gene expression profiles of early and 
late stage tumours were essentially the same, suggesting that a malignant signature 
is present at an early point in carcinogenesis. Comparative genomic hybridisation 
(CGH) analysis was performed in order to investigate whether any of the results from 
the GEM analysis could be correlated with genomic alterations, and showed that the 
main difference was regional gain and/or amplification in late-stage tumours. The 
inconsistency in the microarray and CGH data could be attributed to epigenetic 
mechanisms such as CpG island methylation, which have previously been reported 
to be early events in ovarian tumorigenesis [Cheng et al., 1997]. These are early 
studies with small sample sizes and need to be confirmed in larger prospective 
studies where known prognostic indicators e.g. tumour grade are taken into account. 
However, these studies do suggest that genes identified by microarrays play an 
important role in the future in the prognostic classification of early ovarian cancer.
Well differentiated tumours are generally thought to have a better prognosis than 
undifferentiated cancers. Two groups [Matei et al., 2002;Jazaeri et al., 2003] 
compared the GEM profiles of grade 1 and grade 3 serous adenocarcinomas. 
Different genes were identified by each group, with serine/threonine protein kinase 
15 (STK15) and runt-related transcription factor 2 (runx2 or OSF2) being the two 
most up-regulated genes in grade 3 compared to grade 1 tumours.
1.6.5.2 Ovarian Cancer Biomarkers
Ovarian cancer presents late due to a lack of symptoms at an early stage, and the 
lack of an effective screening strategy. It is likely that advanced ovarian cancer is a 
different disease from limited disease. The initial genetic events leading to 
uncontrolled cell growth in tumours that present as advanced disease might also 
confer to those cells the propensity for early invasion and aggressive clinical 
behaviour. Therefore, screening strategies to detect early disease may not be that 
successful. Having said that, CA125 is currently the only marker in general use for 
ovarian cancer screening, but is neither sensitive nor specific enough to be used as a 
population based screening tool.
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The circulation tumour antigen, CA125 is currently the only marker in general use for 
ovarian cancer screening, but is neither sensitive nor specific enough to be used as a 
population based screening tool. CA125 is elevated in only 50% of stage I tumours, 
so many microarray studies have been directed at discovering new potential 
biomarkers for ovarian cancer which can be used either alone or in conjunction with 
CA125 or other molecular markers.
Welsh et al compared normal ovarian tissue with serous papillary adenocarcinomas 
using oligonucleotide arrays and also included ovarian cancer cell lines, and RNA 
from endothelial and activated B cells to control for blood vessels and infiltrating 
immune cells [Welsh et al., 2001]. Genes most highly expressed in ovarian tumours 
were CD24, HE4, CD9 with tumour-associated antigen GA773-2 (TACSTD1), 
cytokeratins 7,8,18 and 19 and mucin-1 (MUC-1) also being highly up-regulated. 
Ismail et al also compared normal ovary with papillary serous ovarian 
adenocarcinomas, but in this case using primary cultures [Ismail et al., 2000]. There 
is always some concern where cell lines are used as short-term culture may favour 
the growth of only a subset of epithelial cells. However, they identified osteoblast 
specific factor-2 (OSF-2) as a highly ranked gene in primary ovarian cancers. Follow- 
on studies are needed to verify that these genes are up-regulated only in primary 
cancers and not, as is the case for CA125, in a multitude of benign conditions.
Three other studies have also compared normal ovarian tissue with ovarian cancers. 
HE4, matrix metalloproteinase 7 (MMP7 or PUMP1), progesterone binding protein, 
ryudocan, MUC-1, membrane protein E16 and BA46 were reported as over­
expressed in the cancer group. However, the cancers represented a mixed 
population of different EOC subtypes and stages, each of which have widely varying 
clinical outcomes. Therefore only broad conclusions can be drawn from these studies 
[Wang et al., 1999;Schummer et al., 1999;Tonin et al., 2001].
The only study so far to verify biomarkers identified in microarray experiments 
serologically investigated the potential use of prostasin [Mok et al., 2001b]. This 
potential marker was found to be raised in the sera of patients with serous ovarian 
cancer and only marginally raised in mucinous or LMP tumours. It proved to have low
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sensitivity in early-stage disease, and was found to have no correlation with CA125. 
The authors suggest combining the two markers could increase the sensitivity; based 
on screening of 37 patients and 100 controls, a sensitivity of 92% was achieved 
(95% confidence interval (Cl) 78.1-98.3%) and a specificity of 94% (95% Cl 87.4- 
97.7%). This compared with sensitivities of 51.4% (95% Cl 34.4-68.1%) for prostasin 
and 64.9% (95% Cl 47.5-79.8%) for CA125 for a specificity of 94% for prostasin. The 
authors only tested this marker in patients with benign or malignant gynaecological 
conditions. Prostasin can be found in eight normal human tissues: prostate, kidney, 
liver, pancreas, salivary gland, lung, bronchus and colon, so whether it functions as a 
good screening marker remains to be determined.
Microarrays contain thousands of genes and ESTs which represent many different 
gene functions and are involved in numerous pathways. Not all of these are relevant 
to the study of ovarian cancer. Based on findings from SAGE analysis of up- 
regulated genes in ovarian cancer [Hough et al., 2001] and other cDNA array data, 
Sawiris et al have produced the “Ovachip” which consists of 516 cDNA clones 
[Sawiris et al., 2002]. This specialised array does not include irrelevant genes which 
may contribute to biological noise affecting data analyses. However, this assumes 
that all genes thought to be involved in ovarian carcinogenesis have been identified, 
and may miss vital new genes as yet not discovered.
Many studies have investigated the gene expression profile of ovarian cancer using 
microarray technology. Most studies use snap frozen fresh tissue for analysis, 
commonly ovarian serous adenocarcinomas. Results from cell lines give varying 
results, especially as there are significant differences in the gene expression profiles 
of cell lines according to the length of time they have been in culture [Santin et al.,
2004].
A wealth of data has been generated from studies investigating the gene expression 
profiles to differentiate serous adenocarcinoma from normal ovarian tissue, with 
many upregulated genes being involved in cell growth, differentiation, adhesion, 
apoptosis and migration [Donninger et al., 2004;Meinhold-Heerlein et al., 2005;De et 
al., 2004]. Specifically, creatine kinase B [Huddleston et al., 2005], KLK10
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[Shvartsman et al., 2003], osteopontin [Kim et al., 2002b] and FGF2 [De et al., 2004] 
have been proposed as putative novel targets to be further investigated as useful 
markers for ovarian cancer.
Patients with stage 11 I/I V ovarian cancer who respond well to chemotherapy have an 
improved survival than those who respond badly. Studies have identified a gene 
expression signature which distinguishes short-term (<2-3 years) from long-term (>7 
years) survivors [Berchuck et al., 2005], with many of the genes identified being 
involved with immune function [Lancaster et al., 2004]. The expression pattern for 
long-term survivors was similar to a set of stage I/ll cancers, suggesting a common 
favourable biology. In addition The MAL gene, known to be associated with 
chemoresistance was highly expressed in short-term survivors[Berchuck et al.,
2005].
One of the aims of identifying putative markers is to test them either individually or as 
a on a panel of serum markers in order to test whether they can be used to for 
screening of early stage disease. Mor et al tested osteopontin, insulin-like growth 
factor-11, leptin and prolactin and found that any protein individually could not 
distinguish patients with ovarian cancer from those unaffected, but in combination 
could detect the disease with a sensitivity of 95%, a specificity of 95% and a positive 
predictive value of 95% [Mor et al., 2005].
1.6.6 Access to Array Databases
With the enormous amount of data generated from DNA microarray experiments, it 
would be reasonable to conclude that this information should be available in the 
public domain, in order that a re-analysis may be performed by other researchers, to 
verify the original claims, but more importantly to compare these findings with their 
own datasets. This would be best accomplished by posting raw data in a centralised 
public database. In fact, some DNA databases have been generated, due to the 
requirement of certain scientific journals that DNA sequence data are sent to 
GenBank prior to submission of an article.
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Obviously, not all data generated can be compared equally because different arrays 
may be used in different experiments, with different probes for the same gene.
Accession numbers are used to identify genes, and these vary between 
organisations according to which array is being used. Therefore it is imperative to 
confirm that the same genes are being compared. Normalisation of arrays may differ, 
and this must be checked by a trained bioinformaticist. However, even if global 
normalisation is implemented, the actual intensity values for the same gene may 
vary.
Difficulties arise when comparing high-density oligonucleotide arrays and cDNA 
arrays. Oligonucleotide arrays generate robust data and more reproducible results 
than cDNA arrays, where the absolute hybridisation intensities often vary due to 
differences in the amount of DNA deposited on the array for various genes.
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1.7 Screening for Ovarian Cancer
Given the poor prognosis associated with the development of advanced ovarian 
cancer and the clear increased survival at early stage disease, there has been much 
enthusiasm for the development of effective screening strategies aimed at early 
detection. There is currently no evidence to justify mass population screening; 
however, concentrating on subpopulation screening, identification of novel 
serological biomarkers, and multimodality screening with transvaginal ultrasound 
(TVS) and novel imaging, it is hoped that these refinements may eventually translate 
into a reduction in ovarian cancer mortality.
Many features of ovarian cancer have led to the frustrations encountered in 
attempting to screen for the disease; the anatomical location of the ovaries means 
they cannot be directly inspected, and epithelial ovarian cancers have no defined 
precursor lesion and a poorly defined natural history. The time required for localised 
disease to progress to disseminated disease is not known, so it is unclear what the 
screening interval should be. The low prevalence of ovarian cancer in the general 
population means that screening must have a very high specificity in order to avoid 
unnecessary surgical interventions. Suboptimal specificity will lead to high financial 
and personal costs that may not be acceptable when balanced against the benefits 
of screening. Therefore routine screening for ovarian cancer is currently not 
recommended, but studies are underway to identify new screening modalities and 
novel applications for screening regimens in high-risk populations.
Serum CA125 is the tumour marker which has been most extensively studied in 
ovarian cancer screening. Bast et al discovered that serum levels of CA-125 were 
elevated in 82% of women with advanced ovarian cancer but in less than 1% of 
presumed healthy women and it was suggested that it could be used as a serum 
marker for EOC [Bast, Jr. et al., 1983]. Soon afterwards, the JANUS study showed 
encouraging evidence that CA125 levels increase for a period of time before the 
development of clinically apparent ovarian cancer [Zurawski, Jr. et al., 1988]. Despite 
these findings, the usefulness of CA125 in detecting preclinical ovarian cancer is 
limited by a lack of sensitivity in stage I disease and poor specificity in that the
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marker is elevated in numerous benign and malignant conditions such as 
endometriosis, fibroids and any condition leading to peritoneal inflammation [Jacobs 
and Bast, Jr., 1989].
Despite these drawbacks, two large European screening trials have been completed 
that evaluate CA125 as a first-line test, with TVS being performed in cases where 
CA125 is raised. The first of these trials was reported by Einhorn [Einhorn et al., 
1992]. In this trial, 5500 women were screened initially with CA125; 175 women had 
elevated levels and were followed up with serial CA-125 and TVS. 16 laparotomies 
were performed on those with abnormal results, with 6 cases of ovarian cancer 
detected, distributed evenly between stages I, II, and III. Three cases of ovarian 
cancer were diagnosed in the control group. The other large study was reported by 
Jacobs [Jacobs et al., 1993] which involved 22,000 healthy postmenopausal women. 
Again patients with elevated CA125 underwent subsequent TVS. 11 ovarian cancers 
were diagnosed for 41 laparotomies performed. However, eight women with negative 
screens subsequently developed ovarian cancer. As CA125 has insufficient 
specificity, sensitivity, and predictive values, algorithms incorporating age and rate of 
change of CA125 have been developed in order to improve the performance of 
CA125 as a screening tool [Skates et al., 1995].
TVS has been investigated as a tool for ovarian cancer screening. Van Nagell et al. 
[van, Jr. et al., 1990] reported on one thousand asymptomatic women over forty 
years of age who underwent TVS screening. Of these, 31 had abnormal scans and 
24 patients underwent laparotomy. One Krukenberg tumour was found, but no cases 
of primary ovarian carcinoma were detected. Given the unacceptable number of 
laparotomies performed to detect one case of malignancy, subsequent studies have 
focused on postmenopausal populations and defining ovarian scan morphology [van, 
Jr. et al., 1991;DePriest et al., 1993]. The same researchers have reported on the 
results of annual TVS screening performed on 14,469 asymptomatic women [van, Jr. 
et al., 2000]. In this report, 57,214 scans were performed, and 180 patients 
underwent laparotomy for 17 ovarian cancers detected: 11 stage I, 3 stage II, and 3 
stage III. In this study, TVS as a screening modality gave a sensitivity of 81%, 
specificity of 98.9%, positive predictive value of 9.4%, and negative predictive value
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of 99.97%. Excluding cases of nonepithelial and low malignant potential (LMP) 
tumours, the survival of patients with ovarian cancer in the annually screened 
population was 92.9% at 2 years and 83.6% at 5 years. This study was, however, not 
randomised so any assessment regarding the possible reduction in risk of mortality 
cannot be made. However, the financial and personal cost of annual TVS screening 
and subjecting 10 women to a surgical intervention to identify one cancer, make 
population screening with TVS as a single modality unacceptable.
More recent screening trials have focused on multimodal screening designs. Jacobs 
reported the results of the first completed randomised trial of ovarian cancer 
screening [Jacobs et al., 1999]. This prospective study included 22,000 
postmenopausal women aged over 45 who were randomised either to screening 
(10,997 women) or follow-up with no screening (10,958 women). The primary screen 
in this study consisted of serum CA125 measurement. Women who were found to 
have a CA125 level of over 30l)/ml were asked to attend for an ultrasound scan. At 
the beginning of the study the scans were performed abdominally and when TVS 
became available this was the preferred route. 468 women with a CA125 level above 
30U/ml underwent a total of 781 scans. 29 women underwent surgery, with 6 cases 
of ovarian cancer diagnosed, 3 stage I/ll, and 3 stage III cancers. The remaining 23 
women had false-positive results with benign conditions such as benign ovarian 
tumours and fibroids. Four operations were performed for each cancer detected, 
giving a positive predictive value of 21. A further 10 women developed ovarian 
cancer after the period of screening during the 8 year follow-up, bringing the total to 
16 in the screened group. 20 women in the control arm were diagnosed with ovarian 
cancer. The prevalence in the 2 groups was not significantly different, with stage 
distribution and histological type of cancer being similar, but the cancers in the 
screened group were of a lower grade. Although the mortality did not differ 
significantly between the 3 groups, this study was conducted primarily as a basis of 
the feasibility of multi modal screening with CA125 and ultrasound scanning. 
Compliance was good, with 86% of women attending for at least one screen. This 
has prompted the initiation of a large randomised trial, the UK Collaborative Trial of 
ovarian cancer screening (UKCTOCS). The aim is to recruit 200,000 
postmenopausal women aged between 50 and 74 years who will be randomised in a
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1:1:2 ratio to one of 3 arms: ultrasound scan alone, multimodal screening using an 
algorithm for risk of ovarian cancer and a control group. The screened groups will 
undergo 6 screens at annual intervals. The 2 screening strategies will be compared 
in order to evaluate the benefit of adding CA125 measurement to the screening 
procedure. The primary end point will be ovarian cancer mortality 7 years after 
randomisation, with the data being accrued by postal questionnaire and through the 
cancer registry. The results of this trial will provide invaluable information as to the 
benefit of screening employing current tools, in the general population.
Serum markers other than CA125 have been evaluated. Lysophosphatidic acid 
(LPA) was assessed in a small pilot series; LPA levels were elevated in 90% of stage 
I ovarian cancers and in 100% of patients with stages 11—IV [Xu et al., 1998]. Larger 
studies are needed to fully evaluate the usefulness of LPA.
To date, strategies for ovarian cancer screening have had inadequate sensitivity and 
specificity to justify population screening. Efforts aimed at the development of new 
screening strategies, identification of novel serum biomarkers and preventative 
measures are urgently needed; if successful, these strategies and measures could 
have a substantial impact on the lives of women.
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A ims O f T his T hesis
Epithelial ovarian cancer has the highest mortality rate of the gynaecological 
cancers. Approximately 75% of women have advanced stage disease at the time of 
diagnosis. Despite aggressive surgery and improvements in chemotherapeutic 
regimes, the prognosis for these women has remained poor over the past 20 years, 
at around 25% 5 year survival. This is due in part to the lack of effective prevention 
or molecular markers for early stage detection. When detected at stage I, the survival 
rate is around 95%. Clearly, improvements in early detection of this disease are 
paramount.
The aim of this thesis is to identify a gene expression profile for serous epithelial 
ovarian cancer which contributes to the understanding of ovarian cancer and which 
reveals putative novel tumour markers.
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C hapter  2
Materials  A nd M ethods
2.1 Clinical Samples
2.1.1 Collection of Clinical Samples
Clinical samples were obtained at the time of surgery at both University College and 
Royal Free Hospitals. As soon as the specimen was removed from the patient, a 
small representative biopsy from the tissue concerned was cut, placed in a sterile 
container and then immediately into dry ice (at -80°C). The samples were labelled 
then stored in a -80°C freezer until the histology report was available. 47 samples of 
ovary and omentum in total were collected. All patients were undergoing primary 
staging laparotomies prior to chemotherapeutic intervention. This study was only 
concerned with investigating stage INC malignant serous cystadenocarcinomas 
where the corresponding omentum was available; therefore many samples had to be 
discarded as the pathology report showed they represented other histologies. The 
details are summarised in Table 2.1. Eleven patients were diagnosed with stage INC 
serous adenocarcinoma of the ovary and were therefore used in the study; 18 
patients had other malignant histology and 10 patients had benign histologies. In 
addition, biopsies of 8 normal ovaries from patients undergoing elective surgery (total 
abdominal hysterectomy and bilateral salpingoophorectomy) for benign conditions 
were collected, where no abnormality was detected in the ovaries, uterus, cervix and 
fallopian tubes.
Ovarian epithelium was macrodissected from the underlying stroma in the normal 
ovaries for subsequent analysis. For the real-time quantitative RT-PCR data three 
serous tumours of low malignant potential were used in addition, which were 
obtained from the tumour bank at the Royal Free Hospital School of Medicine and 
these were gifts from Dr. Christopher Perrett.
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Sample Histology Stage Summary
1 Mucinous cystadenocarcinoma of the ovary NIC M
2 Serous cystadenocarcinoma of the ovary IMA
3 Clear cell carcinoma of the ovary NIC M
4 Normal ovary - N
5 Benign serous adenoma of the ovary - B
6 Primary fallopian tube carcinoma INC M
7 Mucinous cystadenocarcinoma of the ovary NIC M
8 Normal ovary - N
9 Normal ovary - N
10 Benign fibroadenoma of the ovary - B
11 Serous cystadenocarcinoma of the ovary NIC ✓
12 Serous cystadenocarcinoma of the ovary INC ✓
13 Mucinous cystadenocarcinoma of the ovary IIC M
14 Borderline serous adenocarcinoma of the ovary IIC M
15 Serous cystadenocarcinoma of the ovary NIC ✓
16 Serous cystadenocarcinoma of the ovary NIC ✓
17 Normal ovary - N
18 Serous cystadenocarcinoma of the ovary NIC ✓
19 Primary fallopian tube carcinoma MIC M
20 Normal ovary - N
21 Benign serous adenoma of the ovary - B
22 Benign mucinous adenoma of the ovary - B
23 Mucinous cystadenocarcinoma of the ovary NIC M
24 Serous cystadenocarcinoma of the ovary NIC ✓
25 Endometrioid Adenocarcinoma of the ovary NIC M
26 Endometrial sarcoma II M
27 Benign serous adenoma of the ovary - B
28 Serous cystadenocarcinoma of the ovary NIC /
29 Endometrioid Adenocarcinoma of the ovary NIC M
30 Normal ovary - N
31 Borderline serous adenocarcinoma of the ovary I M
32 Mucinous cystadenocarcinoma of the ovary NIC M
33 Mucinous cystadenocarcinoma of the ovary NIC M
34 Serous cystadenocarcinoma of the ovary NIC ✓
35 Benign serous adenoma of the ovary - B
36 Mucinous cystadenocarcinoma of the ovary NIC M
37 Benign mucinous adenoma of the ovary - B
38 Serous cystadenocarcinoma of the ovary NIC ✓
39 Normal ovary - N
40 Normal ovary - N
41 Brenner tumour of the ovary - B
42 Benign fibroadenoma of the ovary - B
43 Clear cell carcinoma of the ovary NIC M
44 Serous cystadenocarcinoma of the ovary NIC S
45 Benign serous adenoma of the ovary - B
46 Borderline mucinous adenocarcinoma of the 
ovary
IA M
47 Mucinous cystadenocarcinoma of the ovary IIA M
Table 2.1. Summary of all ovarian samples collected from theatre.
Histologies were available from the Pathologist approximately 1 week after collection from theatre. 
Those samples showing entirely normal ovaries with no co-existing pathology were included, as 
were stage MIC serous cystadenocarcinomas of the ovary where samples of metastasis (omentum) 
were also available.
s  Malignant histology suitable for this study (11)
B Benign histology (10)
M Other malignant histology (18)
N Normal ovary (8)
The number of suitable samples included 11 pairs of serous cystadenocarcinoma of 
the ovary and the corresponding omentum from the same individual (Table 2.2) and 
8 normal ovaries (Table 2.3). These samples were used for analysis in this study. 
Ethical approval was granted by the University College Hospitals Trust, and 
preoperative informed consent was obtained from each patient.
In total, 73 samples of ovary and omentum were collected from 47 patients. 39 
patients underwent primary debulking surgery for presumed ovarian cancer prior to 
receiving chemotherapy. I was able to obtain both ovary and omentum samples from 
26 patients, the remaining 13 patients I obtained only ovarian biopsies. Of the 26 
patients, 11 had serous adenocarcinoma and were used in the experiments. 8 
patients underwent hysterectomies for benign conditions and were used as the 
normal ovarian controls.
Sample Histology Tissue adequate 
quality for 
analysis
Designation for 
purpose of study
2 Serous cystadenocarcinoma of the ovary
11 Serous cystadenocarcinoma of the ovary 01, M1
12 Serous cystadenocarcinoma of the ovary
15 Serous cystadenocarcinoma of the ovary 02, M2
16 Serous cystadenocarcinoma of the ovary 03, M3
18 Serous cystadenocarcinoma of the ovary
24 Serous cystadenocarcinoma of the ovary ✓ 04, M4
28 Serous cystadenocarcinoma of the ovary
34 Serous cystadenocarcinoma of the ovary 05, M5
38 Serous cystadenocarcinoma of the ovary
44 Serous cystadenocarcinoma of the ovary 06, M6
Table 2.2. Samples (n=11) with histology showing stage MIC serous cystadenocarcinoma of the 
ovary appropriate for analysis from initial group collected
All samples were grade 3, stage MIC cancers. 0=primary ovarian cancer, M=metastasis
Sample Histology Tissue adequate 
quality for 
analysis
Designation for 
purpose of study
4 Normal ovary ✓ N1
8 Normal ovary
9 Normal ovary
17 Normal ovary ✓ N2
20 Normal ovary ✓ N3
30 Normal ovary
39 Normal ovary s N4
40 Normal ovary N5
Table 2.3. Samples (n=8) with normal histology identified for analysis from initial group 
collected
N=normal ovary
80
2.1.2 Histopathological Verification
Each piece of tissue used for subsequent microarray analysis was embedded in 10% 
buffered formalin and 4pm thick paraffin sections were cut using a microtome in the 
laboratory of Dr. Ming Du. These sections were stained with haematoxylin and eosin 
(H&E) stain as below. H&E-stained sections were initially examined and verified 
histopathologically to be stage ill serous adenocarcinomas of the ovary, then 
reviewed by the Pathologist Dr. Flanagan at the MDT meeting and the histology 
confirmed. The percentage of tumour cells in each tissue block was estimated; all 
samples comprised at least 70% tumour, except one omental sample which had 5% 
tumour content. The normal ovarian samples were verified to be free of any 
pathology, including benign cysts.
2.1.2.1 Haematoxylin and Eosin Staining Protocol
1. Sections were dewaxed and re-hydrated.
2. They were then placed in haematoxylin solution for 5-10 minutes.
3. Sections were washed in running H2 O.
4. Sections were differentiated in 1 % acid-alcohol and then washed well in H2 O.
5. Sections were rinsed ('blued') in ammonia H2 O for 1 minute.
6. Then briefly rinsed in distilled H2 O.
7. Counterstaining was performed with eosin for 2-5 minutes.
8. Sections were washed well in H2 O.
9. Finally, sections were dehydrated, cleared and mounted in neutral mounting 
medium.
2.1.3 Microdissection
Frozen tissue was taken and mounted in Tissue-Tek® O.C.T. compound embedding 
medium (Electron Microscopy Sciences, Washington, USA). Consecutive sections 
6pm thick of frozen tissue were cut in a cryomicrotome at -20°C. The first and final 
sections were stained with H&E as described above and were used to identify the 
location of target cells. Microdissection of neoplastic cells was carried out using
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sterile needles under a dissecting microscope. Target cells were recovered from a 
minimum of 10 consecutive sections. The microdissected cells were transferred into 
a sterile microtube containing RNAIater® which immediately inactivates RNases and 
stabilizes RNA within tissues or cells. RNA is stable for 1 day at 37°C, 1 week at 
25°C, 1 month at 4°C or indefinitely at -20°C.The cells were then either used the 
same day for RNA extraction, or frozen at -20°C for later use.
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2.2 RNA Sample Preparation
2.2.1 RNA Extraction
30mg of tissue was sharply dissected from the tissue mass, placed in 600pl RNeasy 
lysis buffer (buffer RLT, Qiagen, UK) and allowed to thaw on ice. It was then 
disrupted and homogenised using a rotor-stator homogeniser for up to 1 minute at 20 
second bursts, and further homogenised by passing the lysate through a 
QIAshredder column by centrifugation (14,000g for 2 minutes). Total RNA was 
extracted from this tissue using the RNeasy Mini protocol (Qiagen, UK). The lysate 
was further centrifuged at 14,000g for 3 minutes, and the supernatant transferred into 
a new microcentrifuge tube and the pellet discarded. 600pl of 70% ethanol was 
added and the solution immediately mixed. 700pl of the sample at a time was applied 
to an RNeasy mini spin column placed in a 2ml collection tube and centrifuged at 
14,000g for 15 seconds. After each centrifugation step the flow-through was 
discarded. The column was washed once with 700pl buffer RW1 and then twice with 
500pl buffer RPE. The first 2 washes were centrifuged at 14,000g for 15 seconds, 
and the final wash for 2 minutes in order to dry the RNeasy silica-gel membrane. 
Total RNA was eluted by applying 50pl diethylene pyrocarbonate (DEPC)-treated 
distilled water (add 0.1% DEPC (v/v), shake, incubate at 37°C for 16 hours, then 
autoclave), and centrifuging at 14,000g for 1 minute.
2.2.2 RNA Quantification Using the Agilent 2100 Bioanalyzer
The concentration and purity/integrity of the RNA was checked using the Agilent 
2100 Bioanalyzer (Agilent Technologies, CA, USA) and RNA 6000 LabChip® kit 
(Caliper Technologies Corp., CA, USA). The Bioanalyzer is shown in Figure 2.1. The 
traditional methods for analysing the quality of total RNA preparations is by agarose 
gel electrophoresis using ethidium bromide staining; the concentration of the purified 
RNA is calculated from the UV absorbance at 260nm using a UV spectrophotometer 
and the purity of RNA measured by the ratio of the absorbencies at 260nm and 
280nm, taking an absorbance of 1cm'1 to be equivalent to 40pg/ml RNA. The main 
disadvantage of these techniques is that significant amounts of sample are required,
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and RNA extraction of fresh tissue does not always yield much RNA. Therefore the 
Bioanalyzer was used which offers several advantages; a small amount of sample is 
required, there is minimal manual handling of the RNA sample, and the data is 
analysed quickly and accurately. The RNA 6000 LabChip kit was used in conjunction 
with the Bioanalyzer to measure both the quantity and the integrity and purity of the 
RNA samples. The ratio of the 18s and 28s ribosomal RNA bands is determined and 
displayed with the RNA quantitation data on the electropherogram. RNA was initially 
checked using both gel electrophoresis then the spectrophotometer, and the Agilent 
bioanalyzer in order to ensure replication of results. The bioanalyzer was used in all 
subsequent analyses.
Figure 2.1. Agilent 2100 Bioanalyzer machine 
and accompanying laptop.
Taken from www.agilent.com.
All chips were prepared according to the instructions in the chip preparation protocol 
provided with the RNA 6000 LabChip kit. Figure 2.2 shows the RNA 6000 LabChip. 
The kit contains most of the required components: 25 chips, syringe, spin filters, and 
reagents: sample buffer, gel matrix and dye concentrate. The reference ladder used 
was the RNA 6000 ladder (Ambion, Inc. Huntingdon, UK). Firstly, the gel-dye mix 
was prepared by mixing 65 pi of the gel matrix with 1 pi of dye concentrate, and 
centrifuged at 13000g for 10 minutes. 9.0 pi of the gel-dye was pipetted into the three 
gel-dye wells. 5 pi of the sample buffer (RNA 6000 Nano Marker) was added to each 
sample well and the ladder well. 1 pi of RNA sample (up to 12 samples can be run on 
the chip simultaneously) in the concentration range of 10 to 500 ng/pl were loaded 
into the sample wells of the chip. Finally, 1 pi of heat denatured RNA 6000 ladder 
was pipetted into the assigned ladder well. The chip was then vortexed and run on 
the Agilent 2100 bioanalyzer.
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Sample
Gel/dye mix
Chip priming 
Ladder
Figure 2.2. RNA 6000 LabChip
Taken from www.agilent.com.
The RNA 6000 ladder standard is run on every chip from the specified ladder well 
and is used as a reference for data analysis. The RNA 6000 ladder contains six RNA 
fragments ranging in size from 0.2 to 6 kb at a total concentration of 150 ng/pl. The 
software automatically compares the 12 unknown samples to the ladder fragments to 
determine the concentration of the unknown samples and to identify and calculate 
the ratio of the peak areas of the ribosomal bands, 18S/28S. An ideal total RNA 
preparation would result in a ratio of 2. Variability in this ratio may indicate partial 
degradation of the sample by ribonuclease contamination. Figures 2.3, 2.4, 2.5 and
2.6 show representative electropherograms for the RNA 6000 ladder, high quality 
RNA, degraded RNA and genomic DNA contamination, respectively.
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Figure 2.3. Electropherogram of RNA 6000 ladder, and gel-like image (right).
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Figure 2.4. Electropherogram of high quality RNA
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2.2.3 DNase Treatment of RNA
Contaminating DNA was removed from RNA by treatment with DNase 1 (Promega,
UK). The following protocol was used:
RNA (1 Mg/pl) 10pl
DEPC-treated water 7pl
DNase 1 (1U/pl) 1pl
DNase buffer 2pl
The four constituents were mixed together and the solution incubated at 37°C for 1 
hour. The volumes were adjusted according to the amount of RNA used. The 
reaction was terminated by the addition of 0.1 M EDTA pH 8.0 and 1 mg/ml glycogen. 
The DNase enzyme was removed by adding an equal volume of 
phenol:chloroform:isoamylalcohol (25:24:1, Sigma, UK). The mixture was vortexed 
for 15 seconds, centrifuged at 14,000g for 10 minutes and the top aqueous layer 
transferred to a fresh tube. This was then repeated once with 
phenol:chloroform:isoamylalcohol and once with chloroform (Sigma, UK) to remove
any remaining phenol. RNA was precipitated at -20°C for 1 hour with 1/5th volume
ammonium acetate (8M) and 3 volumes of 95% ethanol (-20°C). RNA was pelletted 
by centrifugation at 14,000g for 30 minutes at 4°C, washed with 200pl 70% ethanol (- 
20°C) and dried on the bench at 22°C (for about 10 minutes). RNA was resuspended 
at 5pg/pl and if not used immediately, stored at -80°C.
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2.3 Oligonucleotide Microarray
2.3.1 Generation of Microarray Target
Summary of Process
ss RNA
5’primer
Reverse transcriptase + nucleotides
ss RNA 
ss cDNA
Rnase H 
Remove ssRNA 
strand
ss cDNA
First strand 
synthesis
DNA polymerase & T4 
DNA polymerase Secondstrand
synthesis
ds cDNA
Clean-up and ethanol precipitation
ds cDNA
Hybridisation on to chips
Quantification of cRNA (IVT product)
IVT clean up and ethanol precipitation 
Quiagen Rneasy kit
Fragmentation of cRNA for target 
preparation
In vitro transcription (generate cRNA) 
BioArray High Yield RNA Transcript 
Labeling Kit
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2.3.1.1 Synthesis of Double-Stranded cDNA From Total RNA
First Strand cDNA Synthesis
RNA used was at a concentration of 5pg/pl; 20|jg (4 jjI) RNA was used for each 
experiment.
\). Step 1: Primer Hybridisation
Reagents used: DEPC water 5 pi
RNA (20 pg) 4 pi
T7- (dT) 24 primer (lOOpmol/ pi) 1 pi
T7-(dT)24 primer
5' - GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24 - 3'
Reagents were mixed in an eppendorf tube, incubated at 70°C for 10 minutes, briefly 
spun in the centrifuge to collect the condensation and placed on ice.
ii) Step 2: Temperature Adjustment
Reagents used: 5X First strand cDNA buffer 4 pi
0.1MDTT 2 pi
10mMdNTPmix 1 pi
The reagents were added to those used in step 1, and incubated at 42°C for 2 
minutes.
iii) Step 3: First Strand Synthesis 
Reagent used: SSII RT 3 pi
SSI I RT was added to the reaction, mixed well, and incubated at 42°C for 1 hour. 
The final volume of the mixture was 20 pi.
Second Strand cDNA Synthesis
The First Strand reactions were placed on ice, then briefly centrifuged to bring down 
the condensation on the sides of the tubes. The Second Strand Final Reaction 
Composition listed below were added to the First Strand synthesis tube. The tube
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was gently tapped to mix the reagents. The mixture was again briefly spun in a 
microcentrifuge to remove any further condensation and incubated at 16°C for 2 
hours in a cooling waterbath. 2 pi (10U) T4 DNA Polymerase was added and the 
mixture incubated at 16°C for 5 minutes. 10 pi 0.5M EDTA was added. The mixture 
was then cleaned according to the clean-up protocol for cDNA, or stored at 20°C for 
later use.
Second Strand Final Reaction Composition
Component Volume Final concentration or amount in 
each
DEPC-treated water 90 pi
5X Second Strand Reaction Buffer 30 Ml 1X
10mM dATP.dCTP.DGTP, DTTP 3 Ml 200 mM each
5 U/|jl DNA ligase 2 Ml 10 U
10 U/Ml 4 Ml 40 U
2 U/|jl Rnase H 1 Ml 2 U
Final volume 150 Ml
2.3.1.2 Clean-up of Double-Stranded cDNA
An equal volume of (25:24:1) phenol:chloroform:isoamylalcohol (saturated with 10 
mM Tris-HCL pH 8.0/1 mM EDTA, Sigma, UK) was added to the final cDNA synthesis 
preparation (162 pi) to a final volume of 324 pi. The mixture was vortexed for 15 
seconds, centrifuged at 14,000g for 10 minutes and the top aqueous layer 
transferred to a fresh tube. This was repeated once with 
phenol:chloroform:isoamylalcohol and once with chloroform (Sigma, UK) to remove 
any remaining phenol. 0.5 volumes of ammonium acetate (7.5M) and 2.5 volumes of 
absolute ethanol (stored at -20°C) were added to the sample and vortexed. cDNA 
was pelleted by centrifugation at 14,000g for 20 minutes at 22°C, the supernatant 
carefully removed and the pellet washed with 500pl 80% ethanol (stored at -20°C). 
The mixture was again centrifuged at 14,000g for 5 minutes and the ethanol carefully 
removed. The ethanol wash was repeated once more, and the pellet airdried on the 
bench (about 15 minutes). The dried pellet was resuspended in 12pl Rnase-free 
water.
91
2.3.1.3 In Vitro Transcription
The ENZO BioArrayTM HlghYieldTM RNA Transcript Labelling Kit (T7) was used to 
generate large amounts of hybridisable biotin-labelled RNA targets by in vitro 
transcription from bacteriophage T7 RNA polymerase promoters. By using a T7 RNA 
polymerase and biotin-labelled nucleotides, large amounts of single stranded 
nonradioactive RNA molecules can be produced in vitro.
The following reagents were added in the order indicated in the table below to the 
cleaned-up final cDNA synthesis mixture at 22°C to avoid precipitation of DTT.
Reagent Volume
Template DNA 12 pi
DEPC-treated water 10 Ml
10X HY Reaction buffer 4 Ml
10X Biotin Labelled Ribonucleotides 4 Ml
10X DTT 4 Ml
10X Rnase Inhibitor Mix 4 Ml
20X T7 RNA Polymerase 2 Ml
Total Volume 40 Ml
The reagents were carefully mixed and the mixture collected at the bottom of the 
eppendorf by brief centrifugation. The tube was immediately placed in a 37°C H20 
bath for 5 hours. The contents of the tubes were carefully mixed every 30 minutes 
throughout the incubation. 5 hours is considered an optimum time for incubation; the 
longer the time, the greater the yield, although if left for too long, the increased 
chance of degradation by RNases. The RNA was then purified, or if not immediately 
used, was stored at -20°C.
2.3.1.4 Clean Up and Quantification of In Vitro Transcription Products
1 pi of unpurified IVT product was used for analysis using the bioanalyzer. The clean 
up step was essentially performed in order to remove unincorporated dNTPs so that 
the 260nm absorbance can determine the quantity of cRNA. One half of the IVT 
reaction was purified at a time. This was done firstly in case the sample was lost 
during purification and secondly because when IVT product yields are high, the 
amount of RNA in the whole reaction may exceed the capacity of the device used for
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purification, thereby resulting in better overall yields.
i) Clean Up
The clean up procedure was performed using the RNeasy protocol (Qiagen). The 
reagent mixture was adjusted to 100 pi by the addition of DEPC-treated water. 350 pi 
Buffer RLT was added, then 250 pi 96% ethanol was added, and the reagents mixed 
thoroughly by pipetting. The sample (700 pi) was then applied to an RNeasy mini 
spin column placed in a 2ml collection tube. The sample was centrifuged at 14,000g 
for 15 seconds, and the flow-through discarded. The column was washed twice with 
500pl buffer RPE. The first wash was centrifuged at 14,000g for 15 seconds, and the 
second wash for 2 minutes in order to dry the RNeasy silica-gel membrane. Total 
RNA was eluted by applying 50pl diethylene pyrocarbonate (DEPC)-treated water, 
which is Rnase-free, and centrifuging at 14,000g for 1 minute.
ii) Ethanol Precipitation
0.5 volumes of 7.5M ammonium acetate and 2.5 volumes of 100% ethanol (stored at 
-20°C) were added to the sample and vortexed for 15 seconds. The sample was 
precipitated for 1 hour at -20°C, after which the tube was centrifuged at 14,000g for 
30 minutes at 4°C. The pellet was washed twice with 80% ethanol (-20°C). The pellet 
was airdried on the bench at room temperature before resuspension in 20pl DEPC- 
treated water.
iii) Quantification of the cRNA (IVT Product)
The concentration and purity of the RNA was checked using the Agilent 2100 
Bioanalyzer (Agilent Technologies, CA, USA).
2.3.1.5 Fragmentation of the cRNA for Target Preparation
The following (Rnase-free) components were combined to a total volume of 20ml to 
make the fragmentation buffer and passed through a 0.2pm vacuum filter unit.
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4.0ml 1M Tris acetate pH 8.1
0.64g magnesium acetate
0.98g potassium acetate 
DEPC-treated water made up to 20ml
2pl of 5X fragmentation buffer were used for every 8pl of RNA plus water. The 
mixture was incubated at 94°C for 35 minutes, then put on ice. 1 pi of fragmentation 
product was taken to check the concentration and purity using the Agilent 
Bioanalyzer.
2.3.1.6 Preparation of the Hybridisation Target
Reagents for the hybridisation target for the single probe array were prepared as 
shown below.
Component Standard array Final concentration
Fragmented RNA I5pg 0.05ug/[jl
Control oligonucleotide B2 5|J| 50pM
20X Eukaryotic hybridisation controls 15pl 100pM
Herring sperm DNA (10mg/ml) 3pl 0.1 mg/ml
Acetylated BSA (50mg/ml) 3pl 0.5mg/ml
2X Hybridisation buffer 150jjI 1X
DEPC-treated water To final volume of 300|jI
Final volume 300pl
The reagents were mixed together, heated to 99°C for 5 minutes, then to 45°C for 5 
minutes. The hybridisation cocktail was then centrifuged at 14,000g for 5 minutes to 
remove any insoluble material. Meanwhile, the probe array cartridge was prepared 
by filling it with 250pl 1X Hybridisation Buffer through one of the septa. The probe 
array was incubated at 45°C for 10 minutes with rotation. The buffer solution was 
removed from the probe array cartridge and filled with 200pl of the clarified 
hybridisation cocktail avoiding any insoluble matter in the volume at the bottom of the 
tube. The probe array was placed in a rotisserie box in a 45°C oven at 60rpm. The 
probes were hybridised to the probe array during a 16-hour incubation. Figure 2.7 
shows the appearance of the Affymetrix probe array.
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Figure 2.7. Affymetrix probe array
Immediately following hybridisation, the probe array was processed through an 
automated washing and staining protocol on the fluidics station. Wash buffer A 
(non-stringent) and wash buffer B (stringent) wee used for washing, and SAPE 
and antibody solutions were used for the staining. The components for these 
solutions are shown below.
Solutions Used
Non-Stringent Wash Buffer (Wash buffer A)
(6X SSPE, 0.01% Tween 20)
For 1000 ml:
300 ml of 20X SSPE
1.0 ml of 10% Tween-20 
698 ml of water
Filter through a 0.2 pm filter
Stringent Wash Buffer (Wash buffer B)
(100 mM MES, 0.1 M [Na+], 0.01% Tween 20) 
For 1000 ml:
83.3 ml of 12X MES Stock Buffer
5.2 ml of 5 M NaCI
1.0 ml of 10% Tween 20
910.5 ml of water
Filter through a 0.2 pm filter 
Store at 2-8°C and shield from light
2X Stain Buffer
(Final 1X concentration: 100 mM MES, 1 M [Na+], 0.05% Tween 20) 
For 250 ml:
41.7 ml 12X MES Stock Buffer 92.5 ml 5 M NaCI
2.5 ml 10% Tween 20
112.8 ml water
Filter through a 0.2 pm filter
Store at 2-8°C and shield from light
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Streptavidin Phycoerythrin (SAPE) Stain Solution
(Total 1200|jl)
600 pi 2X MES stain buffer 
540 |jl DEPC water
48 Ml 50mg/ml acetylated BSA (final concentration 2 mq/mO 
12 mI of 1 mg/ml SAPE (final concentration 10 Mg/ml)
Antibody Solution
(Total 600mI)
300 Ml of 2X MES stain buffer
266.4 Ml DEPC water
24 Ml of 50mg/ml acetylated BSA (final concentration 2 Mg/m I)
6.0 Ml of 10mg/ml normal goat IgG (final concentration 0.1 Mg/ml)
3.6 Ml of 0.5 mg/ml biotinylated antibody (final concentration 3 Mg/ml)
Wash and Stain Protocol
Post Hyb 10 cycles of 2 mixes/cycle with
Wash #1 Wash Buffer A at 25°C
Post Hyb 4 cycles of 15 mixes/cycle with
Wash #2 Wash Buffer B at 50°C
Stain Stain the probe array for 10 minutes
in SAPE solution at 25°C
Post Stain 10 cycles of 4 mixes/cycle with
Wash Wash Buffer A at 25°C
2nd Stain Stain the probe array for 10 minutes
in antibody solution at 25°C
3rd Stain Stain the probe array for 10 minutes
in SAPE solution at 25°C
Final Wash 15 cycles of 4 mixes/cycle with
Wash Buffer A at 30°C.
The holding temperature is 25°C
• Wash Buffer A = non-stringent wash buffer
• Wash Buffer B = stringent wash buffer
The hybridized probe array was stained with streptavidin phycoerythrin stain and 
antibody solutions, and scanned by the GeneArray® Scanner at the excitation
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wavelength of 488 nm. The amount of light emitted at 570 nm is proportional to the 
bound target at each location on the probe array. Each probe array was scanned 
twice in order to improve the assay sensitivity and reduce background noise. The 
software calculates an average of the two images, defines the probe cells and 
computes an intensity for each cell. Each complete probe array image was stored in 
a separate data file and was saved with a data image file (.dat) extension.
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2.4 Data Analysis
2.4.1 Expression Summary
Data analysis was performed in conjunction with Stephen Henderson, 
bioinformaticist at University College London. The basic principle behind analysing 
data from high density oligonucleotide arrays is converting the level of hybridisation 
of each gene into a numerical intensity value. Each gene is represented by 16-20 
pairs of oligonucleotides, 25 base pairs in length, referred to as the probe set. Each 
pair of oligonucleotides comprises a perfect match (PM) and a mismatch (MM) 
probe, referred to as the probe pair. The mismatch probe differs from the PM probe 
by one central base pair, and this serves as a measure of non-specific binding (or 
background).
Perfect Match sequence: TACCGTTTAGGTA 
Mismatch sequence: TACCGTTTAGGTT
GGCT CCCATTT C 
GGCT CCCATTT C
Background subtraction, normalisation and expression values of our data were 
calculated using the rma algorithm [Irizarry et al., 2003], available as part of the 
Affymetrix package of the Bioconductor open-source software library for the 
statistical language R (http://www.bioconductor.org). Unlike the Affymetrix MAS5 
algorithm normalisation of each experiment is carried out on all probe values prior to 
calculation of the expression summary for each probe-set rather than after. This is 
similar to the process of normalising the contrast and brightness of photographs or 
video images taken under different light levels. The images are simply quantile 
normalised to the chip with the median brightness. Figure 2.8 demonstrates the 
normalisation process. Again unlike MAS5, the PM values alone are used to 
calculate expression summary values for each probe-set. The rma algorithm was 
used due to its superior precision particularly for RNA transcripts of low abundance 
that is, the variability of repeated measurements is decreased. This has been 
assessed using spike-in experiments with known quantities of bacterial RNAs.
Differential expression between groups was calculated using a t-test and a step-
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down False Discovery Rate (FDR) algorithm set to 0.05, implemented using the 
Bioconductor multtest package. This method controls the number of false positive 
expression difference calls that arise due to the vast degree of multiple testing of 
GEM. P-values from the t-test are adjusted upwards to make the level of all false 
positive results approximately 0.05.
OS
14
12
10
e
6
B
14 
12
<2 10
c  8 
c 0
* I— -I J l .
N1 N2 N3 N4 01 02 03 04 05 06 M1 M2 M3 M4 M5 MB 
Tissue sample
N1 N2 N3 N4 01 02 03 04 05 06 Ml M2 M3 M4 M5 MB 
Tissue sample
Figure 2.8. Boxplot showing image intensities of 16 chips before (A) and after (B) 
normalisation.
Box and whisker plots show a central median line, an interquartile box (25% and 75% range) and 
whiskers at 1.5 times the interquartile range. N=normal ovary, 0=primary ovarian cancer, M=omental 
metastasis. A represents all 16 chips with image intensities before normalisation. N2 and M4 have 
high background intensities. B shows 16 chips normalised to each other, with the medians at the 
same value.
2.4.2 Average Linkage Hierarchical Clustering
Average linkage hierarchical clustering was performed using the Pearson correlation 
coefficient as a distance measure. Initially, each experiment is assigned to its own 
cluster, then the algorithm proceeds iteratively at each stage joining the two most 
similar clusters, continuing until there is just a single cluster. At each stage distances 
between clusters are recomputed to the average distance of the members of the 
clusters.
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2.4.3 Comparative GEM Data
Publicly available GEM data from normal epithelial rich tissues and whole blood were 
obtained in CEL format from the Genomics Institute of the Novartis Foundation 
expression atlas (http://expression.gnf.org). Prostate and lung adenocarcinoma data 
were obtained in CEL format from the Whitehead Institute Centre for Genomic 
Research (http://www-genome.wi.mit.edu/cgi- bin/cancer/datasets.cgi). This was all 
analysed with our own data using rma (see section 2.4.1).
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2.5 Real-Time Quantitative Reverse Transcriptase 
Polymerase Chain Reaction (QRT-PCR)
In order to confirm the results of the microarrays, 4 genes were selected for 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis.
2.5.1 General
Experiments involving the handling of nucleic acids were performed in accordance 
with standard practice [Sambrook and Gething, 1989]. Sterile glassware, tubes and 
disposable pipette tips were used and latex gloves were worn at all times. All 
aqueous solutions were either autoclaved (121°C, 20mins) or filtered through a 0.2 
pm filter (Millipore Corp., Bedford, MA, USA).
2.5.2 Prevention of contamination
Precautions were taken to avoid false positives and to monitor the occurrence of 
cross-contamination. The specific measures taken were:
1. Separate rooms allocated for different sections of the optimisation experiment:
RNA extractions 
PCR mixture preparation 
RNA sample dilutions 
cDNA loading 
Gel loading
PCR run in the instrument
2. The inclusion of H20  control tubes in all PCRs. H20  was also used as a control 
to extract RNA from in parallel with the tested samples. Positive results with test 
samples were only accepted where all controls were negative.
3. Exposure of reaction components (H20, buffer) and instruments (Gilson pipettes, 
filtered pipette tips, microtubes) to ultra-violet light (UV 254nm) prior to the
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addition of template. This was performed using a UV cross-linker (Stratagene
2Stratalinker 2400, 1 J/cm ). Primer, probes and dNTP stock solutions were not 
exposed to UV light but were diluted in UV-treated H20  or TE (Qiagen) and 
stored in aliquots at -20°C.
4. Use of designated sets of Gilson pipettes and ‘filtered’ pipette tips for setting up 
PCRs, for DNA loading, for post-PCR analysis and for handling plasmids 
containing cloned fragments.
5. Frequent changes of gloves and physical separation of solutions of target 
RNA/cDNA and from PCR products.
2.5.3 Instrumentation and Chemistry
The ABI PRISM® 7000 Sequence Detection System (ABI PRISM, Applera UK, 
Cheshire) was used in combination with SYBR® Green I dye chemistry.
2.5.4 Definitions Used in Real-Time PCR
The increase of the fluorescence is a direct consequence of the target amplification 
and is measured by the thermal cycler. Each signal is then divided by the 
fluorescence emitted by an internal reference dye (ROX), which is incorporated into 
the SYBR® Green I dye mix, in order to normalise for non-PCR related fluorescence 
fluctuations occurring well-to-well or over time.
The threshold cycle or C j is the cycle at which a statistically significant increase in 
fluorescence is first detected.
The standard curve is a graph showing CT values plotted against the log of the initial 
amount of nucleic acid for a set of cDNA dilutions from a specific template and has 
been shown to be a straight line (Figure 2.9). In theory, the components of the PCR 
reaction are not limiting during the exponential phase of the amplification, therefore, 
the measurement of the fluorescence during this phase is proportional to the amount
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of PCR product [Higuchi et al., 1993].
Standard Curve
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Figure 2.9. Standard curve graph.
Representative example of a standard curve showing the threshold cycle against the logarithm 
of the initial copy number in a set of standards
2.5.5 Genes Selected for QRT-PCR
Complementary DNA (cDNA) sequences from the encoding regions of hepsin, KLK6, 
SAA1 and the human glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH, 
endogenous control) were retrieved from the NCBI (GenBank, 
www.ncbi.nlm.nih.gov/BLAST) database and used as templates for the primer 
design.
2.5.6 Oligonucleotide design
2.5.6.1 Primer Express® Software
Primers (QIAGEN-OPERON, Cologne, Germany) were designed using Primer 
Express® software programme (PE Applied Biosystems, UK). The selection of 
primers is based on default parameters and guidelines (Table 2.4.). The target genes 
and GAPDH cDNA sequences were imported to the programme to be analysed. All 
primers have a similar annealing temperature. The amplicons are designed to be
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between 50 and 150bp in length. This allows the amplification to be more efficient 
and it can be done in universal thermal cycling parameters.
Primers Amplicon
Tm = 58 -  60°C 50 -  150bp long
30 -  80% GC content
9 - 4 0  bases long
<2°C difference in Tm between the two 
primers
Maximum of 2 out of 5 Gs or Cs at 3’ end
Table 2.4. Guidelines set in Primer Express® software for automatic 
selection of oligonucleotides
(From Applied Biosystems handouts). Tm = Melting temperature,
G or C = Guanine and cytosine
2.5.6.2 Primer sequences
The primer sequences shown in Table 2.5 were selected using the primer express 
software as mentioned in section 2.5.6.1 then re-entered into the NCBI (GenBank, 
www.ncbi.nlm.nih.gov/BLAST) database to confirm the specificity of the sequences.
Gene of 
Interest
Sense Primer Antisense Primer Product 
Size (bp)
MGB2 S'-CCGCTGCAGAGGCTATGG-S’ 5-CAT CAGT CCAAAGTTTTT CAG AGTT CT -3’ 86
HPN 5'-GGCTCGAGTCCCCATAATCAG-3' 5-G GT AGCCAGCACAGAACAT CTT G-3' 92
KLK6 5'-GCGGACCCTGCGACAAG-3' 5'-GGATAAGGACCCCACCACAGA-3' 84
SAA1 S'-TTCTCACGGGCCTGGTTTT-S’ 5-GCCT CGCCAAGGAACGA-3' 76
GAPDH 5'-GGAGTCAACGGATTTGGTCGTA-3' 5'GGCAACAATATCCACTTTACCAGAGT-3' 78
Table 2.5. Genes used for real time quantitative RT-PCR.
MGB2: mammaglobin 2, HPN: Hepsin or transmembrane protease, serine 1; TMPRSS1, KLK6: 
Kallikrein 6; Protease, serine, 9; PRSS9 or Protease M or neurosin, SAA1: Serum amyloid A1 
or amyloid A, serum; SAA, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
Primers were further diluted in UV treated H20  at the concentration of 10pM and 
100pl aliquots were stored at -20°C.
2.5.7 Conventional PCR
[For principles of the PCR reaction, see section 2.6.4. The Polymerase Chain 
Reaction (PCR)]. The specificity of GAPDH and target gene primers was tested by a 
standard PCR amplification of template cDNA derived from a fetal library using the 
Expand High Fidelity PCR System (Roche, Germany). For a 25pl PCR reaction the 
conditions were as follows:
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Constituent Final Concentration
10 X Expand™ high fidelity buffer (15mM MgCI2) 2.5pl (1 X)
dNTPs mix (1.25mM) 4ul (200uM)
Primers (10pM) 0.5pl (5pM each)
Taq High Fidelity 0.25|jl (0.875Units)
cDNA (approx. 1ng/pl) 5pl
dH20 11.85ul
The reaction conditions were:
1 cycle 95°C 2mins
95°C 30secs
35 cycles -< 60°C 30secs
72°C 15secs
1 cycle 72°C 20secs
2.5.8 Gel Electrophoresis of Small Fragments
The GAPDH and target PCR product gene fragments were too small in size to be 
observed with a low percentage agarose gel. Therefore, a 4% agarose gel was 
prepared in 0.5 X TAE gel running buffer with 0.1pg/ml ethidium bromide (SIGMA). A 
50bp DNA (GIBCO, Invitrogen) step ladder was included to estimate the size of the 
bands. Gels were captured by the Versadoc Imaging System (BioRad) for analysis.
2.5.9 Purification of cDNA fragments
Bands of the correct size were excised from the gel and cDNA was purified using the 
QIAquick gel extraction protocol (QIAGEN). The gel slice was weighted and 3 or 6 
volumes (if the gel contained >2% agarose) of buffer QG (v/w) were added to the gel 
and incubated at 50oC till the gel was completely dissolved. One gel volume of 
isopropanol was added to the sample, mixed and applied to a QIAquick spin column. 
After 1min spin at 10,000g another 0.5ml of buffer QG was added, centrifuged and
0.75ml of buffer PE was applied to the column to wash for another minute. The cDNA 
was eluted at 20pl dH20. The concentration of the cDNA products was measured 
using the Agilent 2100 bioanalyzer.
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2.5.10 DNA Sequencing
The identity of the PCR products was verified by DNA sequencing using an 
automated application of the chain-termination method. The PCR purified product 
with the primers were given to our local PCR facility and the analysis was done using 
software (Beckman, CEQ 2000) supplied by the manufacturer (Beckman Coulter). 
Fifty to hundred fmoles of DNA template and 5pmoles/pl each of the primers were 
provided. The sequences were imported into BLAST as before to confirm the target 
genes.
2.5.11 QRT-PCR Consumables and Parameters 
2.5.11.1 Consumables
The SYBR Green PCR Master Mix (4309155, Applied Biosystems) was used for 
every test. This kit is supplied at a 2X concentration. It contains SYBR Green 1 dye, 
AmpliTaq Gold DNA Polymerase, dNTPs with dUTP, Passive Reference 1 (ROX) 
and optimised buffer components. The reactions were transferred to MicroAmp® 
Optical 96-well Reaction Plates with Barcode (4306737, Applied Biosystems) and the 
plates were covered with ABI PRISM optical adhesive covers (4311971, Applied 
Biosystems) before they were transferred to the thermal cycler.
2.5.11.2 Parameters and PCR Conditions
The qPCR conditions used (primer concentration and amplification efficiencies), for 
the amplification of each cDNA sequence, were optimised individually for each gene. 
Primer optimisations were done in triplicate with triplicate non-template controls. 
Universal thermal cycling parameters were used for both genes as shown in Table 
2.6. 1 pi of cDNA was used in a 25pl PCR mixture containing IxSYBR® Green PCR 
mix (Applied Biosystems) and 0.3pM each primer for all genes apart from HPN 
where 0.6pM forward and reverse was used, and KLK6 where 0.9pM reverse primer 
was used. The threshold cycle (CT) which represents the PCR cycle at which an 
increase in reporter fluorescence above a baseline signal can first be detected, was 
calculated as previously described [Heid et al., 1996]. The relative expression of
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each gene was determined on the basis of the CT value. The housekeeping gene 
GAPDH was used to normalise the quantity of cDNA used. Average GAPDH CT 
value was subtracted from that of each target gene to obtain a ACT value, i.e. 
normalise target gene expression relative to GAPDH. An average ACT value was 
obtained for each of the 5 groups of 19 cDNA ovarian samples (Normal: n=5, Low 
Malignant Potential (LMP): n=3, Primary: n=4 and Metastasis: n=2). Each average 
ACT was also subtracted from that of a calibrator (Average ACT value of all the 
Normal samples which provide the physiological expression of each gene target) to 
give the AACT value, i.e. normalised target gene expression in the different groups 
relative to Normal. Since CT values are measured when PCR amplification is still in 
the exponential phase then the relative quantitative value can be expressed as 2- 
AACT as 2 corresponds to the PCR product doubling in each cycle in the exponential 
phase.
Times And Temperatures
Initial steps Each of 40 cycles
Melting | Annealing/Extension
Hold Hold* Cycle
10secs 10mins 15secs 1min
50°C 95°C 95°C 60°C
Table 2.6. Universal thermal cycling parameters for the qRT-PCR.
The 10mins hold at 95°C is required for the AmpliTaq Gold® DNA Polymerase activation
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2.6 Semi-Quantitative Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) For Chemokine Analysis
As part of the search to identify factors which may be instrumental in metastasis of 
ovarian cancer, chemokines were investigated further by RT-PCR. The cDNA 
sequences for chemokines CXCR2, CXCR4, CCR1, CCR2, CCR3, CCR5, CCR7, 
CCR8 and CCR10 were obtained from the NCBI (GenBank, 
www.ncbi.nlm.nih.gov/BI_AST) database.
2.6.1 Primer Design
The chemokine primers were designed according to the following principles:
1. The primers should be 20-26 base pairs in length, to ensure uniqueness within 
the template DNA.
2. The G+C content should be around 50%.
3. The primer should end with a G or C nucleotide to ensure strong annealing of the
primer to the template for the initiation of extension by Taq polymerase.
4. Lengths of more than 3 of the same nucleotide should be avoided.
5. Sequences which could form secondary structures such as hairpins should be 
avoided.
6. A pair of primers used together for the amplification of a particular target
sequence should be designed to have the same annealing temperature (Ta) of
50-60°C. This can be calculated using the following formula:
Ta (C) = 4(G+C) + 2(A+T)
Chemokine Sense Primer Antisense Primer Product
size
(bp)
CXCR2 5’-CT GCT GAT CATG CTGTT CTGC-3’ 5’-CT CACAG GT CT CCT GG AT CAC-3’ 160
CXCR4 5’-GACTATTCCCGACTT CAT CTTT GCC-3’ 5-CAGAT GAAT GT CCACCT CGCTTT CC-3’ 492
CCR1 5’-CGT GTTTGCCTT GCGGGCACGGACC-3’ 5’-CT CAT GGGT GAACAGGAAGT CTTG-3’ 377
CCR2 5’-GGACT GCCT GAGACAAGCCACAAGC-3’ 5-GAT G ACT CT CACT GCCCT AT GCCT C-3’ 787
CCR3 5’-G GG AG AAGT G AAAT G ACAACCT CAC-3’ 5-TGCAT GAGCAAGTGCCT GT GGAAGA-3’ 954
CCR5 5’-GCACAGGGCTGTGAGGCTTATCTTC-3’ 5-G GT GT AAACT GAGCTTGCT CGCT CG-3’ 305
CCR7 5’-GTAT GCCT GT GT CAAGAT GAGGT CAC-3’ 5-G TT GAGCAGGT AGGT AT CGGT CAT GG-3’ 210
CCR8 5’-CCGCCATTATGGCTACCATCCCATTG-3’ 5-CCAACCT GAT GGCCTTGGTCTT GTT G-3’ 213
CCR10 5’-CAACG ACGCT GT CGCCT CAT CTT CC-3’ 5-GACATCCTTGCGTTTGCTGGCAGGG-3’ 303
Table 2.7. Primers for chemokine genes
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The primer sequences shown in Table 2.7 were selected using the primer express 
software as mentioned in section 2.5.6.1 then re-entered into the NCBI (GenBank, 
www.ncbi.nlm.nih.gov/BLAST) database to ensure that they only anneal to the 
desired sequence. The control housekeeping gene for this experiment was GAPDH 
Primers were ordered on the internet from MWG Biotech (Ebersberg, Germany), 
resuspended in 1ml distilled DEPC water and stored at -20°C. Each set of primers 
resulted in successful amplification of the correctly-sized amplicon from a suitable 
positive control.
2.6.2 Reverse Transcription: Basic Principles
Reverse transcription was performed using the SuperscriptTM first-strand synthesis 
system for RT-PCR (Invitrogen, Paisley, UK). Sample RNA, control RNA and Rnase- 
free water were used in this step in order to exclude DNA contamination. The 
essential steps are demonstrated in Figure 2.10.
mRNA
AAAAAA
TTTTTT (primer)
V
First-strand
synthesis
AAAAAA
TTTTTT
Removal of 
RNA
TTTTTT
First strand cDNA ready for PCR
Figure 2.10. Summary of reverse transcription
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RNA from 2 samples of normal ovary (N1 and N2) and 2 samples of primary ovarian 
cancer (01 and 02) was purified as described in section 2.2.1 and contaminating 
DNA removed by treatment with DNase I (section 2.2.3). The reverse transcription 
step was performed on sample RNA, control RNA and distilled DEPC water to 
ensure all contaminating DNA was excluded.
2.6.3 Experimental Conditions
1 pi of oligo-dT primers (0.5 pg/ pi) were annealed to 1 pg of total RNA and 1 pi of 
10mM dNTPs to a total volume of 10 pi by heating to 65°C for 5 minutes then chilling 
on ice for at least 1 minute. cDNA was synthesised by the addition of the following 
components:
RNA and primers 10 pi
10X RT buffer 2 pi
25mM MgCb 4 pi
0.1M Dithiothreitol 2 pi
(DTT)
RnaseOUT 1 pi
This was incubated at 42°C for 2 minutes, then 1 pi of Superscript II (50 U/ pi) 
added, and incubated for a further 50 minutes. The reaction was terminated by 
heating to 70°C for 15 minutes. The tube was chilled on ice, the reaction collected by 
brief centrifugation then 1 pi of Rnase H added to the tube and incubated at 37°C for 
20 minutes. The resulting cDNA template was then amplified in the polymerase chain 
reaction.
2.6.4 The Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) was then performed in order to amplify the 
number of copies of the target cDNA sequence. This reaction consists of a chain 
reaction mediated by a DNA-dependent DNA polymerase. The essential steps are 
shown in Figure 2.11.
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Template DNA
1§t cycle
Gene of 
interest
4tt cycle
2“  cycle
<
<
cycle
<
< Exponential
amplification
<
C
<
2 copies 4 copies copies 16 copies
Figure 2.11. Basic steps of a PCR reaction.
2.6.5 Prevention of Contamination
PCR is used to amplify specific DNA sequences. Hence, it is susceptible to 
contamination by foreign DNA, from other objects or the atmosphere, resulting in the 
amplification of this DNA, rather than the experimental DNA. Therefore, the following 
strict precautions were taken to minimise this risk:
1. The use of a designated “PCR room” where no DNA is permitted. All
components of the reaction mixture were added here; the target DNA was then
added afterwards in a separate room.
2. All equipment and surfaces were cleaned with 100% ethanol prior to use.
3. A clean laboratory coat was worn, which remained in the PCR room at all times.
4. A clean, ultraviolet (UV)-irradiated containment hood with filtered air.
5. The use of autoclaved, double-distilled water.
6. The use of filter pipette tips to avoid aerosol contamination.
111
7. UV irradiation of all reaction tubes and water before setting up the PCR reaction.
8. Not touching anything with the pipette tip, except the inside of the reagent and 
reaction tubes.
9. Opening the reaction tubes for as short a time as possible to permit the addition 
of each reagent whilst preventing the entry of contaminants.
10. The use of small batches of samples so that any contamination affects only a 
small number of reactions.
11. The inclusion of negative controls containing water instead of DNA between 
every 3-4 samples.
12. The storage of reagents and pipette tips separately to other users.
2.6.6 Basic Principles
The components of a PCR reaction include the target sequence to be amplified, in 
this case, cDNA, oligonucleotide primers which are specific for the sequences 
flanking the target DNA fragment, buffer solution which contains salts to facilitate the 
polymerisation, DNA polymerase and dNTPs (deoxynucleotide triphosphates). Taq 
polymerase has been used in this study because it can resist temperatures above 
96°C without becoming denatured, thereby being able to withstand the thermal 
cycling necessary to continuously denature and re-anneal the strands of synthesised 
DNA. A standard thermal cycling program consists of 30 cycles of amplification, and 
this typically results in the production of 230 copies of target DNA.
The PCR reaction works at different temperatures, depending upon the optimum 
temperature of each reaction. The first step is a denaturing step to break any double 
stranded DNA to single strands. Next, the temperature is lowered (50-60°C) so the 
primers can anneal to their complementary sites on the single-stranded genomic 
DNA. The temperature is then held at a short time for the Taq polymerase to work 
optimally (72°C), allowing the extension of the DNA chain from the annealed primers. 
The single-stranded DNA acts as a template on which the polymerase builds the 
complementary strand using the dNTP molecules. Once this extension step is 
completed, the temperature is raised to 96°C in order to denature the newly-formed 
double-stranded DNA, then the process repeats itself. This cyclical procedure results
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in the exponential amplification of target DNA sequence situated between the 
primers.
2.6.7 PCR Amplification
PCR was performed using control for each pair of primers in a Primus 96 thermal 
cycler (MWG Biotech, Ebersberg, Germany) using the following constituents, with the 
Taq polymerase being added last:
Forward (sense) primer 2 pi
Reverse (antisense) primer 2 pi
10X buffer (with MgCI at 5 pi
10 mM dNT mix 1 pi
Distilled water 37.5 pi
Taq polymerase 0.5 pi
Final volume 48 pi
2 pi of cDNA was then added outside of the PCR room.
The reaction conditions for the chemokine primers were:
1. Lid heat at 110°C
2. 2 minutes at 94°C
3. 35 cycles of: 1 minute at 95°C
1 minute 30 seconds at Ta°C 
1 minute 30 seconds at 72°C
4. 10 minutes at 72°C
5. Lid heat off
6. Hold at 4°C
The reaction conditions for GAPDH control primers were:
1. Lid heat at 110°C
2. 5 minutes at 95°C
3. 40 cycles of: 30 seconds at 95°C
30 seconds at 50°C 
1 minute 30 seconds at 72°C
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4. 20 minutes at 72°C
5. Lid heat off
6. Hold at 4°C
2.6.8 Visualisation Using Agarose Gel
When the amplification step was completed, 5 pi of each PCR reaction was 
separated by electrophoresis on a 1% agarose gel (agarose from Sigma, Saint Louis, 
Missouri, USA) in 0.5% Tris-acetate-EDTA (TAE) buffer. 10mg/ml ethidium bromide 
(Bio-Rad, California, USA) was used to stain the gel and detect DNA bands. 1 pi of 
1-kb DNA ladder (GibcoBRL, Life Technologies, UK) was used as a size marker. The 
gels were viewed under ultra-violet light and photographed using a Kodak digital 
camcera 120. Figure 2.12 shows a typical gel of RT-PCR of sample RNA, RNA and 
water controls. Reverse transcription is performed for RNA where superscript is 
added, and where it is omitted. This is to control for DNA contamination. If DNA was 
found to be present, the sample was DNased (see section 2.2.3) and re-run.
DNA
ladder
Figure 2.12 RT-PCR reaction.
RNAs N1, 01 and 0 2  are run with (+) and without (-) reverse transcriptase to check for DNA 
contamination. N1 = normal ovary, 01 & 0 2  = primary ovarian cancer. There is no gel band for N1 -  
RT signifying this is a clean sample. RNA 01 and 0 2  show bands when RT is not added, signifying 
there is DNA contamination in the RNA samples. The 2 H20  controls check for general DNA 
contamination in the experiment. There are no bands visible, therefore the experiment was clean.
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For the semi-quantitative RT-PCR, 10 |jl of RT product were taken and sequential 
dilutions made so that each dilution was 1/5th of the previous reaction, down to a 
dilution of 1/625. Figure 2.13 shows a typical gel of a semi-quantitative RT-PCR of 
chemokines, with the intensity of the gel bands corresponding to serial dilutions.
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Tube 1
10fil RT product
Dilution 1/1
Take 2|il
Tube 2 2|il tube 1+ 8pl H20 Dilution 1/5
Take 2pl
Tube 3 2pl tube 2 + 8|il H20 Dilution 1/25
Take 2|il
Tube 4
Tube 5
2pl tube 3 + 8pl H20 Dilution 1/125
Take 2pl
r
2[i\ tube 4 + 8pl H20 Dilution 1/625
Tube 6 10jxl h2o
f&r -
DNA 1/1 
ladder
1/125
Figure 2.13 Serial dilutions of CCR5 chemokine in sample 0 2  (primary ovarian cancer).
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2.7 Immunohistochemistry
Immunohistochemistry was performed on a further 30 paraffin blocks (10 normal 
ovary, 10 primary serous adenocarcinomas and 10 omental secondaries) which were 
taken from the histopathology archive. These patients are not related to the samples 
used for the array experiments. Sections were cut at 4pm, deparaffinised and 
rehydrated in a series of graded alcohols, before being heated in a microwave in TE 
for 25 minutes. Endogenous peroxidase activity was blocked by 10 minute incubation 
with 0.5% H2 O2 in methanol prior to application of the primary antibody, hepsin (goat 
polyclonal primary antibody, 1:50; Santa Cruz Biotechnology Inc., Insight 
Biotechnology Ltd, Wembley UK) for 1 hour at 22C. A biotinylated, anti-goat 
secondary antibody (1:400; DAKO, Cambridgeshire UK) was applied for 30 minutes 
after which slides were incubated with the streptavidin-peroxidase complex (DAKO) 
for a further 30 minutes. Sections were visualized by application of diaminobenzidine 
(DAB) substrate (DAKO) for 7 minutes, followed by a wash in running H20  and 
counterstaining for 2 minutes with Mayer’s haematoxylin (DAKO). All sections were 
then dipped in acid alcohol to remove excess haematoxylin and immediately placed 
in running H20. After dehydration in graded alcohols, slides ended in xylene and 
were mounted in DPX.
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Chapter  3
Results
3.1 Clinical Material
Of the 47 clinical samples collected, 11 were diagnosed histopathologically as stage 
III primary serous cystadenocarcinomas of the ovary. Six of these were of adequate 
quality for analysis, as were the corresponding omental metastases from the same 
patients. The remaining 5 samples demonstrated degraded RNA. Four of the 8 
normal ovarian samples were adequate for analysis and were included.
3.1.1 Microdissection
Sections of primary and secondary tumour were cut at 6pm thickness in the 
cryomicrotome for microdissection. The aim was to separate cancer cells from the 
underlying stromal cells in order to obtain a gene expression profile for the each 
subpopulation. Figure 3.1 shows the pre- and post-microdissection sections of one 
sample of primary serous adenocarcinoma. Microdissection was actually performed 
on non-stained tissue, but with the H&E sections adjacent in order to identify the 
relevant areas. H&E sections are used here for the purposes of demonstration.
Even though the tissue samples were placed immediately into RNAIater® (see 
section 2.1.3) in order to preserve the RNA, no RNA was subsequently obtained after 
RNA extraction. This could be due to two factors: an inadequate number of cells 
were retrieved or the microdissection process took too long, so the RNA had 
degraded by the time it was placed in the RNA preserving medium.
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Figure 3.1. Microdissection
Slide A shows a pre-microdissection H&E staining of primary serous adenocarcinoma. The area at the 
top right of the picture bounded by the white line represents solid tumour. Slide B shows the post­
microdissection view where tumour tissue has been removed.
Therefore the procedure was abandoned. Instead, block tissue was used for the 
cancer samples, and for the normal ovaries, epithelial tissue was macrodissected 
from the underlying stroma, in order to obtain a gene expression profile for mainly 
ovarian epithelium.
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3.2 RNA Quality
The quality of the RNA extracted from the clinical samples was initially verified by gel 
electrophoresis and later by the Agilent 2100 bioanalyzer when it became available. 
Typical gels for gel electrophoresis are shown in Figure 3.2.
DNA 0 1  0 2  0 3  0 4  0 5  0 6  M1 M2 M 3 M4 M5 M6
ladder
Figure 3.2. Purified total RNA
Total RNA was separated by 1% agarose gel electrophoresis. A composite of 12 samples 
(01-6, and M1-6) is shown. The position of 28 and 18S ribosomal RNA is indicated.
The bioanalyzer presents the RNA data as an electropherogram (Figure 3.3) for each 
individual sample, with detailed data analysis (Figure 3.4), as a 12-well
representation (Figure 3.5) in order to compare all samples to each other and as a 
simulation of the classic agarose gel (Figure 3.6).
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Figure 3.3. Bioanalyzer data for total RNA of sample 01
The electropherogram shows the 18 and 28S rRNA; there is clearly no RNA degradation 
or DNA contamination.
BioSizing_Total-RNA-Nano_00266_2002-03-18_14-39-35 01
Fragment Name Start_Time(secs) End_Time(secs) Area %_of_total_Area
1 18S 39.33 40.90 95.44 18.87
2 28S 44.17 47.60 183.08 36.21
RNA Area 505.67
RNA Concentration(ng/ul) 1,742.09
rRNA Ratio [28S/18S] 1.92
Figure 3.4. Bioanalyzer data.
The bioanalyzer calculates the RNA concentration and the rRNA ratio, which in this case is 1.92. 
The ideal RNA ratio is 2.0.
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M1
M5
UL
Figure 3.5. Electropherogram showing 12 well plate
L 1 2 3 4 5 6 7 8 9  10 11 12
Figure 3.6. Electropherogram to resemble classic 
agarose gel
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3.3 Oligonucleotide Array Target Preparation
At each step of the preparation of the oligonucleotide array target, checks are made 
to ensure the presence and quality of the product.
3.3.1 In Vitro Transcription
As such small amounts of RNA are retrieved from fresh tissue, amplification of 
product is necessary to generate sufficient target for the arrays. An in vitro 
transcription step is performed where cRNA is amplified and labelled with biotin. 1pl 
of product was analysed on the Bioanalyzer to ensure sufficient quantity of cRNA 
was generated. Figure 3.7 shows a representative gel.
Figure 3.7. Electropherogram of in vitro transcription step
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3.3.2 Fragmentation of cRNA
Following in vitro transcription, the products are cleaned up and precipitated in order 
to reduce the volume; they are then analysed using the Agilent Bioanalyzer (Figure 
3.8).
/ o ' -  &  J  &
■all
Figure 3.8. Electropherogram of fragmentation products.
The smears on the gel view are approximately half that of the post-IVT 
products. Fragmentation is necessary in order for hybridisation on to the 
array to be more efficient.
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3.4 Scanning and Generation of Array Image
Hybridisation essentially allows the target oligonucleotides to bind to the relevant 
probes on the array. The amount of bound target gives a visual image of 
fluorescence. A large amount of target binding shows as a yellow dot; a low amount 
of binding shows as a black dot. The visual images are stored as dat files and 
converted into numerical cel files for analysis. Arrays are manually inspected for 
abnormalities; if irregularities are visible on the surface, then the array is discarded 
(Figure 3.9).
Figure 3.9. Macroscopic image of oligonucleotide arrays
A-acceptable chip. B-large circular scratch in the centre of the array, which would cause 
interference with data analysis. This chip was discarded.
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3.5 GEM Profiling of Serous Ovarian Cancer: Primary 
Ovarian Disease
3.5.1 Hierarchical Clustering
Figure 3.10 shows a cluster dendogram (average linkage) of the 4 normal ovaries, 6 
primary serous ovarian cancers and their corresponding omental metastases. There 
is clear separation between normal and cancer tissues. What is less clear is the 
clustering of primary and secondary cancer samples: there is no clear distinction 
between primary and omental tissue; in fact, sample pairs from the same patient are 
more likely to group together (01/M1, 02/M2, 03/M3, 05/M5).
05 ------------------------------ 1
M5 ------------------------------
M4 ----------------------------------------------
06 ----------------------------
03 ----------------------,
M3 ---------------------- ---------
01 --------------
M1 -------------
02 ---- 1 ______________
M2 ---------------------1
04 -----------------------
M6 _____________
N ________________  ___
N ________  _
N ______  _______
N ______ I
Figure 3.10. Cluster dendogram of normal and ovarian cancer samples.
Normal (N) ovarian tissue, primary ovarian cancer (P) and metastatic deposits (M).
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3.5.2 Primary Ovarian Cancer Compared to Normal Ovarian Tissue
421 genes were more than 2-fold and 118 genes were more than 3-fold over­
expressed in primary compared to normal tissue. Figure 3.11 shows significantly 
over-expressed genes in primary ovarian cancer sorted into functional groups. These 
groups include genes associated with epithelia and cell-cell contact such as secreted 
phosphoprotein 1 (OP), folate receptor 1, claudins-3 and 4 (CLDN3, 4), keratins-8, 
18 and 19 (KRT8, 18, 19), and agrin (AGRN). These are also shown in Figure 3.12B 
and could reflect the epithelial origin of these tumours. Genes involved in cell division 
and growth include cyclin D1, cellular retinoic acid binding protein 2, and lipocalin 2 
(oncogene 24p3). Metastasis and angiogenesis genes include jagged 2, tumour- 
associated calcium signal transducer 2 (TACSTD2), vascular endothelial growth 
factor (VEGF), CD24 antigen and neuromedin U.
The consistency of this data was compared with that of another study [Welsh et al.,
2001] where over-expression of tumour genes in cancer were ranked according to a 
combined metric using normal ovary as a baseline. The four genes CD24, WAP four- 
disulfide core domain 2 (HE4), CD9, and Lutheran blood group (LU) were found to be 
the most highly expressed by their method and are also highly over-expressed in the 
data-set in this study (Figure 3.12A). Where the datasets overlap, they are highly 
consistent.
A number of kallikreins (KLKs), a family of trypsin-like serine proteases that include 
prostate-specific antigen (PSA/KLK3) were found to be over-expressed in ovarian 
cancer. KLKs are being investigated as potential serum markers for 
adenocarcinomas such as prostate (KLK2), breast (KLK10, 12, 13) and ovary 
(KLK6, 8, 10, 11) [Diamandis and Yousef, 2002b] (Figure 3.12C). In addition, KLK7 
has been identified in this study as being over-expressed in ovarian cancer.
Table 3.1 lists the genes which are over-expressed in primary ovarian serous 
adenocarcinomas compared to normal ovarian tissue.
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Figure 3.11. Heatmap showing genes up-regulated in serous ovarian primary and omental 
metastatic tumours compared to normal ovary.
A number of over-expressed genes previously associated with ovarian- and other 
cancers were identified, including VEGF, osteopontin (OP) [Kim et al., 2002a], 
preferentially expressed antigen in melanoma (PRAME) [Steinbach et al., 2002], 
TACSD2 (or GA733-1) [Shetye et al., 1989;Szala et al., 1990], and prostasin 
(PRSS8) [Mok et al., 2001a] (Figure 3.12D). These may all play a role in ovarian 
carcinogenesis.
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Figure 3.12. Box and whisker plots show expression of selected genes in both normal (shaded, 
n=4) and primary tissues (unshaded, n=6).
The selected genes are split into 5 categories (A-E) from left to right. (A) For comparison with previous 
ovarian cancer GEM studies, (B) Epithelial markers, (C) Kallikrein serine protease family, (D) A 
selection of previously described serous ovarian cancer markers and (E) Genes with loss of 
expression in primary tumours. Box and whisker plots show a central median line, an interquartile box, 
whiskers at 1.5 times the interquartile range, and outliers of these shown as circles.
172 genes were 3 fold down-regulated in primary ovarian cancer compared to normal 
ovary (Figure 3.13). Among these were putative tumour suppressors including the 
p53 mediator paternally expressed gene-3 (PEG-3) [Deng and Wu, 2000;Relaix et 
al., 1998], wnt-inducible signalling protein-2 (WISP-2) a member of the connective 
tissue growth factor family [Pennica et al., 1998], and the Rho-associated 
transcriptional coactivator four-and-a-half LIM domains 2 (FHL2) [Muller et al.,
2002]. However, the recently reported putative tumour suppressor in ovarian cancer, 
opioid-binding protein (OPCML) did not appear to have any significant loss of 
expression in any of the samples studied here [Sellar et al., 2003] (Figure 3.12E).
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Figure 3.13. Genes down-regulated in primary and secondary serous ovarian cancer compared 
to normal ovary.
All differences are significant at the p<0.05 level after multiple testing adjustment (see methods).
3.5.3 Omental metastasis
Whilst there were 300 genes with more than 3-fold difference between normal and 
primary sample , there were only 35 equ lly large differ nces between primary n
omental metastases, all greater in metastases (Figure 3.14). These genes fell into 
two main groups. Firstly, those that were over-expressed in just the omental samples 
compared to both primary ovarian cancers and normal ovarian tissue (Figure 3.15). 
These included serum amyloid A1 (SAA1), which is a marker of inflammation and 
immunoglobulin (Ig) lamda-locus which may reflect leucocyte infiltration. Many of the 
gene differences between primary and paired omental samples reflect the high 
adipocyte content in the omentum, such as adipsin, lipoprotein lipase, and perilipin. 
The second group comprised genes which were equally over-expressed in primary 
and secondary cancers compared to normal tissue. These included enhancer of 
zeste homolog 2 (EZH2) previously described as a predictor of metastasis in prostate 
[Varambally et al., 2002], and pituitary tumour-transforming 1 interacting protein 
(PTTG1) and Lamin B1 (LMNB1) predictors of metastasis in adenocarcinoma 
[Ramaswamy et al., 2003] (Figure 3.15). Table 3.2 shows genes over-expressed in 
Omental metastases compared to primary ovarian adenocarcinoma.
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Figure 3.14. genes up-regulated in omental metastasis relative to normal ovary and primary 
ovarian cancer.
The predominance of genes associated with adipocytes reflects the omental background. All 
differences
are significant at the p<0.05 level after multiple testing adjustment (see methods).
<1>
CJC=
CD
<5
■O
o
CO
CO<I>
cL
x<D
C O  —
C N  —
O  —
C N SAA1 EZH2 PTTG1 LMNB1 ADN LPL PLIN IGL
sample 1-6
Figure 3.15. Expression of genes in metastatic and primary ovarian cancer samples (n=12, 6- 
paired).
The log difference of selected genes between the paired metastatic and primary ovarian cancer 
samples is plotted (metastatic -  primary), so that upwards is higher in metastasis and downwards is 
lower. The paired p-values were SAA1- 0.03, EZH2-0.82, PTTG1-0.47, LMNB1-0.41, ADN-0.04, LPL- 
0.01, PLIN-0.01, IGL-0.01.
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3.5.4 New biomarkers
A potential new biomarker MGB2 has been identified in this study which has (a) 
higher expression in both primary and metastatic samples compared to normal ovary, 
(b) high gross expression above the 80th percentile of all genes in primary and 
metastatic samples and (c) with high homology (58% amino acid identity) to the 
known serum marker MGB. Figure 15 shows the GEM profile of MGB2 compared to 
that of six other proteins that have been suggested as potential biomarkers: HPN 
[Tanimoto et al., 1997], IFI-15K, KLK6 [Diamandis and Yousef, 2002a], CP [Hough et 
al., 2001], SLPI [Shigemasa et al., 2001] and HE4 [Schummer et al., 1999] across a 
panel of epithelia rich tumours and tissues. This panel was comprised of publicly 
available Affymetrix data from: a) prostate adenocarcinoma [Singh et al., 2002] b) 
lung adenocarcinoma [Bhattacharjee et al., 2001] and c) the GNF gene expression 
atlas containing various primary epithelial tissues [Su et al., 2002] (see section 2.4.3). 
MGB2 in particular is very specific to ovarian adenocarcinoma.
Table 3.3 gives a summary of the names and abbreviations of all genes discussed in 
the text.
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Figure 3.16. Gene expression profile of putative biomarker MGB2 in 
ovarian serous adenocarcinoma and a panel of other tissues.
Comparison with six previously described biomarkers HPN, IFI-15K, KLK6, 
CP, SLPI and HE4. Serous ovarian AdC=primary serous ovarian 
adenocarcinoma, Omental Metastasis=serous ovarian omental metastasis, 
Lung AdC=lung adenocarcinoma, Prostate AdC=prostate adenocarcinoma. 
Adrenal gland, Kidney, Liver, Pancreas, Pituitary Gland, Lung, Spleen, 
Thymus, Thyroid, Trachea and Uterus all represent corresponding normal 
tissue specimens.
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Table 3.1. Genes over-expressed in primary ovarian serous adenocarcinomas compared to 
normal ovary.
Average difference and p values are shown.____________________________________  i___
Probe set Acc no. Gene description P-value Avg. diff.
34342_s_at AF052124 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1)
0.00005 4.74559
266 s at L33930 CD24 antigen (small cell lung carcinoma cluster 4 antigen) 0.00002 4.47336
291 s at J04152 tumor-associated calcium signal transducer 2 0.00035 4.23852
2092_s_at J04765 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1)
0.00049 4.19776
32275 at X04470 secretory leukocyte protease inhibitor (antileukoproteinase) 0.00001 4.14516
575 s at M93036 tumor-associated calcium signal transducer 1 0.00010 3.94321
33933 at X63187 WAP four-disulfide core domain 2 0.00000 3.81258
41066 at AF071219 secretoglobin, family 2A, member 1 0.00111 3.48639
36133 at AL031058 desmoplakin 0.00116 3.44008
700 s at X52229 mucin 1, transmembrane 0.00098 3.33690
668 s at L22524 matrix metalloproteinase 7 (matrilysin, uterine) 0.00906 3.21742
41294 at AJ238246 keratin 7 0.00378 3.17625
38784 g at J05581 mucin 1, transmembrane 0.00129 3.16934
33904 at AB000714 claudin 3 0.00006 3.10898
38324 at AD000684 liver-specific bHLH-Zip transcription factor 0.00051 2.98481
35766 at M26326 keratin 18 0.00006 2.96373
36861 at AL049946 adlican 0.00030 2.91318
35822 at L15702 B-factor, properdin 0.00558 2.76628
37534 at Y07593 coxsackie virus and adenovirus receptor 0.00000 2.71204
35995 at AF067656 ZW10 interactor 0.00133 2.70696
38783 at J05581 mucin 1, transmembrane 0.00064 2.63835
36100 at AF022375 vascular endothelial growth factor 0.00007 2.59976
32821 at AI762213 lipocalin 2 (oncogene 24p3) 0.00710 2.54362
39008 at M 13699 ceruloplasmin (ferroxidase) 0.00014 2.46470
31792 at M20560 annexin A3 0.00312 2.42945
1953 at AF024710 vascular endothelial growth factor 0.00029 2.42295
38631 at M92357 tumor necrosis factor, alpha-induced protein 2 0.00143 2.39254
33232 at AI017574 cysteine-rich protein 1 (intestinal) 0.00638 2.38955
1107 s at M 13755 interferon, alpha-inducible protein (clone IFI-15K) 0.00546 2.37402
927 s at J05582 mucin 1, transmembrane 0.00138 2.35302
2017 s at M64349 cyclin D1 (PRAD1 0.00246 2.34518
39704 s at L17131 high mobility group AT-hook 1 0.00001 2.29549
32715 at N90862 vesicle-associated membrane protein 8 (endobrevin) 0.00073 2.27559
40401 at AL050069 docking protein 5 0.00105 2.27378
40690 at X54942 CDC28 protein kinase regulatory subunit 2 0.01344 2.27151
35207 at X76180 sodium channel, nonvoltage-gated 1 alpha 0.00031 2.26287
35937 at U65416 MHC class I polypeptide-related sequence B 0.00486 2.20814
41377 f at J05428 UDP glycosyltransferase 2 family, polypeptide B7 0.01159 2.17544
1882_g_at D43969 runt-related transcription factor 1 (acute myeloid leukemia 1; 
amll oncogene)
0.00458 2.16153
1057 at M97815 cellular retinoic acid binding protein 2 0.00283 2.16073
32072 at U40434 mesothelin 0.00284 2.15042
36869 at X69699 paired box gene 8 0.00004 2.14389
40074_at X16396 methylene tetrahydrofolate dehydrogenase (NAD+ 
dependent), methenyltetrahydrofolate cyclohydrolase
0.00172 2.13215
38418 at X59798 cyclin D1 (PRAD1 0.00305 2.13167
37892 at J04177 collagen, type XI, alpha 1 0.05986 2.11769
37558 at U97188 IGF-II mRNA-binding protein 3 0.06410 2.10125
40035 at AB012917 kallikrein 11 0.00072 2.07794
572 at M86699 TTK protein kinase 0.00483 2.06860
36197 at Y08374 chitinase 3-like 1 (cartilage glycoprotein-39) 0.00134 2.06780
977 s at Z35402 cadherin 1, type 1, E-cadherin (epithelial) 0.00212 2.06536
39389 at M38690 CD9 antigen (p24) 0.00033 2.06004
35276 at AB000712 claudin 4 0.00000 2.03504
33824 at X74929 keratin 8 0.00043 2.02756
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1585_at M34309 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian)
0.00424 2.02086
1651 at U73379 ubiquitin-conjugating enzyme E2C 0.00607 2.00288
40093 at X83425 Lutheran blood group (Auberger b antigen included) 0.00104 1.99645
37591 at U94592 uncoupling protein 2 (mitochondrial, proton carrier) 0.01026 1.97942
35127 at AI039144 histone 1, H2ae 0.00745 1.93914
37554 at U62801 kallikrein 6 (neurosin, zyme) 0.00021 1.91208
157 at U64871 preferentially expressed antigen in melanoma 0.00943 1.90772
38749 at AI936826 G protein-coupled receptor 39 0.00062 1.89624
38482 at AJO11497 claudin 7 0.00013 1.89609
31888 s at AF001294 pleckstrin homology-like domain, family A, member 2 0.00471 1.88840
33338 at M97936 signal transducer and activator of transcription 1, 91kDa 0.00164 1.87689
634 at L41351 protease, serine, 8 (prostasin) 0.00047 1.87432
33454 at AFO16903 agrin 0.00111 1.87267
34213 at AB020676 KIBRA protein 0.00002 1.86377
149 at U88629 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 0.00177 1.84815
41376 i at J05428 UDP glycosyltransferase 2 family, polypeptide B7 0.00914 1.84647
36113 s at AJ011712 troponin T1, skeletal, slow 0.00241 1.83573
1591 s at J03242 insulin-like growth factor 2 (somatomedin A) 0.07240 1.82431
41783 at M97815 cellular retinoic acid binding protein 2 0.00953 1.81372
37890_at X69398 CD47 antigen (Rh-related antigen, integrin-associated signal 
transducer)
0.00080 1.81157
286 at L19779 histone 2, H2aa 0.00313 1.81048
39677 at X97671 KIAA0186 gene product 0.00245 1.79995
38116 at D14657 KIAA0101 gene product 0.02134 1.79617
534 s at U20391 folate receptor 1 (adult) 0.00432 1.79504
39109_at AB024704 TPX2, microtubule-associated protein homolog (Xenopus 
laevis)
0.01122 1.79492
37168 at ABO13924 lysosomal-associated membrane protein 3 0.01126 1.78649
2027 at M87068 S100 calcium binding protein A2 0.00392 1.76465
38432 at AA203213 interferon, alpha-inducible protein (clone IFI-15K) 0.00039 1.76152
37263_at U55206 gamma-glutamyl hydrolase (conjugase, 
folylpoiygammaglutamyl hydrolase)
0.00402 1.75929
35699_at AB017430 BUB1 budding uninhibited by benzimidazoles 1 homolog 
beta (yeast)
0.00235 1.74772
926 at J03910 metallothionein 1G 0.00037 1.74531
40412 at AA203476 pituitary tumor-transforming 1 0.00009 1.74209
40541 at X01630 argininosuccinate synthetase 0.00074 1.73492
649 s at L06797 chemokine (C-X-C motif) receptor 4 0.02078 1.72424
1603 fl at L33881 protein kinase C, iota 0.01249 1.72282
34194 at AL049313 NA 0.00198 1.72169
33436_at Z46629 SRY (sex determining region Y)-box 9 (campomelic 
dysplasia, autosomal sex-reversal)
0.00004 1.72078
32787_at M34309 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian)
0.00381 1.71659
543 g at S74445 cellular retinoic acid binding protein 1 0.00155 1.69414
121 at X68742 paired box gene 8 0.00091 1.68969
38763 at L29254 sorbitol dehydrogenase 0.00689 1.67330
39660 at X97671 defensin, beta 1 0.02558 1.67303
36643 at L20817 discoidin domain receptor family, member 1 0.00101 1.66935
39728 at J03909 interferon, gamma-inducible protein 30 0.01070 1.66164
33143_s_at U81800 solute carrier family 16 (monocarboxylic acid transporters), 
member 3
0.00053 1.65206
39579 at U89916 claudin 10 0.00955 1.65030
36879 at M63193 endothelial cell growth factor 1 (platelet-derived) 0.00071 1.64496
1602 at L33881 protein kinase C, iota 0.01202 1.64451
32609 at AI885852 histone 2, H2aa 0.03471 1.64135
39175 at D25328 phosphofructokinase, platelet 0.00239 1.63881
37985 at L37747 lamin B1 0.00867 1.63785
40407 at U28386 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 0.00314 1.63750
36813 at U96131 thyroid hormone receptor interactor 13 0.00592 1.62873
1225 fl at X66363 PCTAIRE protein kinase 1 0.01062 1.62485
32163 f at AA216639 NA 0.00696 1.62133
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38545 at M31682 inhibin, beta B (activin AB beta polypeptide) 0.07096 1.61934
2020 at M73554 cyclin D1 (PRAD1 0.00877 1.60957
34743 at D63481 scribble 0.00137 1.59423
36204 at Y00815 protein tyrosine phosphatase, receptor type, F 0.00071 1.59381
38551 at U52112 renin binding protein 0.01759 1.59193
41812 s at AB020713 nucleoporin 210 0.00012 1.59052
36101 s at M63978 vascular endothelial growth factor 0.00565 1.58999
33323 r at X57348 stratifin 0.00184 1.58898
925 at J03909 interferon, gamma-inducible protein 30 0.00760 1.58895
38248 at AB011124 ProSAPiPI protein 0.01706 1.58870
33710 at U72515 putative protein similar to nessy (Drosophila) 0.01118 1.58546
36108 at M 16276 major histocompatibility complex, class II, DQ beta 1 0.02411 1.57870
40746 at L20814 glutamate receptor, ionotropic, AMPA 2 0.08211 1.56861
35756 at AF089816 regulator of G-protein signalling 19 interacting protein 1 0.02303 1.56415
39610 at X16665 homeo box B2 0.00032 1.56177
38978 at AFO13758 polyadenylate binding protein-interacting protein 1 0.03101 1.55990
36308 at D76435 Zic family member 1 (odd-paired homolog, Drosophila) 0.14669 1.55561
32818 at X78565 tenascin C (hexabrachion) 0.01302 1.55443
1620 at D31784 cadherin 6, type 2, K-cadherin (fetal kidney) 0.05776 1.55222
39791 at M23114 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 0.00307 1.54812
39043 at AF006084 actin related protein 2/3 complex, subunit 1B, 41kDa 0.00390 1.54778
1224 at X66363 PCTAIRE protein kinase 1 0.01408 1.54289
41355 at N95229 B-cell CLL/lymphoma 11A (zinc finger protein) 0.00570 1.54115
2053 at M34064 cadherin 2, type 1, N-cadherin (neuronal) 0.02566 1.54049
1945 at M25753 cyclin B1 0.02435 1.53807
36446_s_at L24521 hepatoma-derived growth factor (high-mobility group protein 
1-like)
0.02083 1.53583
34390_at U90441 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 
4-hydroxylase), alpha polypeptide II
0.00286 1.53152
41579 s at AI952267 protein kinase C, iota 0.00648 1.53010
40726 at U37426 kinesin family member 11 0.00162 1.52805
408_at X54131 chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)
0.00527 1.52736
37305 at U61145 enhancer of zeste homolog 2 (Drosophila) 0.00035 1.52729
37117 at Z83838 Rho GTPase activating protein 8 0.00063 1.52478
1521 at X17620 non-metastatic cells 1, protein (NM23A) expressed in 0.00336 1.52346
38138 at D38583 S100 calcium binding protein A11 (calgizzarin) 0.00205 1.52167
33661 at U66589 ribosomal protein L5 0.01055 1.51688
41047 at Al885170 chromosome 9 open reading frame 16 0.00221 1.51675
40347_at AA913812 acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member E
0.00065 1.51463
37782 at AI636761 somatostatin 0.04020 1.51041
38546 at AB006537 interleukin 1 receptor accessory protein 0.00797 1.50564
32880 at AW015055 secretoglobin, family 1D, member 2 0.00304 1.50134
1083 s at M35093 mucin 1, transmembrane 0.00746 1.49359
35226 at U71207 eyes absent homolog 2 (Drosophila) 0.02891 1.49310
860 at U03911 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 0.04414 1.48594
38853 at X81892 G protein-coupled receptor 64 0.01116 1.48047
37749 at D78611 mesoderm specific transcript homolog (mouse) 0.04367 1.47420
41400 at K02581 thymidine kinase 1, soluble 0.00033 1.47195
41632 at D38550 E2F transcription factor 3 0.00379 1.47048
37347 at AA926959 CDC28 protein kinase regulatory subunit 1B 0.01438 1.46902
41356 at W27619 B-cell CLL/lymphoma 11A (zinc finger protein) 0.10799 1.46895
38592 s at AI828210 NA 0.00263 1.46624
37302 at U30872 centromere protein F, 350/400ka (mitosin) 0.00808 1.46584
37273 at AF007153 NA 0.00521 1.46200
34512 at J03853 adrenergic, alpha-2C-, receptor 0.00824 1.46059
36029 at U57911 chromosome 11 open reading frame 8 0.01545 1.45539
37956 at U37519 aldehyde dehydrogenase 3 family, member B2 0.02835 1.45532
39625 at AL050204 NA 0.00898 1.45518
39829 at AB016811 ADP-ribosylation factor-like 7 0.00235 1.45385
35829 at AL080181 immunoglobulin superfamily, member 4 0.04575 1.44866
136
41310 f at X12794 nuclear receptor subfamily 2, group F, member 6 0.00027 1.44827
425 at X67325 interferon, alpha-inducible protein 27 0.04049 1.44215
37310 at X02419 plasminogen activator, urokinase 0.03443 1.43447
32134 at AL050162 testis derived transcript (3 LIM domains) 0.00849 1.43182
35769 at AJ011001 G protein-coupled receptor 56 0.00002 1.42600
39073 at AL038662 non-metastatic cells 1, protein (NM23A) expressed in 0.00336 1.41893
35277 at AB018305 spondin 1, (f-spondin) extracellular matrix protein 0.01476 1.41656
35778 at AB011103 kinesin family member 5C 0.02658 1.41170
37343 at U01062 inositol 1,4,5-triphosphate receptor, type 3 0.00021 1.40987
1914 at U66838 cyclin A1 0.01191 1.40931
36651 at X15525 acid phosphatase 2, lysosomal 0.00452 1.40803
1368 at M27492 interleukin 1 receptor, type I 0.00632 1.40696
38086 at AB007935 immunoglobulin superfamily, member 3 0.00691 1.40183
36821 at AL050367 hypothetical protein LOC221061 0.10519 1.38749
40445_at AFO17307 E74-like factor 3 (ets domain transcription factor, epithelial- 
specific )
0.01387 1.38084
904 s at L47276 topoisomerase (DNA) II alpha 170kDa 0.00107 1.37950
37200 at J04162 Fc fragment of IgG, low affinity Ilia, receptor for (CD16) 0.05250 1.37816
182 at S82470 inositol 1,4,5-triphosphate receptor, type 3 0.00035 1.37682
1218 at X12794 nuclear receptor subfamily 2, group F, member 6 0.00534 1.37250
36658 at D13643 24-dehydrocholesterol reductase 0.02935 1.36964
40134_at AF047436 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit f, isoform 2
0.02582 1.36188
38143 at L33404 kallikrein 7 (chymotryptic, stratum corneum) 0.03574 1.36161
37218 at D64110 BTG family, member 3 0.00423 1.35371
36497 at W28438 NA 0.00370 1.35310
1985 s at X73066 non-metastatic cells 1, protein (NM23A) expressed in 0.00393 1.35050
36761 at AL079276 zinc finger protein 339 0.00004 1.34994
36782 s at J03242 insulin-like growth factor 2 (somatomedin A) 0.13410 1.34344
36070 at AL049389 KIAA1199 protein 0.00083 1.33864
32140 at Y08110 sortilin-related receptor, L(DLR class) A repeats-containing 0.00830 1.33334
613_at M21389 keratin 5 (epidermolysis bullosa simplex, Dowling- 
Meara/Kobner/Weber-Cockayne types)
0.00888 1.33264
40899 at Y00503 keratin 19 0.04301 1.32738
34348 at U78095 serine protease inhibitor, Kunitz type, 2 0.00601 1.32600
32317_s_at U34804 sulfotransferase family, cytosolic, 1A, phenol-preferring, 
member 2
0.00765 1.32555
36484 at AI935146 UDP-N-acetyl-alpha-D-galactosamine 0.00112 1.32439
32137 at AF029778 iagged 2 0.01487 1.32362
895_at L19686 macrophage migration inhibitory factor (glycosylation- 
inhibiting factor)
0.00513 1.31965
1402_at M 16038 v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog
0.00644 1.31894
1490_at M 19720 v-myc myelocytomatosis viral oncogene homolog 1, lung 
carcinoma derived (avian)
0.00497 1.31885
38391 at M94345 capping protein (actin filament), gelsolin-like 0.01717 1.31658
36457 at U10860 guanine monphosphate synthetase 0.00496 1.31602
40145 at AI375913 topoisomerase (DNA) II alpha 170kDa 0.00516 1.31519
37883 i at AI375033 hypothetical protein AF038169 0.02814 1.31352
32559_s_at AJ238096 LSM4 homolog, U6 small nuclear RNA associated (S. 
cerevisiae)
0.00637 1.31015
33920 at AF051782 diaphanous homolog 1 (Drosophila) 0.00013 1.30575
38158 at D79987 extra spindle poles like 1 (S. cerevisiae) 0.00005 1.30475
1877_g_at M29893 v-ral simian leukemia viral oncogene homolog A (ras 
related)
0.04273 1.30296
35803 at S82240 ras homolog gene family, member E 0.04300 1.30268
38411 at U90916 sortilin-related receptor, L(DLR class) A repeats-containing 0.04444 1.29505
36610_at D21852 R3H domain (binds single-stranded nucleic acids) 
containing
0.01735 1.29282
32263 at AL080146 cyclin B2 0.00268 1.29103
40041 at AFO17790 highly expressed in cancer, rich in leucine heptad repeats 0.00932 1.29044
1713_s_at U26727 cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4)
0.04628 1.28546
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628 at L37882 frizzled homolog 2 (Drosophila) 0.01558 1.28295
37360 at U66711 lymphocyte antigen 6 complex, locus E 0.01072 1.27492
33130 at AW001001 homeo box D1 0.03137 1.27400
37961_at U90907 phosphoinositide-3-kinase, regulatory subunit, polypeptide 3 
(p55, gamma)
0.03890 1.27165
34563 at D26361 kinesin family member 14 0.00393 1.26557
38111 at X15998 chondroitin sulfate proteoglycan 2 (versican) 0.16088 1.26490
741 g at D49394 5-hydroxytryptamine (serotonin) receptor 3A 0.08229 1.26452
34852_g at AFO11468 serine/threonine kinase 6 0.00066 1.25970
41688 at AI688299 transmembrane 4 superfamily member 11 (plasmolipin) 0.00420 1.25919
32767 at M74558 TAL1 (SCL) interrupting locus 0.01290 1.25897
32051_at AJ224875 asparagine-linked glycosylation 8 homolog (yeast, alpha- 
1,3-glucosyltransferase)
0.01614 1.25778
431 at X02530 chemokine (C-X-C motif) ligand 10 0.10188 1.25688
36167 at D89052 ATPase, H+ transporting, lysosomal 21kDa, VO subunit c" 0.00172 1.25633
1385 at M77349 transforming growth factor, beta-induced, 68kDa 0.08975 1.25396
41585 at ABO18289 KIAA0746 protein 0.00504 1.25372
36454 at AF037335 carbonic anhydrase XII 0.05908 1.25176
32156 at AF044968 poliovirus receptor-related 2 (herpesvirus entry mediator B) 0.00091 1.24900
37784 at AL049227 NA 0.00934 1.24887
34308 at U90551 histone 1, H2ac 0.02767 1.24540
34736 at M25753 cyclin B1 0.01274 1.24260
32959_at M25809 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit 
B, isoform 1 (Renal tubular acidosis with deafness)
0.01109 1.24078
41732 at AA310786 similar to My016 protein 0.00074 1.23986
35807 at M21186 cytochrome b-245, alpha polypeptide 0.00042 1.23976
36927 at AB000115 chromosome 1 open reading frame 29 0.08658 1.23739
38313 at AB028985 ATP-binding cassette, sub-family A (ABC1), member 2 0.00164 1.23620
33272 at AA829286 serum amyloid A1 0.04305 1.22919
35631 at U37689 polymerase (RNA) II (DNA directed) polypeptide H 0.00320 1.22596
39396 at AF081281 lysophospholipase I 0.07865 1.22335
41168 at AF029750 TAP binding protein (tapasin) 0.01571 1.21901
39092 at AW007731 histone H2A.F/Z variant 0.04113 1.21844
34693 at D13814 sialyltransferase 0.00117 1.21690
41060 at M74093 cyclin E1 0.01429 1.21674
36499_at Z16411 cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo 
homolog, Drosophila)
0.00099 1.21557
41470 at AF027208 prominin 1 0.02018 1.21483
34177 at AF038660 UDP-Gal 0.00813 1.20943
1007 s at U48705 discoidin domain receptor family, member 1 0.00387 1.20073
33484 at Y10571 ring finger protein 2 0.03278 1.19997
35828 at D42123 cysteine-rich protein 2 0.01135 1.19894
38087_s_at W72186 S100 calcium binding protein A4 (calcium protein, 
calvasculin, metastasin, murine placental homolog)
0.03813 1.19807
38442 at U19718 microfibrillar-associated protein 2 0.10931 1.19697
39056_at X53793 phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide 
synthetase
0.01290 1.19551
32509 at AI307607 HBxAg transactivated protein 2 0.04726 1.19368
38576 at AJ223353 histone 1, H2bd 0.03352 1.19352
40303_at U85658 transcription factor AP-2 gamma (activating enhancer 
binding protein 2 gamma)
0.00872 1.19238
39219 at U20240 CCAAT/enhancer binding protein (C/EBP), gamma 0.03060 1.19115
38123 at D14878 chromosome 10 open reading frame 7 0.03775 1.18766
34251 at M92299 homeo box B5 0.03894 1.18722
34970 r at Al655458 5-oxoprolinase (ATP-hydrolysing) 0.00253 1.18706
39253_s_at M29893 v-ral simian leukemia viral oncogene homolog A (ras 
related)
0.03881 1.18588
33253 at D50919 tripartite motif-containing 14 0.03258 1.18490
32963 s at W27549 Ras-related GTP binding D 0.03099 1.18400
36512 at L32179 arylacetamide deacetylase (esterase) 0.00847 1.18214
34715 at U74612 forkhead box M1 0.00102 1.17668
41610 at AB011105 laminin, alpha 5 0.02048 1.17590
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38161_at Y09022 asparagine-linked glycosylation 3 homolog (yeast, alpha- 
1,3-mannosyltransferase)
0.00188 1.17313
41696 at AI620381 chromosome 7 open reading frame 24 0.00532 1.17054
40888 f at W28170 eukaryotic translation elongation factor 1 alpha 1 0.07186 1.16916
40193 at X68985 enolase 2, (gamma, neuronal) 0.01002 1.16887
41188 at W28186 lysosomal associated protein transmembrane 4 beta 0.01470 1.16852
37727 i at X78669 reticulocalbin 2, EF-hand calcium binding domain 0.04904 1.16792
35858 at AA996066 PRKR interacting protein 1 (IL11 inducible) 0.01383 1.16698
41193 at ABO13382 dual specificity phosphatase 6 0.00873 1.16528
37761 at ABO15020 BAM-associated protein 2 0.00317 1.16385
34699 at D13814 CD2-associated protein 0.04690 1.16155
36898 r at X74331 primase, polypeptide 2A, 58kDa 0.02863 1.15825
38160 at AFO11333 lymphocyte antigen 75 0.02219 1.15686
41189 at Y09392 tumor necrosis factor receptor superfamily, member 25 0.00253 1.15560
39183 at X66363 PCTAIRE protein kinase 1 0.01779 1.15519
1173 g at M77693 spermidine/spermine N1-acetyltransferase 0.01001 1.15094
40788 at U84371 adenylate kinase 2 0.00129 1.15029
38336 at AB023230 GRP1-binding protein GRSP1 0.03611 1.15024
39353 at A I912041 heat shock 10kDa protein 1 (chaperonin 10) 0.05187 1.15018
41058 g at AI760162 thioesterase superfamily member 2 0.03412 1.14864
36145 at U51586 fuse-binding protein-interacting repressor 0.01590 1.14795
2035 s at M55914 enolase 1, (alpha) 0.00102 1.14710
36804 at M34455 indoleamine-pyrrole 2,3 dioxygenase 0.08612 1.14543
36575 at S59049 regulator of G-protein signalling 1 0.06883 1.14305
35615 at D50914 block of proliferation 1 0.00352 1.14255
33702 f at L05144 phosphoenolpyruvate carboxykinase 1 (soluble) 0.00310 1.14237
1803 at X05360 cell division cycle 2, G1 to S and G2 to M 0.01169 1.14114
31935_s_at U75968 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1- 
like helicase homolog, S. cerevisiae)
0.00018 1.14095
38618 at AC002073 HGFL gene 0.00408 1.14035
36581 at U09510 glycyl-tRNA synthetase 0.02578 1.13487
35320_at AB004857 solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2
0.01757 1.13329
31600 s at D38435 postmeiotic segregation increased 2-like 1 0.05851 1.13270
41096 at AM 26134 S100 calcium binding protein A8 (calgranulin A) 0.03939 1.13021
34661 at AB002348 KIAA0350 protein 0.00916 1.12959
36561 at X73424 propionyl Coenzyme A carboxylase, beta polypeptide 0.02912 1.12685
41198 at AF055008 granulin 0.00137 1.12658
1451 s at U80987 osteoblast specific factor 2 (fasciclin l-like) 0.21497 1.12399
41485 at X02152 lactate dehydrogenase A 0.00695 1.12267
38257_at AF038406 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase)
0.00686 1.12082
821 s at U78793 folate receptor 1 (adult) 0.11578 1.12047
40434 at U97519 podocalyxin-like 0.00541 1.12015
41223 at M22760 cytochrome c oxidase subunit Va 0.03355 1.12013
37677 at V00572 phosphoglycerate kinase 1 0.02627 1.11657
35630 at X87342 lethal giant larvae homolog 2 (Drosophila) 0.00006 1.11489
34304 s at AL050290 spermidine/spermine N1 -acetyltransferase 0.01292 1.11480
34865_at Al360249 NADH dehydrogenase (ubiquinone) Fe-S protein 6 , 13kDa 
(NADH-coenzyme Q reductase)
0.03250 1.11476
36863 at AF032862 hyaluronan-mediated motility receptor (RHAMM) 0.00196 1.11396
33247_at U86782 proteasome (prosome, macropain) 26S subunit, non- 
ATPase, 14
0.04130 1.10643
37603 at X52015 interleukin 1 receptor antagonist 0.00991 1.10624
39812 at X79865 mitochondrial ribosomal protein L12 0.00132 1.10555
41451 s at W28498 SAR1a gene homolog 1 (S. cerevisiae) 0.09838 1.10390
39311 at AF000381 folate receptor 1 (adult) 0.03019 1.10359
40417 at D43950 chaperonin containing TCP1, subunit 5 (epsilon) 0.03949 1.10101
33266 at AFO15254 aurora kinase B 0.00035 1.10065
38967 at AF054175 chromosome 14 open reading frame 2 0.08320 1.10032
40536 f at AI254524 translation initiation factor IF2 0.00431 1.10031
41583 at AC004770 flap structure-specific endonuclease 1 0.03718 1.09851
295 s at U14755 LIM homeobox 1 0.01326 1.09326
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1599_at L25876 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase)
0.01271 1.09248
34885 at AJ002308 synaptogyrin 2 0.00194 1.09095
32034 at AF041259 zinc finger protein 217 0.05755 1.08850
33374 at L09708 complement component 2 0.06814 1.08817
41084 at AI659108 hypothetical protein MGC51082 0.07846 1.08784
34878_at ABO19987 SMC4 structural maintenance of chromosomes 4-like 1 
(yeast)
0.02926 1.08578
40161_at L32137 cartilage oligomeric matrix protein (pseudoachondroplasia, 
epiphyseal dysplasia 1, multiple)
0.05491 1.08559
38429 at U29344 fatty acid synthase 0.00428 1.08525
33132 at U37012 cleavage and polyadenylation specific factor 1 ,1 60kDa 0.00014 1.08488
38949 at L01087 protein kinase C, theta 0.00540 1.08431
38389 at X04371 2\5'-oligoadenylate synthetase 1, 40/46kDa 0.06910 1.08408
39158 at AB021663 activating transcription factor 5 0.00143 1.08293
32579_at U29175 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4
0.03963 1.07996
33260 at L13857 son of sevenless homolog 1 (Drosophila) 0.00264 1.07962
37926 at D14520 Kruppel-like factor 5 (intestinal) 0.00254 1.07940
35227 at U72066 retinoblastoma binding protein 8 0.02136 1.07924
38647 at AJ131182 coatomer protein complex, subunit epsilon 0.00749 1.07769
39969 at AA255502 histone 1, H4c 0.11568 1.07559
1242 at U15655 Ets2 repressor factor 0.00363 1.07458
35844 at D79206 syndecan 4 (amphiglycan, ryudocan) 0.00387 1.07354
38112 g at X15998 chondroitin sulfate proteoglycan 2 (versican) 0.18393 1.07280
36811 at U24389 lysyl oxidase-like 1 0.07861 1.07229
32332 at X69433 isocitrate dehydrogenase 2 (NADP+), mitochondrial 0.00162 1.07155
37984 s at M57763 ADP-ribosylation factor 6 0.15424 1.07121
39105 at Z46389 vasodilator-stimulated phosphoprotein 0.00826 1.07048
40535 i at AI254524 translation initiation factor IF2 0.01108 1.07019
37686 s at Y09008 uracil-DNA glycosylase 0.03756 1.06374
33212 at AF006751 ribosome binding protein 1 homolog 180kDa (dog) 0.01116 1.06343
1979 s at U29656 nucleolar protein 1, 120kDa 0.00943 1.06326
36008 at AF041434 protein tyrosine phosphatase type IVA, member 3 0.00209 1.06321
35666_at U38276 sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3F
0.01827 1.06289
757 at D28364 annexin A2 0.00944 1.05996
35703 at X06374 platelet-derived growth factor alpha polypeptide 0.03963 1.05929
32154_at M36711 transcription factor AP-2 alpha (activating enhancer binding 
protein 2 alpha)
0.03236 1.05915
34795_at U84573 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine 
hydroxylase) 2
0.11881 1.05760
1592 at J04088 topoisomerase (DNA) II alpha 170kDa 0.01884 1.05644
2088 s at M94151 EphB2 0.05732 1.05558
41320 s at U69609 leucine rich repeat (in FLII) interacting protein 1 0.04510 1.05496
32796 f at U66061 trypsinogen C 0.03956 1.05416
36957 at W22296 protein kinase C binding protein 1 0.02970 1.05373
41250 at U24169 JTV1 gene 0.00254 1.05260
37740_r_at J02683 solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5
0.04286 1.05169
36687 at N50520 cytochrome c oxidase subunit Vllb 0.07891 1.05014
35576 f at AL009179 putative G-protein coupled receptor pseudogene 0.05843 1.04933
41045 at U77643 secreted and transmembrane 1 0.06572 1.04919
32622 at L36983 dynamin 2 0.00004 1.04644
37576 at U52969 Purkinje cell protein 4 0.05114 1.04637
36838 at AF055481 kallikrein 10 0.03228 1.04608
36135 at U86602 EBNA1 binding protein 2 0.00944 1.04565
36598 s at L36818 inositol polyphosphate phosphatase-like 1 0.00105 1.04434
40504 at AF001601 paraoxonase 2 0.02857 1.04417
1741 s at S37730 insulin-like growth factor binding protein 2, 36kDa 0.04851 1.04312
32670 at L38969 thrombospondin 3 0.00542 1.04151
38617 at D45906 LIM domain kinase 2 0.00097 1.04128
38127 at Z48199 syndecan 1 0.01473 1.04095
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1616 at U44105 fibroblast growth factor 9 (glia-activating factor) 0.14962 1.04072
40195 at X68985 H2A histone family, member X 0.08174 1.04068
36155_at D87465 sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 2
0.00180 1.04039
34022 at M36821 chemokine (C-X-C motif) ligand 3 0.00018 1.03837
36388 at U25128 parathyroid hormone receptor 2 0.03885 1.03825
40813 at AI768188 mitochondrial ribosomal protein S6 0.09149 1.03693
39817 s at AF040105 putative c-Myc-responsive 0.00862 1.03675
32859 at M97935 signal transducer and activator of transcription 1,91 kDa 0.02852 1.03619
40422 at X16302 insulin-like growth factor binding protein 2, 36kDa 0.09028 1.03543
41733 at AC003007 KIAA0220 protein 0.07920 1.03468
38264 at U74324 RAB interacting factor 0.00789 1.03432
36591 at X06956 tubulin, alpha 1 (testis specific) 0.00991 1.03416
33791 at Y15227 deleted in lymphocytic leukemia, 1 0.02683 1.03280
31859_at J05070 matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase)
0.01469 1.02883
36885 at L28824 spleen tyrosine kinase 0.00098 1.02824
39837 s at AC004877 KIAA0543 protein 0.00108 1.02606
330 s at Z14227 tubulin, alpha 1 (testis specific) 0.00867 1.02324
37162 at S72869 DNA segment on chromosome 10 (unique) 170 0.14687 1.02112
32046 at D10495 protein kinase C, delta 0.02677 1.02102
32616_at M 16038 v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog
0.01885 1.01941
41073 at AI743745 G protein-coupled receptor 49 0.07575 1.01816
34301 r at Z19574 keratin 17 0.00100 1.01725
40167 s at AF038187 WD repeat and SOCS box containing protein 2 0.11648 1.01659
34472 at AB012911 frizzled homolog 6 (Drosophila) 0.03319 1.01599
38328 at H10201 solute carrier family 25, member 13 (citrin) 0.01348 1.01507
32378 at M26252 pyruvate kinase, muscle 0.00446 1.01442
2047 s at M74297 junction plakoglobin 0.02540 1.01410
40763_at U85707 M eisl, myeloid ecotropic viral integration site 1 homolog 
(mouse)
0.01658 1.01288
38661 at X75315 RNA-binding region (RNP1, RRM) containing 1 0.00183 1.01239
2054 g at M34064 cadherin 2, type 1, N-cadherin (neuronal) 0.06239 1.00964
41171_at D45248 proteasome (prosome, macropain) activator subunit 2 (PA28 
beta)
0.02266 1.00953
39342 at X94754 methionine-tRNA synthetase 0.00205 1.00834
36676 at AL031659 chromosome 20 open reading frame 132 0.08707 1.00728
32801 at AB002315 KIAA0317 gene product 0.00192 1.00539
31523 f at Z80780 histone 1, H2be 0.02069 1.00193
1630 s at Z29630 spleen tyrosine kinase 0.00246 1.00188
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Table 3.2. Genes over-expressed in omental metastases compared to primary ovarian serous 
adenocarcinomas.
Average difference and p values are shown._________________________________________ _____________ ___
Probe set Acc no. Gene description P-value Avg. diff
38430 at AA128249 fatty acid binding protein 4, adipocyte 0.83304 5.18163
40657 r at H15814 adipose most abundant gene transcript 1 0.13398 3.74608
37122 at AB005293 perilipin 0.53899 3.48806
41209 at M 15856 lipoprotein lipase 0.04191 2.83884
33273 f at X57809 immunoglobulin lambda locus 0.34906 2.69798
35730 at X03350 alcohol dehydrogenase IB (class I), beta polypeptide 0.72553 2.67887
33274 f at M 18645 immunoglobulin lambda joining 3 0.45705 2.63531
38326 at M69199 putative lymphocyte G0/G1 switch gene 0.53372 2.42394
37864 s at Y14737 immunoglobulin heavy constant gamma 3 (G3m marker) 0.90520 2.26880
33272 at AA829286 serum amyloid A1 0.68327 2.15547
38299 at X04430 interleukin 6 (interferon, beta 2) 0.39328 2.09411
37032 at U08021 nicotinamide N-methyltransferase 0.83388 2.05498
37565 at X85750 monocyte to macrophage differentiation-associated 0.19630 1.99608
38038 at U21128 lumican 0.23649 1.99192
36984 f at X89214 haptoglobin-related protein 0.87366 1.96664
41827 f at AI932613 hypothetical protein LOC51233 0.82525 1.96001
40082 at D10040 fatty-acid-Coenzyme A ligase, long-chain 2 0.55850 1.92182
41164 at X67301 immunoglobulin heavy constant mu 0.57179 1.83487
32243_g at AL038340 crystallin, alpha B 0.84334 1.82972
35334 at U94362 glycogenin 2 0.64430 1.81367
32805_at U05861 aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase)
0.89452 1.81327
40282 s at M84526 D component of complement (adipsin) 0.18182 1.78729
37006_at Al660656 immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides
0.74250 1.77665
32552 at X00129 retinol binding protein 4, plasma 0.35500 1.76447
34637 f at M 12963 alcohol dehydrogenase 1A (class I), alpha polypeptide 0.06184 1.75604
41772 at M68840 monoamine oxidase A 0.33343 1.68798
819 at U76456 tissue inhibitor of metalloproteinase 4 0.59229 1.66460
32242 at AL038340 crystallin, alpha B 0.00919 1.65875
36686 at U07919 aldehyde dehydrogenase 1 family, member A3 0.97414 1.65696
32542 at AF063002 four and a half LIM domains 1 0.05803 1.65223
32527 at AI381790 adipose specific 2 0.24944 1.64180
37221 at M31158 protein kinase, cAMP-dependent, regulatory, type II, beta 0.69461 1.63584
41771_g at AA420624 monoamine oxidase A 0.25128 1.63101
37954 at X16662 annexin A8 0.81388 1.62047
38194 s at M63438 NA 0.19657 1.62039
36119 at AF070648 caveolin 1, caveolae protein, 22kDa 0.59093 1.58713
40658 r at D45371 adipose most abundant gene transcript 1 0.75835 1.55862
190 at U09937 nuclear receptor subfamily 4, group A, member 3 0.62999 1.44802
160030 at X06562 growth hormone receptor 0.34167 1.41245
39031 at AA152406 cytochrome c oxidase subunit Vila polypeptide 1 (muscle) 0.76618 1.40486
1814 at D50683 transforming growth factor, beta receptor II (70/80kDa) 0.70846 1.40278
39673_i_at X97671 extracellular matrix protein 2, female organ and adipocyte 
specific
0.64976 1.38750
32488_at X14420 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, 
autosomal dominant)
0.77319 1.37023
37671 at S78569 laminin, alpha 4 0.38676 1.36187
36606 at X51405 carboxypeptidase E 0.46794 1.35424
296 at X79535 tubulin, beta polypeptide 0.39319 1.34455
35926_s_at AF004230 leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and HIM domains), member 1
0.36236 1.34442
32747 at X05409 aldehyde dehydrogenase 2 family (mitochondrial) 0.14789 1.33655
37157 at X56667 calbindin 2, 29kDa (calretinin) 0.21031 1.33111
40841 at AF049910 transforming, acidic coiled-coil containing protein 1 0.22341 1.32999
41385 at AB023204 erythrocyte membrane protein band 4.1-like 3 0.21258 1.32431
36983 f at X00442 haptoglobin 0.61263 1.31547
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31687 f at M25079 hemoglobin, beta 0.24644 1.31382
38379 at X76534 glycoprotein (transmembrane) nmb 0.48483 1.28754
39114 at AB022718 decidual protein induced by progesterone 0.79641 1.27741
32664 at D37931 ribonuclease, RNase A family, 4 0.83442 1.27635
37215_at AF046798 phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI)
0.79541 1.27147
37951 at AF035119 deleted in liver cancer 1 0.60724 1.26986
37279 at U10550 GTP binding protein overexpressed in skeletal muscle 0.34465 1.25872
339 at AF005887 caveolin 2 0.52424 1.25705
40659 at U12767 nuclear receptor subfamily 4, group A, member 3 0.43938 1.25444
32227 at X17042 proteoglycan 1, secretory granule 0.27930 1.24057
38052 at M 14539 coagulation factor XIII, A1 polypeptide 0.96497 1.22270
1815 a at D50683 transforming growth factor, beta receptor II (70/80kDa) 0.36818 1.20849
33702 f at L05144 phosphoenolpyruvate carboxykinase 1 (soluble) 0.78227 1.20112
32551 at U03877 EGF-containing fibulin-like extracellular matrix protein 1 0.87925 1.20028
36627 at X86693 SPARC-like 1 (mast9, hevin) 0.08451 1.19862
38717 at AL050159 DKFZP586A0522 protein 0.17110 1.19037
658 at L12350 thrombospondin 2 0.63158 1.18974
34793 s at M22299 plastin 3 (T isoform) 0.09126 1.18566
40071 at U03688 cytochrome P450, family 1, subfamily B, polypeptide 1 0.89737 1.18504
38786 at AL079279 likely ortholog of mouse polydom 0.51225 1.18355
35704 at X92814 HRAS-like suppressor 3 0.21244 1.17772
39350 at U50410 glypican 3 0.47079 1.17404
1451 s at U80987 osteoblast specific factor 2 (fasciclin l-like) 0.36087 1.17125
479_at U53446 disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila)
0.50660 1.17051
37630 at AL049176 neuralin 1 0.75663 1.16027
40077 at Z11559 aconitase 1, soluble 0.34717 1.15561
32052 at L48215 hemoglobin, beta 0.37760 1.15239
38378 at M37033 CD53 antigen 0.05886 1.15072
1403 s at M21121 chemokine (C-C motif) ligand 5 0.19086 1.14807
38466 at X82153 cathepsin K (pycnodysostosis) 0.09103 1.13912
32538 at S95936 transferrin 0.48220 1.13290
36681 at J02611 apolipoprotein D 0.73660 1.12565
39616 at AL050227 prostaglandin E receptor 3 (subtype EP3) 0.18890 1.12307
35303 at U96876 insulin induced gene 1 0.68307 1.12170
39333 at M26576 collagen, type IV, alpha 1 0.24210 1.12124
35785 at W28281 GABA(A) receptor-associated protein like 1 0.06910 1.10516
40496 at J04080 complement component 1, s subcomponent 0.44320 1.10184
859 at U03688 cytochrome P450, family 1, subfamily B, polypeptide 1 0.46561 1.09714
37015 at K03000 aldehyde dehydrogenase 1 family, member A1 0.54460 1.09559
33902 at L34041 glycerol-3-phosphate dehydrogenase 1 (soluble) 0.86058 1.09193
34311 at X76648 glutaredoxin (thioltransferase) 0.23254 1.08808
37104 at L40904 peroxisome proliferative activated receptor, gamma 0.94652 1.08614
34797 at AFO14402 phosphatidic acid phosphatase type 2A 0.22838 1.08183
41165 g at X67301 immunoglobulin heavy constant mu 0.17729 1.08008
40375 at X63741 early growth response 3 0.55743 1.07870
32755 at X13839 actin, alpha 2, smooth muscle, aorta 0.78592 1.06898
37398 at AA100961 platelet/endothelial cell adhesion molecule (CD31 antigen) 0.07307 1.06559
41123_s_at L35594 ectonucleotide pyrophosphatase/phosphodiesterase 2 
(autotaxin)
0.18518 1.05975
40202 at D31716 basic transcription element binding protein 1 0.74951 1.05402
37908 at U31384 guanine nucleotide binding protein (G protein), gamma 11 0.13786 1.05386
40856_at U29953 serine (or cysteine) proteinase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), member 1
0.93324 1.05227
41096 at AM 26134 S100 calcium binding protein A8 (calgranulin A) 0.54709 1.05122
37762 at Y07909 epithelial membrane protein 1 0.84863 1.04912
33890 at AF005887 regulator of G-protein signalling 5 0.74310 1.04778
34303 at AL049949 hypothetical protein FLJ90798 0.36417 1.04672
408_at X54131 chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)
0.49865 1.04631
38220 at U20938 dihydropyrimidine dehydrogenase 0.41881 1.04527
36543 at J02931 coagulation factor III (thromboplastin, tissue factor) 0.38411 1.04507
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659 g at L12350 thrombospondin 2 0.49672 1.04362
37187 at M36820 chemokine (C-X-C motif) ligand 2 0.91301 1.03605
38653 at D11428 peripheral myelin protein 22 0.05092 1.03595
41504_s_at AF055376 v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (avian)
0.47673 1.03343
32612 at X04412 gelsolin (amyloidosis, Finnish type) 0.19343 1.03305
40419 at X85116 stomatin 0.78835 1.03231
40518 at Y00062 protein tyrosine phosphatase, receptor type, C 0.35216 1.03203
41770 at AA420624 monoamine oxidase A 0.13208 1.03064
34375 at M28225 chemokine (C-C motif) ligand 2 0.44729 1.02818
36227 at AF043129 interleukin 7 receptor 0.46876 1.02437
844 at U48707 protein phosphatase 1, regulatory (inhibitor) subunit 1A 0.82696 1.02085
39945 at U09278 fibroblast activation protein, alpha 0.57437 1.01594
40456 at AL049963 solute carrier family 39 (metal ion transporter), member 8 0.84436 1.00622
37185_at Y00630 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 2
0.81569 1.00611
39331 at X79535 tubulin, beta polypeptide 0.97246 1.00473
37407 s at AFO13570 myosin, heavy polypeptide 11, smooth muscle 0.36565 1.00273
37842 at AF054589 l-mfa domain-containing protein 0.34788 1.00052
1105 s at M 12886 T cell receptor beta locus 0.57650 0.99848
37701 at L13463 regulator of G-protein signalling 2, 24kOa 0.04506 0.99524
40398_s_at AI743406 mesenchyme homeo box 2 (growth arrest-specific homeo 
box)
0.51023 0.99475
32666_at U19495 chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1)
0.03370 0.99384
38427 at L25286 collagen, type XV, alpha 1 0.52617 0.99230
38096 f at M83664 major histocompatibility complex, class II, DP beta 1 0.52742 0.99195
37599 at Z84718 aldehyde oxidase 1 0.79059 0.98266
33756_at U39447 amine oxidase, copper containing 3 (vascular adhesion 
protein 1)
0.41119 0.97798
38363 at W60864 TYRO protein tyrosine kinase binding protein 0.12534 0.97567
1717 s at U45878 baculoviral IAP repeat-containing 3 0.78374 0.97352
614 at M22430 phospholipase A2, group IIA (platelets, synovial fluid) 0.30086 0.96972
1372 at M31165 tumor necrosis factor, alpha-induced protein 6 0.05372 0.96971
39568_g at AB006190 aquaporin 7 0.09472 0.96835
AFFX-BioDn- 
5 at
J04423 NA 0.26944 0.96745
32535 at X63556 fibrillin 1 (Marfan syndrome) 0.17916 0.96562
33703 f at L12760 phosphoenolpyruvate carboxykinase 1 (soluble) 0.22253 0.96491
36617_at X77956 inhibitor of DNA binding 1, dominant negative helix-loop- 
helix protein
0.24602 0.96441
38095 i at M83664 major histocompatibility complex, class II, DP beta 1 0.81686 0.95950
37402 at D26129 ribonuclease, RNase A family, 1 (pancreatic) 0.54967 0.95694
875 g at M26683 chemokine (C-C motif) ligand 2 0.55219 0.95621
37724 at V00568 v-myc myelocytomatosis viral oncogene homolog (avian) 0.12227 0.95473
1370 at M29696 interleukin 7 receptor 0.38951 0.94853
996 at X59065 fibroblast growth factor 1 (acidic) 0.82072 0.94779
32855_at L00352 low density lipoprotein receptor (familial 
hypercholesterolemia)
0.81001 0.94606
36247 f at M 12272 alcohol dehydrogenase 1C (class I), gamma polypeptide 0.42675 0.94441
1788 s at U48807 dual specificity phosphatase 4 0.95242 0.94343
38059 _g at Z22865 dermatopontin 0.71328 0.94064
36073 at U35139 necdin homolog (mouse) 0.94366 0.93991
39597 at AB020650 KIAA0843 protein 0.30672 0.93553
32686 at D86096 prostaglandin E receptor 3 (subtype EP3) 0.67392 0.93520
38111 at X15998 chondroitin sulfate proteoglycan 2 (versican) 0.68240 0.93174
33821_at AL034374 ELOVL family member 5, elongation of long chain fatty 
acids (FEN1/Elo2, SUR4/Elo3-like, yeast)
0.70269 0.93159
37203_at L07765 carboxylesterase 1 (monocyte/macrophage serine esterase
D
0.34762 0.92906
40698_at X96719 C-type (calcium dependent, carbohydrate-recognition 
domain) lectin, superfamily member 2 (activation-induced)
0.09360 0.92811
36792 at Z24727 tropomyosin 1 (alpha) 0.99798 | 0.92748
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671 at J03040 secreted protein, acidic, cysteine-rich (osteonectin) 0.39330 0.92399
36533 at D83402 prostaglandin 12 (prostacyclin) synthase 0.77145 0.92383
39690 at X97671 alpha-actinin-2-associated LIM protein 0.69538 0.92217
1106 s at M 12959 T cell receptor alpha locus 0.12654 0.92215
37023 at J02923 lymphocyte cytosolic protein 1 (L-plastin) 0.59217 0.92173
38454 g at X15606 intercellular adhesion molecule 2 0.07295 0.92090
39814 s at AI052724 retinal short-chain dehydrogenase/reductase 4 0.97797 0.91142
AFFX-BioB- 
M at
J04423 NA 0.24036 0.91054
33328 at W28612 NA 0.30594 0.90977
1596_g_at L06139 TEK tyrosine kinase, endothelial (venous malformations, 
multiple cutaneous and mucosal)
0.53476 0.90756
34644 at AB021288 beta-2-microglobulin 0.54540 0.90168
36790 at M 19267 tropomyosin 1 (alpha) 0.01332 0.89796
770 at D00632 glutathione peroxidase 3 (plasma) 0.39374 0.89785
36239 at Z49194 POU domain, class 2, associating factor 1 0.30462 0.89532
33440 at U19969 transcription factor 8 (represses interleukin 2 expression) 0.75506 0.89436
38057 at AL049798 dermatopontin 0.08318 0.89354
38319 at AA919102 CD3D antigen, delta polypeptide (TiT3 complex) 0.97716 0.89335
AFFX-BioC- 
3 at
J04423 NA 0.29338 0.88838
35872 at D50640 phosphodiesterase 3B, cGMP-inhibited 0.36364 0.88657
41738 at M64110 caldesmon 1 0.93779 0.88126
31855 at U61374 sushi-repeat-containing protein, X-linked 0.46189 0.88085
38006 at M37766 CD48 antigen (B-cell membrane protein) 0.60797 0.88034
39593 at AI432401 fibrinogen-like 2 0.24127 0.87936
40775 at AL021786 integral membrane protein 2A 0.19208 0.87898
33113_at U65093 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2
0.11774 0.87351
35681 r at AB011141 zinc finger homeobox 1 b 0.73793 0.87238
36577_at Z24725 pleckstrin homology domain containing, family C (with 
FERM domain) member 1
0.93442 0.86990
297 g at X79535 tubulin, beta polypeptide 0.75944 0.86942
428 s at V00567 beta-2-microglobulin 0.48596 0.86863
35792 at U67963 monoglyceride lipase 0.12384 0.86721
40019 at M60830 ecotropic viral integration site 2B 0.68539 0.85520
37604 at U44111 histamine N-methyltransferase 0.77680 0.85382
647 at L35545 protein C receptor, endothelial (EPCR) 0.25995 0.85366
36629 at AI635895 delta sleep inducing peptide, immunoreactor 0.83372 0.85247
40607 at U97105 dihydropyrimidinase-like 2 0.46060 0.85074
34407 at U77594 retinoic acid receptor responder (tazarotene induced) 2 0.72896 0.84738
39994 at D10925 chemokine (C-C motif) receptor 1 0.42855 0.84580
37403 at X05908 annexin A1 0.28166 0.84437
40480 s at M 14333 FYN oncogene related to SRC, FGR, YES 0.72578 0.84119
35717 at AB020629 ATP-binding cassette, sub-family A (ABC1), member 8 0.61682 0.83843
39470 at AL049974 NA 0.76538 0.83821
39674_r_at X97671 extracellular matrix protein 2, female organ and adipocyte 
specific
0.35367 0.83716
268 at L34657 platelet/endothelial cell adhesion molecule (CD31 antigen) 0.80953 0.83540
581 at M61916 laminin, beta 1 0.96636 0.83503
40063 at U22897 nuclear domain 10 protein 0.56927 0.83151
33243 at AF099935 TNF-induced protein 0.94215 0.83130
40399_r_at X69878 mesenchyme homeo box 2 (growth arrest-specific homeo 
box)
0.17933 0.82724
35985 at AB023137 A kinase (PRKA) anchor protein 2 0.81831 0.82505
33705_at L20971 phosphodiesterase 4B, cAMP-specific (phosphodiesterase 
E4 dunce homolog, Drosophila)
0.89911 0.82439
35435 s at AF001903 L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain 0.66616 0.82415
36156 at U41518 aquaporin 1 (channel-forming integral protein, 28kDa) 0.09910 0.82258
AFFX-BioC- 
5 at
J04423 NA 0.81549 0.82119
39174 at X77548 nuclear receptor coactivator 4 0.53537 0.82056
37573 at AF007150 angiopoietin-like 2 0.49852 | 0.81946
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595 at M59465 tumor necrosis factor, alpha-induced protein 3 0.14558 0.81468
39799 at M94856 fatty acid binding protein 5 (psoriasis-associated) 0.43247 0.81291
35649 at U80055 cysteine dioxygenase, type I 0.14954 0.81248
37598 at Z84718 Ras association (RalGDS/AF-6) domain family 2 0.83524 0.80873
37688 f at M31932 Fc fragment of IgG, low affinity lla, receptor for (CD32) 0.24103 0.80813
32067 at S68271 cAMP responsive element modulator 0.94492 0.80744
31508 at S73591 thioredoxin interacting protein 0.18059 0.80713
36874 at M26004 complement component (3d/Epstein Barr virus) receptor 2 0.67153 0.80349
1709 g at U07620 mitogen-activated protein kinase 10 0.37241 0.80319
39372 at W26480 fatty acid desaturase 1 0.34998 0.80307
40978 s at X56468 cerebellar degeneration-related protein 1, 34kDa 0.92176 0.80274
37399_at Z84718 aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II)
0.24018 0.80111
39839 at M24069 cold shock domain protein A 0.41781 0.80096
39760 at AL031781 quaking homolog, KH domain RNA binding (mouse) 0.21344 0.80056
39317_at D86324 cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase (CMP-N-acetylneuraminate monooxygenase)
0.69175 0.80056
1478 at L10717 IL2-inducible T-cell kinase 0.19676 0.79901
34183 at AL080169 DKFZP434C171 protein 0.90779 0.79830
40509_at J04058 electron-transfer-flavoprotein, alpha polypeptide (glutaric 
aciduria II)
0.09221 0.79652
33803 at J02973 thrombomodulin 0.48197 0.79538
37637 at U27655 regulator of G-protein signalling 3 0.92563 0.79527
37233 at AF079167 oxidised low density lipoprotein (lectin-like) receptor 1 0.22272 0.79457
39081 at AI547258 metallothionein 2A 0.39656 0.79255
37009 at AL035079 catalase 0.52818 0.79234
41530_at D16294 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3- 
oxoacyl-Coenzyme A thiolase)
0.80070 0.79163
38420 at Y14690 collagen, type V, alpha 2 0.29804 0.79034
583 s at M30257 vascular cell adhesion molecule 1 0.50438 0.79014
32249 at M65292 H factor (complement)-like 1 0.77091 0.78892
37394 at J03507 complement component 7 0.88468 0.78842
34853 at AB007865 fibronectin leucine rich transmembrane protein 2 0.80388 0.78727
41237 at D32129 major histocompatibility complex, class I, A 0.28894 0.78696
36650 at D13639 cyclin D2 0.87683 0.78594
40471 at Y09048 peroxisomal farnesylated protein 0.16642 0.78421
41454 at W27949 heme binding protein 2 0.89897 0.78331
39781 at U20982 insulin-like growth factor binding protein 4 0.90959 0.78282
36878 f at M60028 major histocompatibility complex, class II, DQ beta 1 0.56955 0.78267
37200 at J04162 Fc fragment of IgG, low affinity Ilia, receptor for (CD16) 0.43079 0.78199
34820_at M57399 pleiotrophin (heparin binding growth factor 8, neurite 
growth-promoting factor 1)
0.89579 0.78032
36053 at AF041248 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 0.93854 0.77941
32112 s at AI800499 absent in melanoma 1 0.92581 0.77936
37025 at AL120815 lipopolysaccharide-induced TNF factor 0.74421 0.77875
37624 at M29458 carbonic anhydrase III, muscle specific 0.05846 0.77732
37397 at L34657 platelet/endothelial cell adhesion molecule (CD31 antigen) 0.29506 0.77704
31438 s at Z22971 CD 163 antigen 0.26524 0.77696
37623 at X75918 nuclear receptor subfamily 4, group A, member 2 0.92410 0.77515
32363 at AF059214 cholesterol 25-hydroxylase 0.52167 0.77404
AFFX-BioB- 
5 at
J04423 NA 0.61173 0.77271
37024 at AF010312 lipopolysaccharide-induced TNF factor 0.64247 0.77229
33849 at U02020 pre-B-cell colony-enhancing factor 0.55197 0.77117
34235 at AB018301 G protein-coupled receptor 116 0.33874 0.76857
33499 s at M36612 hypothetical protein MGC27165 0.78312 0.76763
40079 at AA156240 retinoic acid induced 3 0.84259 0.76667
39567 at AB006190 aquaporin 7 0.79193 0.76611
38458 at L39945 cytochrome b-5 0.60312 0.76508
41433 at M73255 vascular cell adhesion molecule 1 0.16200 0.76489
38893_at X80907 colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage)
0.75044 0.76451
37310 at X02419 plasminogen activator, urokinase 0.14086 0.76289
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37493_at H04668 colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage)
0.44555 0.76163
39691 at X97671 SH3-domain GRB2-like endophilin B1 0.62041 0.76018
37543 at D25304 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 0.06580 0.75901
160029 at X07109 protein kinase C, beta 1 0.90609 0.75656
41839 at L13698 growth arrest-specific 1 0.75905 0.75577
36980 at U03105 proline-rich nuclear receptor coactivator 1 0.74753 0.75531
38796_at X03084 complement component 1, q subcomponent, beta 
polypeptide
0.59629 0.75407
39338_at AI201310 S100 calcium binding protein A10 (annexin II ligand, 
calpactin I, light polypeptide (p11))
0.74818 0.75386
37219 at X72755 chemokine (C-X-C motif) ligand 9 0.31991 0.75180
38578 at M63928 tumor necrosis factor receptor superfamily, member 7 0.38356 0.75052
36674 at J04130 chemokine (C-C motif) ligand 4 0.64903 0.74902
38774 at U77942 syntaxin 7 0.88811 0.74894
37391 at X12451 cathepsin L 0.29832 0.74864
1147 at X12795 nuclear receptor subfamily 2, group F, member 1 0.55784 0.74829
1761 at D37965 platelet-derived growth factor receptor-like 0.39293 0.74760
40749 at X07203 membrane-spanning 4-domains, subfamily A, member 1 0.52601 0.74672
36979_at M20681 solute carrier family 2 (facilitated glucose transporter), 
member 3
0.54528 0.74617
AFFX-
HSAC07/X00 
351 3 st
X00351 actin, beta 0.18568 0.74588
36159_s_at U29185 prion protein (p27-30) (Creutzfeld-Jakob disease, 
Gerstmann-Strausler-Scheinker syndrome, fatal familial 
insomnia)
0.24095 0.74470
41871 at Al660929 lung type-l cell membrane-associated glycoprotein 0.69013 0.73979
38026 at U01244 fibulin 1 0.37915 0.73944
36635 at AB023173 ATPase, Class VI, type 11B 0.41069 0.73838
38745_at X76488 lipase A, lysosomal acid, cholesterol esterase (Wolman 
disease)
0.42809 0.73745
35012 at M81750 myeloid cell nuclear differentiation antigen 0.36484 0.73706
33500 i at S71043 immunoglobulin heavy constant mu 0.84541 0.73669
37707 i at M81118 alcohol dehydrogenase 5 (class III), chi polypeptide 0.39630 0.73550
41755 at AB023194 KIAA0977 protein 0.93761 0.73513
36656_at M98399 CD36 antigen (collagen type I receptor, thrombospondin 
receptor)
0.17093 0.73254
2036_s_at M59040 CD44 antigen (homing function and Indian blood group 
system)
0.31270 0.73123
38077 at X52022 collagen, type VI, alpha 3 0.73445 0.73037
41505_r_at AF055376 v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (avian)
0.48056 0.72973
35410_at U81234 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic 
protein 2)
0.94371 0.72808
227_g_at M33336 protein kinase, cAMP-dependent, regulatory, type I, alpha 
(tissue specific extinguisher 1)
0.29303 0.72703
36773 f at M81141 major histocompatibility complex, class II, DQ beta 1 0.36558 0.72696
36659 at X05610 collagen, type IV, alpha 2 0.50209 0.72574
40767_at M59499 tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor)
0.83878 0.72385
37383 f at X58536 major histocompatibility complex, class I, C 0.34433 0.72299
33305_at M93056 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 1
0.62059 0.72142
39822 s at AF078077 growth arrest and DNA-damage-inducible, beta 0.22866 0.71960
38374 at AF050110 TGFB inducible early growth response 0.48733 0.71756
31897 at D64142 downregulated in ovarian cancer 1 0.86622 0.71664
33809_at AL049933 guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 1
0.62795 0.71438
34210 at N90866 CDW52 antigen (CAMPATH-1 antigen) 0.90640 0.71168
37684_at AB020687 solute carrier family 21 (organic anion transporter), member 
9
0.22353 0.71162
1323 at X04803 ubiquitin B 0.25016 0.71151
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32689 s at D86096 prostaglandin E receptor 3 (subtype EP3) 0.54627 0.71026
38768 at X96752 L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain 0.44397 0.70748
36889_at M33195 Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide
0.87477 0.70726
36753_at AF072099 leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 4
0.21325 0.70714
33834_at L36033 chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1)
0.65288 0.70577
38320 s at L11706 lipase, hormone-sensitive 0.85459 0.70553
39864 at D78134 cold inducible RNA binding protein 0.03460 0.70520
41747_s_at U49020 MADS box transcription enhancer factor 2, polypeptide A 
(myocyte enhancer factor 2A)
0.82787 0.70229
1461_at M69043 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha
0.26793 0.70224
37017 at M22430 phospholipase A2, group IIA (platelets, synovial fluid) 0.40704 0.70055
1368 at M27492 interleukin 1 receptor, type I 0.48205 0.70039
37747 at U05770 annexin A5 0.30298 0.69915
767 at AF001548 myosin, heavy polypeptide 11, smooth muscle 0.98159 0.69879
33730 at AF095448 retinoic acid induced 3 0.13372 0.69718
37043 at AL021154 E2F transcription factor 2 0.62130 0.69715
39640 at X97671 glutamine-fructose-6-phosphate transaminase 2 0.30512 0.69628
1062 a at U00672 interleukin 10 receptor, alpha 0.61732 0.69585
39959 at AL031983 gamma-aminobutyric acid (GABA) B receptor, 1 0.91080 0.69518
41422 at D78011 dihydropyrimidinase 0.29684 0.69469
32424 at D84424 hyaluronan synthase 1 0.20338 0.69396
33790 at AI720438 chemokine (C-C motif) ligand 15 0.83255 0.69263
41609 at U15085 major histocompatibility complex, class II, DM beta 0.40963 0.69210
AFFX-CreX- 
5 at
X03453 NA 0.29783 0.69181
36711_at AL021977 v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian)
0.26017 0.69127
41225_at AL049417 dual specificity phosphatase 3 (vaccinia virus phosphatase 
VH1-related)
0.06542 0.69117
590 at M32334 intercellular adhesion molecule 2 0.09082 0.69055
38826 at D50918 septin 6 0.62091 0.69032
35752 s at M 15036 protein S (alpha) 0.14335 0.68997
37983 at S77410 angiotensin II receptor, type 1 0.17657 0.68889
1491 at M31166 pentaxin-related gene, rapidly induced by IL-1 beta 0.16336 0.68852
37078 at J04132 CD3Z antigen, zeta polypeptide (TiT3 complex) 0.55008 0.68760
34378 at X97324 adipose differentiation-related protein 0.74773 0.68751
36908 at M93221 mannose receptor, C type 1 0.99474 0.68687
36130 f at R92331 metallothionein 1E (functional) 0.22509 0.68636
33813 at AI813532 tumor necrosis factor receptor superfamily, member 1B 0.97424 0.68581
39091 at AF070523 cytoskeleton related vitamin A responsive protein 0.59294 0.68568
35832 at AB029000 sulfatase 1 0.97249 0.68558
661 at L13698 growth arrest-specific 1 0.19500 0.68417
41439 at AJ001381 myosin IB 0.38664 0.68316
39397 at M64497 nuclear receptor subfamily 2, group F, member 2 0.04674 0.68183
36892 at AF032108 integrin, alpha 7 0.59819 0.67952
36503 at AB002409 chemokine (C-C motif) ligand 21 0.35965 0.67922
174 s at U59325 intersectin 2 0.40345 0.67828
AFFX-BioB- 
3 at
J04423 NA 0.85266 0.67802
35331 at U97067 catenin (cadherin-associated protein), alpha-like 1 0.48925 0.67779
38254 at AB020689 KIAA0882 protein 0.21533 0.67762
36280 at U26174 granzyme K (serine protease, granzyme 3; tryptase II) 0.75900 0.67748
159 at U40992 vascular endothelial growth factor C 0.48649 0.67659
1377_at M58603 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1 (p105)
0.41563 0.67559
34198_at U12128 protein tyrosine phosphatase, non-receptor type 13 (APO- 
1/CD95 (Fas)-associated phosphatase)
0.15005 0.67549
40522 at X59834 glutamate-ammonia ligase (glutamine synthase) 0.79914 0.67515
35261 at W07033 glia maturation factor, gamma 0.48414 0.67215
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41124_r_at L35594 ectonucleotide pyrophosphatase/phosphodiesterase 2 
(autotaxin)
0.54091 0.67179
31575 f at M 14087 NA 0.45839 0.67158
33943 at L20941 ferritin, heavy polypeptide 1 0.54136 0.66974
1767 s at X14885 transforming growth factor, beta 3 0.79004 0.66900
AFFX-BioDn- 
3 at
J04423 NA 0.42264 0.66798
39069 at AF053944 AE binding protein 1 0.13066 0.66791
376_at Z84718 sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3C
0.73801 0.66361
610 at M15169 adrenergic, beta-2-, receptor, surface 0.26832 0.66313
37892 at J04177 collagen, type XI, alpha 1 0.28326 0.66131
38995_at AF000959 claudin 5 (transmembrane protein deleted in 
velocardiofacial syndrome)
0.79053 0.66095
41257 at D16217 calpastatin 0.33747 0.66029
34760 at D14664 type I transmembrane C-type lectin receptor DCL-1 0.45971 0.65662
37148_at AF025533 leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 3
0.52118 0.65620
37294 at X61123 B-cell translocation gene 1, anti-proliferative 0.20484 0.65533
37542 at D86961 lipoma HMGIC fusion partner-like 2 0.74916 0.65180
837 s at U43944 malic enzyme 1, NADP(+)-dependent, cytosolic 0.99374 0.65128
33501 r at S71043 immunoglobulin heavy constant mu 0.97950 0.64949
35790 at AF054179 vacuolar protein sorting 26 (yeast) 0.94219 0.64923
38833 at X00457 major histocompatibility complex, class II, DP alpha 1 0.40055 0.64820
41531 at AI445461 transmembrane 4 superfamily member 1 0.22557 0.64817
37645 at Z22576 CD69 antigen (p60, early T-cell activation antigen) 0.39886 0.64667
39409 at M 14058 complement component 1, r subcomponent 0.18833 0.64537
33390 at AA203487 serine/threonine kinase 17b (apoptosis-inducing) 0.40573 0.64442
36976 at D21255 cadherin 11, type 2, OB-cadherin (osteoblast) 0.90470 0.64311
32091 at AB007915 KIAA0446 gene product 0.16846 0.64302
245 at M25280 selectin L (lymphocyte adhesion molecule 1) 0.55771 0.64229
33830 at AW026535 leptin receptor 0.69626 0.64228
35776 at AF064243 intersectin 1 (SH3 domain protein) 0.58109 0.64136
37420 i at AL022723 major histocompatibility complex, class I, F 0.73519 0.64066
37544 at X64318 nuclear factor, interleukin 3 regulated 0.35854 0.63987
216 at M98539 prostaglandin D2 synthase 21kDa (brain) 0.37453 0.63808
38666_at M85169 pleckstrin homology, Sec7 and coiled-coil domains 
1 (cytohesin 1)
0.76049 0.63776
38323 at AC005162 carboxypeptidase, vitellogenic-like 0.97692 0.63717
40575 at AB011155 discs, large homolog 5 (Drosophila) 0.59008 0.63636
37692_at Al557240 diazepam binding inhibitor (GABA receptor modulator, acyl- 
Coenzyme A binding protein)
0.39246 0.63501
41000 at U68723 checkpoint suppressor 1 0.95874 0.63487
36030 at AL080214 HOM-TES-103 tumor antigen-like 0.50402 0.63487
35267 g at AL049288 bladder cancer associated protein 0.49798 0.63435
32184 at X61118 LIM domain only 2 (rhombotin-like 1) 0.46845 0.63283
37459 at X57527 collagen, type VIII, alpha 1 0.58842 0.63278
36515_at AJ238764 UDP-N-acetylglucosamine-2-epimerase/N- 
acetylmannosamine kinase
0.38986 0.63244
149
Symbol probe-id Acc ID Full Name
ADN 40282 s at M84256 adipsin
AGRN 33454 at AF016903 agrin
BF 35822 at L15702 B-factor
CD24 266 at L33930 CD24 antigen
CD9 39389 at M38690 CD9 antigen
CLDN3 33904 at AB000714 claudin 3
CLDN4 35276 at AB000712 claudin 4
CP 39008 at M13699 ceruloplasmin
EZH2 37305 at U61145 enhancer of zeste homolog 2
FHL2 38422 at U29332 four and a half LIM domains 2
FOXOIA 40570 at AF032885 forkhead box 0 1 A
HE4 33933 at X63187 WAP four-disulfide core domain 2
HPN 37639 at X07732 hepsin
IFI-15K 1107 at M13755 interferon, alpha-inducible protein, 15kDa
IGL 33273 f at X57809 immunoglobulin lambda locus
KLK10 36838 at AF055481 kallikrein 10
KLK11 40035 at AB012917 kallikrein 11
KLK13 36406 at AA401397 kallikrein 13
KLK2 217 at S39329 kallikrein 2
KLK3 1804 at X07730 kallikrein 3
KLK6 37554 at U62801 kallikrein 6
KLK7 38143 at L33404 kallikrein 7
KLK8 37131 at AB008390 kallikrein 8
KRT18 35766 at M26326 keratin 18
KRT19 40899 at Y00503 keratin 19
KRT8 33824 at X74929 keratin 8
LMNB1 37985 at L37747 lamin B1
LPL 41209 at M 15856 lipoprotein lipase
LU 40093 at X83425 Lutheran blood group
OP 2092 at J04675 osteopontin
OPCML 41093 at AF070577 opioid binding protein/cell adhesion molecule like
PEG3 39701 at AB006625 paternally expressed 3
PLIN 37122 at AB005293 Perilipin
PRAME 157 at U65011 preferentially expressed antigen of melanoma
PRSS8 634 at L41351 protease, serine 8
PTTG1 40412 at AF095288 pituitary tumour transforming 1
SAA1 33272 at AA829286 serum amyloid A1
SCGB2A1 41066 at NM 002407 secretoglobin, family 2A, member 1
SLPI 32275 at X04470 secretory leukocyte protease inhibitor
TACSTD2 575 s at J04152 tumour-associated calcium signal transducer 2
VEGF 36100 at AF024710 vascular endothelial growth factor
WISP2 35898 at AF100780 WNT1 inducible signalling pathway protein 2
Table 3.3. Summary of the names and abbreviations of genes discussed.
Symbol here is the most commonly used abbreviation, usually from OMIM (Online Mendelian 
Inheritance in Man). Probe is the unique Affymetrix probe ID. The Accession is the NCBI Refseq, 
or reference sequence for this gene.
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3.6 Real-Time Quantitative Reverse Transcription PCR 
(QTR-PCR)
3.6.1 Primer Optimisation
In order to perform real-time qRT-PCR, forward and reverse primers were chosen for 
each gene (see section 2.5.6.2). Primer optimisation for all genes was based on 
varying forward and reverse primers. Every combination was run in triplicate with and 
without template (non-template control, NTC) and with the PCR thermal cycle 
conditions described in Table 2.6.
Reverse 
primer (nM)
Forward primer (nM)
50 300 900
50 50/50 50/300 50/900
300 300/50 300/300 300/900
900 900/50 900/300 900/900
Table 3.4. Primer concentrations used in the primer optimisation matrix.
Nine different combinations were used for each optimisation (modified from the Taqman® Universal 
PCR Master Mix protocol).
The optimal performance is achieved by selecting the primer concentrations that 
provide the lowest threshold cycle (CT) for a fixed amount of template and no 
amplification was observed in the NTC for all genes (Figure 3.17 below).
I
45
40 -
35
30 -
MGB2 primer optimisation
ifl *
I25 -
5 0F/5 OR 50F/300R 50F/900R 300F/50R 300F/300R 300F/900R 900F/50R 900F/300R 900F/900R
□  average Ct +cDNA 36.97 31.29 30.49 31.74 29.95 29.25 33.89 29.8 29.43
□  average Ct +NTC 45 44.45 45 45 45 43.56 45 42.81 44.37
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SAA1 Primer optimisation
45 -| 
40 
35 H 
30 
25 H
£ nzu -
50F/50R 50F/300R 50F/900R 300F/50R 300F/300R 300F/900R 900F/50R 900F/300R 900F/900R
□  average Ct +cDNA 29.28 25.77 26.43 25.51 22.43 21.87 23.65 21.68 21.5
□  average Ct +NTC 45 45 45 45 44.91 45 45 45 44.33
H EPSIN Prim er optim isation
40
35 -
30 -
E-
50F/50R 50F/300R 5 0F/900R 300F/50R 300F/300R 300F/900R 900F/50R 900F/300R 900F/900R
□ average + cDNA 32.116667 30.343333 29.313333 29.563333 28.28 27.843333 29.923333 27.946667 27.816667
□  average NTC 40 40 40 39.883333 37.04 40 40 40 40
KLK6 primer optimisation
40
35 -
30 -
50F/50R 50F/300R 50F/900R 300F/50R 300F/3 00 
R
300F/900
R 900F/50R
900F/300
R
L _
900F/900
R
□  average Ct +cDNA 39.52 36.02 34.83 37.35 32 31.19 36.07 31 30.94
| □  average Ct +N TC 40 40 40 40 40 40 40 37.88 40
<DXI13e
o>,u
40
35
30
25
20
15
GAPDH Primer optimisation
10 -
50F/50R 50F/300R 50F/900R 300F/50R 300F/300R 300F/900R 900F/50R 900F/300R 900F/900R
□  average Ct +cDNA 22.89 19.6 19.63 18.27 16.15 16.04 17.55 16.1 15.89
□  average Ct +NTC 40 40 40 40 40 40 40 37.64 37.46
Figure 3.17. Optimisation graphs for MGB2, KLK6, hepsin, SAA1 and GAPDH.
See 5 graphs on previous 2 pages.Primer concentrations are plotted against the 
threshold cycle for genes MGB2, SAA1, KLK6, HPN and GAPDH. The experiments 
were done in triplicate and the standard error of the mean is shown. F=forward primer,
R=reverse primer in nM. cDNA= cDNA template, NTC= non-template control, Ct=time 
at which amplification starts.
The optimum primer concentrations for all genes used is given in chapter 2 section 
2.5.11.2.
3.6.2 Validation Experiment
The validation experiment describes the efficiency of amplification at different 
template concentrations. cDNA template was diluted in a series of 5-fold dilutions at 
1/1, 1/5, 1/25, 1/125, 1/625 and 1/3125. 1pl of cDNA was used from each dilution in 
duplicate. Every assay performed was considered valid only if the correlation 
coefficient R2 , for the standard curves was >0.98 and the slope values for the 
regression line ranged from -3.3 to -3.9 i.e. the efficiency of the PCR reaction was at 
least 80% (efficiency = 10(-1/slope) -  1 x 100).
The efficiencies of target (gene of interest) and reference (GAPDH) must be 
approximately equal. The absolute value of the slope of log input amount vs DCt 
should be <0.2. The genes in Figure 3.18 are all below 0.2 except for SAA1 where 
the value is 0.28, but this is unlikely to disrupt the experiment. If the value is >0.2 
then either standard curves need to be run or the primers need to be redesigned.
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Figure 3.18. Ct validation experiment.
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Figure 3.19. Relative efficiency plot
154
3.6.3 Expression Levels
After optimisation and validation experiments, the RNA levels for each gene were 
determined in all tissues (normal, LMP, primary and secondary cancers). The design 
of the experiment for each gene is shown in Figure 3.20.
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Figure 3.20. 96 w ell p late
This template illustrates the layout of cDNA samples for the expression level step, with each 
sample run in duplicate. N=normal ovary, LM=low m alignant potential, 0=prim ary ovarian cancer, 
M=omental metastasis, NTC=non-template control.
The RNA expression levels for each gene in each tissue was calculated by 
comparison to GAPDH levels in Normal tissues (see chapter 2 section 2.5.11.2). An 
example of the calculation of the expression levels for one of the genes, KLK6, is 
shown in Table 3.5, and the fold expression is shown in Figure 3.21.
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Tissue
SYBR
Green
KLK6 Ct GAPDH
Ct
Average 
KLK6 Ct
Average 
GAPDH Ct
ACt AACt 2A(-AACt)
N1 32.08 26.63 32.53 26.765 5.765 0 1
32.98 26.9
N2 31.79 19.73 31.415 19.94 11.475
31.04 20.15
N3 30.08 19.96 30.06 19.93 10.13
30.04 19.9
N4 29.86 20.45 29.53 20.45 9.08
29.2 20.45
N5 34.71 24.14 34.67 24.1 10.57
34.63 24.06
LMP1 24.97 18.3 25.045 18.235 6.81 4.135666667 17.57760572
25.12 18.17
LMP2 23.22 19.15 23.07 19.15 3.92
22.92 19.15
LMP4 31.94 30.26 32.21 30.225
32.48 30.19
LMP5 25 19.94 24.985 19.91 5.075
24.97 19.88
02 26.06 20.25 26.115 20.195 5.92 -3.16275 8.955351131
26.17 20.14
03 23.36 17.41 23.455 17.445 6.01
23.55 17.48
04 23.05 16.85 23.205 16.955 6.25
23.36 17.06
05 23.27 16.4 23.135 16.35 6.785
23 16.3
M2 37.19 29.58 36.395 29.62 -1.644 3.125311521
35.6 29.66
M3 28.48 20.2 28.515 20.485 8.03
28.55 20.77
M4 25.28 17.56 25.235 17.745 7.49
25.19 17.93
Table 3.5. Relative quantitation of KLK6 in normal (N), low malignant potential (LMP), primary 
ovarian cancer (O) and omental secondaries (M).
AACt = ACt relative to Normal (ACt for KLK6 in normal ovary - ACt for KLK6 in LMP/cancer tissue. Ct = 
threshold cycle, ACt = Ct for KLK6 -  Ct for GAPDH. 2A(-AACt) = measure of KLK6 over-expression 
relative to normal tissue.
The remaining genes, MGB2, SAA1 and HPN were calculated in the same fashion.
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NORMAL(n=5) LOW MALIGNANT(n=3) OVARlAN(n=4) METASTASIS(n=2)
Tissue
Figure 3.21. KLK6 fold expression based on above expression data (Table 3.5).
HEPSIN MGB2
N LMP o M N LMP 0 M
Figure 3.22. Fold expression of hepsin, MGB2, KLK6 and SAA1 in low malignant potential 
(LMP) tumour, primary ovarian cancer (O) and omental metastasis (M) relative to normal ovary.
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3.6.4 Validation of Array Data with QRT-PCR
In order to validate the gene expression levels from the microarray experiments, we 
performed real-time quantitative RT-PCR (qRT-PCR) with GAPDH as a control in 5 
normal ovaries, 3 low malignant potential (LMP) ovarian serous cancers, 4 primary 
ovarian serous cystadenocarcinomas and 2 omental metastases. Figure 3.22 shows 
corresponding gene expression patterns by qRT-PCR of the four genes, 
mammaglobin B2 (MGB2), serum amyloid A1 (SAA1), kallikrein-6 (KLK6) and hepsin 
(HPN) for normal ovary, primary and secondary disease on the microarrays 
compared to that on qRT-PCR. Figure 3.23 demonstrates that the differential 
expression pattern and the quantitative expression level of each of these four genes 
as determined by qRT-PCR were similar to those observed with the microarrays, 
confirming the reliability of our array expression data. Notably, qRT-PCR showed 
high expression of MGB2 and KLK6 in the LMP samples.
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Figure 3.23. Comparison of quantitative RT-PCR and GEM data.
QRT-PCR data: (clear bars, Normal (n=5), Primary (n=5), LMP (n=3), and Metastasis (n=2)) and 
GEM data: (shaded bars, Normal (n=4), Primary (n=6), and Metastasis (n=6)) for MGB2, SAA1, 
KLK6, and HPN in normal, primary and omental metastasis samples. GEM data is in original 
Log2 scale, and qRT-PCR is single Log2 unit per round of amplification, error bars show 
the standard deviation. The Normal level is taken as a 0 baseline reference for both.
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3.7 Immunohistochemistry
IHC was performed with one gene, hepsin. This prostate cancer serum biomarker 
was over-expressed in both primary ovarian cancer tissue and further over­
expressed in omental tissue. There was staining of both normal ovarian surface 
epithelium (OSE) and malignant epithelial cells in primary cancer and omental 
metastasis. The pattern in malignant cells was distinct in being localised to the 
membrane. (Figure 3.24).
Normal ovary
Primary ovarian 
cystadenocarcinoma
Metastasis
v V ' * ~ s  ' +
\ x
‘VA. t X . ^
4s •* r ' - h '  '» ^
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Figure 3.24. Immunohistochemical Staining for hepsin.
Hepsin stained normal and malignant epithelial cells. However, a prominent 
membrane staining (arrowheads) was only seen in malignant epithelial cells. 
Pictures 40x; Inset 100x.
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3.8 Chemokine Receptor Expression In Ovarian Cancers
Semi-quantitative RT-PCR was performed to verify expression of chemokines in 
ovarian cancer. The most highly expressed chemokine in primary ovarian cancer is 
CXCR4 for both the semi-quantitative RT-PCR and the GEM data.
□ 01
□ 02
□  N1
□  N2
0 4
C X C R 2 C X C R 4 CC R 1 C C R 2  C C R 3  C C R 5  C C R 7  C C R 8  C C R 1 0
Chem okine
Figure 3.25. Semi-quantitative RT-PCR expression data for chemokines in ovarian cancer.
01 &02= 2 samples of primary ovarian cancer, N1 & N2= 2 samples of normal ovary. Expression 
levels are relative to GAPDH.
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Figure 3.26. GEM data for chemokines in ovarian cancer.
01 &02= 2 samples of primary ovarian cancer, N1 & N2= 2 samples of normal ovary. Expression 
levels are relative to GAPDH.
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Chapter  4
D iscussion
4.1 GEM Profile of Primary Ovarian Cancer
One of the aims of this study was to discover a GEM profile for serous ovarian 
adenocarcinoma which would allow us to understand more fully the progression 
pathway from normal ovarian tissue through primary cancer and then on to 
metastatic spread. To this end, the GEM profiles of normal ovaries, primary ovarian 
cancer and omental metastases were determined using oligonucleotide microarrays 
representing -12,000 genes. The classic paradigm of cancer progression involves 
the multistep accumulation of genetic and epigenetic changes, and progressive 
alterations in gene expression in single cells. These allow the cells to escape the 
normal constraints of cell growth, and become malignant; they include self-sufficiency 
in proliferation signals, insensitivity to growth inhibitory signals, evasion from 
apoptosis, limitless replicative potential, and aberrant angiogenesis [Hanahan and 
Weinberg, 2000]. This enables a few malignant cells to form a clinically recognisable 
tumour mass. As the tumour grows, more genetic aberrations are accumulated in 
order to then allow the cancer to invade surrounding tissues and metastasise to 
distant organs. Multistep progression pathways have been proposed for most 
cancers [Kinzler and Vogelstein, 1996;Beckmann et al., 1997].
My study identified 421 genes which were more than 2-fold over-expressed and 118 
genes more than 3-fold over-expressed in primary ovarian cancer than in normal 
ovaries. Some of these genes will have functional importance in carcinogenesis and 
disease progression; others will be over-expressed due to a reaction to the increase 
in growth stimulatory pathways. I will discuss here some of the genes identified as 
dysregulated in ovarian cancer (Figure 3.11).
In the epithelial markers cluster (Figure 3.11), claudin proteins are a large family of 
integral membrane proteins which play an important role in tight junction (TJ)
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formation and function. Claudins-3 and -4 have been shown to be up-regulated in 
ovarian cancers and have been suggested as possible biomarkers and targets for 
therapy [Hough et al., 2001;Rangel et al., 2003]. Ovarian adenocarcinomas are 
characterized by initial local growth followed by spread into the peritoneal cavity at 
later stages of tumour progression. The cell-adhesion molecule E-cadherin (E-cad) 
plays an important role in maintaining tissue integrity. E-cadherin expression is rare 
in normal ovarian tissue but increases in benign and neoplastic ovarian epithelial 
tumours [Maines-Bandiera and Auersperg, 1997;Sundfeldt et al., 1997]. Secreted 
phosphoprotein 1 (SPP1), the gene encoding osteopontin (OP), is over-expressed in 
many human carcinomas [Agrawal et al., 2002;Hotte et al., 2002;Korkola et al., 
2003]. OP is an integrin-binding protein and is involved in carcinogenesis and tumour 
spread.
In the cell division and growth cluster (Figure 3.11), cyclin D1 is over-expressed; this 
has previously been shown to be over-expressed in ovarian cancers and is related to 
prognosis [Diebold et al., 2000]. C-myc oncogene codes for a DNA binding protein 
which plays an important role in the regulation of cell growth. When over-expressed 
in tumours, it is involved in metastatic progression, and there is evidence that it is 
associated with poor prognosis in ovarian cancer [Wu et al., 2003], as well as 
cancers of the breast [Naidu et al., 2002] and prostate [Sato et al., 1999]. Lipocalin 2 
and E2F transcription factor 3 have not previously been associated with ovarian 
cancer.
CD24 antigen (Figure 3.11) has been shown to be over-expressed in ovarian cancer 
and may have potential as a marker of poor prognosis [Kristiansen et al., 2002]. 
Hepsin is a serine protease and is present in the plasma membranes of most tissues, 
with highest expression in liver. Tanimoto et al noted increased expression in LMP 
and invasive ovarian tumours and concluded that hepsin is associated with the 
invasive process [Tanimoto et al., 1997]. Hepsin is also over-expressed in prostate 
cancers [Stephan et al., 2004;Dhanasekaran et al., 2001].
GEM profiling studies have reported several genes which are up- and down- 
regulated in ovarian cancers compared to normal ovaries. Table 4.1 lists a series of
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22 up-regulated genes which have been identified by different studies and validated 
by independent methods such as Northern blot analysis or RT-PCR. These genes 
are only a few of the hundreds of genes which have been identified by GEM profiling. 
As these profiles represent gene expression, no information can be inferred 
regarding the function of these genes in the carcinogenic process. However, as 
various studies have identified the same genes, these represent a true biological 
difference between normal and tumour tissue. Some of these genes, e.g. Muc-1, 
keratin 18 and CD9 are over-expressed in many other cancers.
Gene Study Validation
CD24 Welsh et al. RT-PCR
HE4 Welsh et al., Schummer et al. RT-PCR
CD9 Welsh et al. RT-PCR
LU Welsh et al. RT-PCR
MUC-1 Welsh et al., Schummer et al. RT-PCR
Keratin-18 Welsh et al. RT-PCR
Keratin-8 Welsh et al. RT-PCR
PRAME Welsh et al., RT-PCR
ERBB3 Welsh et al. RT-PCR
MEIS 1 Welsh et al. RT-PCR
Paired box gene 8 
(PAX8)
Welsh et al. RT-PCR
TACSTD1 Welsh et al. RT-PCR
DDR1 Welsh et al. RT-PCR
OSF2 Matei et al., Ismail et al. RT-PCR, Northern blot
PAI-2 Matei et al. RT-PCR
Integrin, a subunit Matei et al. RT-PCR
Proto-oncogene (Wnt-5a) Matei et al. RT-PCR
Frizzled-7 Matei et al. RT-PCR
SPARC/osteonectin Ismail et al. Northern blot
Prostasin Mok et al. RT-PCR
Ryudocan Schummer et al. RT-PCR
Beta actin Schummer et al. RT-PCR
Table 4.1. Selected genes more than 2-fold over-expressed in my study and others
(Welsh et al, Schummer et al., Matei et al., Ismail et al. and Mok et al.) in primary ovarian 
cancer compared to normal ovarian tissue.
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4.2 GEM Profile of Primary and Secondary Ovarian Serous 
Adenocarcinoma
My study found that the GEM profile of normal ovarian tissue was markedly different 
from that of the cancers studied. It was expected that the primary tumour would 
contain a gene expression profile consistent with growth and differentiation, and the 
secondary deposits to contain genes expressed consistent with metastasis. The 
gene signature of primary tissue was, however, very similar to that of the secondary 
spread. This is contrary to the classic model of carcinogenesis. If the metastatic 
signature is already present in primary cancers, this implies they have the ability to 
metastasise from the outset. This is now becoming the prevailing view of 
carcinogenesis. Bernards and Weinberg suggest that a few cells in the initial tumour 
mass have the molecular signature which confer the ability both for growth and, later, 
metastasis [Bernards and Weinberg, 2002]. Figure 4.1 demonstrates the two models 
of metastasis; the emerging view is of a genetic alteration occurring early in 
carcinogenesis which confers the ability to the tumour to metastasise even at an 
early stage, so both primary and metastatic tumours have the same GEM profile. The 
traditional view is that the tumour grows and only later when the tumour is 
established are the genes necessary for metastasis expressed, so the primary and 
secondary tumours have different GEM profiles. There are three consequences of 
this theory: firstly, the mutations necessary for metastasis are already present in the 
early stages of tumorigenesis; secondly, metastasis-specific genes do not exist; and 
thirdly, because the metastatic ability is present at the outset, even small tumours 
can metastasise early. Evidence supporting this view is accumulating:
1. The first comes from the fact that a major risk factor for developing recurrence with 
solid tumours is the presence of lymph node metastases. Antibodies against 
epithelial differentiation antigens such as cytokeratins have been developed to detect 
micrometastases in lymph nodes. Studies have shown that apparently localised 
(Stage 1) tumours which are found to have occult spread have a worse prognosis; in 
breast cancer [McGuckin et al., 1996], prostate cancer [Freeman et al., 1995], colon 
cancer [Greenson et al., 1994] and melanoma [Carlson et al., 2003].
164
2. Microarray data on breast cancer has been used to subdivide locally advanced 
tumours into 2 groups, according to their gene profiles, and correlate this to the 
clinical outcome [Sorlie et al., 2001]. The basal-like and ERBB2+ subtypes had the 
worst prognoses. This study has demonstrated that the GEM profiles of Stage 1 
tumours can be used to predict which tumours will metastasise and that the 
metastatic signature is already present when the cancer is locally confined. This 
could have implications for treatment of early stage disease.
3. Further evidence comes from studies showing that metastatic signatures within 
primary tumours can predict subsequent metastasis. Ramaswamy et al 
[Ramaswamy et al., 2003] examined the GEM profiles of primary adenocarcinomas 
of multiple tumour types and compared these to unmatched adenocarcinoma 
metastases in order to identify differences in GEM profiles between primary tumours 
and metastases. A distinct profile for each was established, although the GEM profile 
of metastases was also found in a subset of primary tumours. These tumours were 
associated with a significantly worse prognosis. Seventeen critical genes were 
identified to be predictive of spread, some up-regulated, others down-regulated. 
These same genes were present irrespective of the tumour type, supporting the 
notion that adenocarcinomas from different sites have similar pathways to 
metastasis.
My study has found that within the stage III primary serous ovarian adenocarcinomas 
a number of metastatic predictive genes including EZH2 [Varambally et al., 2002], 
PTTN and Lamin-B [Ramaswamy et al., 2003] are over-expressed in primary tissue 
at least as highly as in omental metastases (Figure 3.15). This supports the notion 
that most tumour cells in advanced primary ovarian lesions have acquired the 
genetic signature enabling invasion and metastasis. A GEM study comparing stage 
la with stages II, III and IV might identify genes that infer the propensity of ovarian 
tumour cells to metastasise, although it would be challenging to obtain sufficient 
material.
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Hypotheses
Genetic alteratii
V
o  —
Metastatic potential acquired early during carcinogenesis, therefore primary 
and metastatic tumours have the same GEM profile Q
Metastatic potential only acquired by a few cells in the primary tumour, therefore 
primary and secondary tumours have different GEM profiles
Figure 4.1. Models of metastasis.
The first hypothesis implies a genetic event causing an alteration in the GEM profile of an early 
cancer which confers the ability to metastasise. Therefore both the primary and secondary 
tumours have the same GEM profile. This is the hypothesis confirmed by my study, as 
both the primary tumours and omental lesions have very similar profiles. The classic 
view implies the metastatic signature is acquired later in the tumour’s evolution. This 
view is now being questioned.
A great number of genes over-expressed in primary tumours were associated with 
epithelia. This might reflect the epithelial origin of these tumours or a transformed 
phenotype. HPN for example was marginally over-expressed in both primary and 
secondary ovarian cancer tissue compared to normal ovary (approximately 2-fold). 
HPN is a serine protease which has been shown to be over-expressed in prostate 
cancer cells, and significantly correlates with poor clinical outcome [Dhanasekaran et 
al., 2001]. Hepsin was further investigated by performing immunohistochemistry; the 
staining was found to be localised to the epithelial cells, suggesting it may be a 
marker of epithelia rather than of malignancy (Figure 3.24). However there was a 
notable difference in the pattern with malignant cells showing a distinct membranous 
staining, suggestive of heightened secretion.
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4.3 Metastatic Spread
Once cancer cells have successfully evaded cell death in the circulation e.g. anoikis, 
cells lodge in certain organs and extravasate in a very specific manner, depending 
on the tumour type. In 1889, Paget proposed the “seed and soil” theory where the 
“seed”, the tumour cell, metastasised to a specific organ, the “soil” [Paget, 1889]. It 
has since then become clear that the sites of metastasis are governed not purely by 
the neoplastic cells, but also by the microenvironment of the target organ. The exact 
mechanism is still to be fully elucidated. Ovarian cancer metastasises predominantly 
to the omentum and peritoneal surfaces. One theory purposes the role of 
chemokines. Chemokines are immune/inflammatory cytokines that mediate 
chemotaxis of leukocytes involved in autoimmune and inflammatory diseases 
[Gerard and Rollins, 2001]. The receptors for chemokines are part of the seven- 
transmembrane G-protein-coupled receptor family (GPCR) and are mainly expressed 
on immune and inflammatory cells, such as T and B lymphocytes, dendritic cells, and 
granulocytes, in which ligand-receptor interactions lead to cell migration. Chemokine 
expression is either induced at sites of inflammation to recruit inflammatory cells that 
mediate tissue destruction, or is constitutive in lymphoid organs (i.e., lymph nodes 
and spleen) to orchestrate the response to antigens, including autoantigens that 
drive autoimmune diseases. The process of leucocyte maturation, subsequent entry 
into the circulation and eventual homing to specific tissue sites closely resembles 
that of tumour cell invasion and metastasis to distant organs. Therefore Muller et al. 
hypothesised that tumour cells may utilise the same chemokines to control 
metastatic organ specificity [Muller et al., 2001]. Their study demonstrated that 
specific expression of chemokine receptors on breast cancer cells is an essential 
event that leads to the homing and metastasis of these tumour cells in a chemokine 
ligand and receptor-dependent, organ-specific manner. Namely, the chemokine 
receptors CXCR4 and CCR7 are highly expressed on breast cancer cells and their 
corresponding ligands, CXCL12/SDF-1a and CCL21/6Ckine are present in the 
organs to which the breast cancer cells metastasise to (Figure 4.2). This was verified 
by in vitro work, where the CXCL12 ligand induced breast cancer cells to undergo 
the process of invasion [Muller et al., 2001], including pseudopodial protrusion, 
directed migration and penetration of ECM barriers. In vivo work on mice confirmed 
these findings, where metastasis to lung tissue containing CXCL12 was blocked by a
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neutralising CXCR4 monoclonal antibody.
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Figure 4.2. Mechanism of chemokine-mediated 
metastasis of breast cancer.
Figure taken from Muller et al., (2001).
Scotton et al researched a panel of chemokines in primary ovarian cancers, and 
ascites samples, and found that only CXCR4 was reliably expressed on cancer cells 
[Scotton et al., 2001]. Other chemokines, such as CCR1 were also expressed 
although only on leucocytes. The ligand for CXCR4, CXCL12, was found in ascites 
from 63 patients. An in vitro migration assay demonstrated ovarian cancer cell 
movement towards CXCL12. They therefore suggested that a chemokine gradient 
exists which enables ovarian cancer cells to migrate from the primary tumour mass 
into the peritoneum. In addition, when ovarian cancer cell lines were treated with 
CXCL12, (3i integrin expression on the cell surface was greatly increased, affecting
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peritoneal adhesion of cells. This could be a mechanism by which ovarian cancer 
cells spread to the peritoneal cavity.
My study has shown very similar results (see section 3.8) in that CXCR4 was the 
most highly expressed chemokine in ovarian cancers. Figures 3.25 and 3.26 show 
that chemokine expression levels by both semi-quantitative qRT-PCR and microarray 
analysis are highly concordant.
Chemokines also regulate angiogenesis, both positively and negatively. 
Angiogenesis is essential for growth, survival, invasion and metastasis of tumours. 
There is also evidence that chemokines activate tumour cells to secrete enzymes 
such as MMPs and serine proteases in order to allow migration through the ECM, 
penetration of the basement membrane and entry into the circulation. CXCL8 
induces expression of MMP-2 and MMP-9 in malignant melanoma and prostate 
cancer cells, respectively [Luca etal., 1997;lnoue eta!., 2000].
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4.4 Origin of Epithelial Ovarian Cancers
A number of groups have previously investigated gene expression profiling of ovarian 
cancer using microarrays [Wang et al., 1999;Welsh et al., 2001 ;Ono et al., 
2000;lsmail et al., 2000;Mok et al., 2001b;Shridhar et al., 2001]. These studies have 
focussed on either the identification of gene products which can serve as ovarian 
cancer specific markers [Mok et al., 2001b] or on the initiation and progression of 
ovarian cancer [Ismail et al., 2000;Shridhar et al., 2001]. This has been achieved by 
comparing normal ovarian epithelium with ovarian cancer samples, as the majority of 
ovarian cancers are thought to arise from the ovarian surface epithelium [Feeley and 
Wells, 2001] which exists as a single layer of cells covering the ovaries. The surface 
epithelium represents a minute cellular component of the ovary, compared to the 
numerous stromal and germ cells. The epithelial layer easily sloughs off at the time 
of surgery by manual handling, and it is a challenge to obtain enough cells for use in 
any experimental procedures. Researchers have overcome this problem by firstly 
using short-term cell culture to increase the number of cells available [Ismail et al., 
2000], secondly by RNA amplification [Ono et al., 2000] and thirdly by using 
commercially available RNA [Welsh et al., 2001]. These approaches however have 
drawbacks ; (i) short-term culture favouring the growth of only a subset of epithelial 
cells, (ii) RNA amplification leading to unequal amplification of all RNA transcripts in 
the cell population and (iii) the inclusion of a stromal component in commercially 
available RNA. Table 4.2 summarises ovarian cancer GEM profiling studies 
comparing ovarian cancer tissue with normal ovaries, the type of array used and the 
normal ovarian baseline used. Table 4.3 summarises those studies using ovarian 
cancer cell lines.
170
Study Array type Number 
of genes
Cancer tissue 
histology
Normal tissue baseline
Welsh et al Oligonucleotide
(glass)
6,800 Serous
adenocarcinomas
Normal ovary, macro OSE 
enrichment
Schummer 
et al
cDNA 
microarray 
(nylon filter)
21,500 Mostly serous 
adenocarcinomas
OSE cells, normal ovarian 
tissue (mostly stroma), fetal 
ovary pool
Ono et al cDNA
microarray
9,121 Serous and mucinous Adjacent normal tissue from the 
same patients
Wang et al cDNA 
microarray 
(nylon filter)
5,766 Serous, mucinous, 
clear cell, endometrioid
Commercial ovarian RNA 
(nonenriched)
Shridhar et 
al
cDNA 
microarray 
(nylon filter)
25,000 Serous, clear cell, 
endometrioid (high 
grade, variable stage)
OSE brushings
Table 4.2 GEM profiling studies using cancer cell tissue.
Study Array type Number 
of genes
Cancer cells Normal cells
Wong et al cDNA
microarray
(glass)
2,400 In-house developed 
cell lines; SKOV-3
OSE short-term culture
Ismail et al Subtractive
hybridisation/
cDNA
microarray
255 In-house cancer cell 
culture
OSE short-term culture
Tonin et al Oligonucleotide 
array (glass)
6,416 In-house developed 
cell lines
OSE short-term culture
Table 4.3 GEM profiling studies using cancer cell lines.
In my study, ovarian epithelium was macrodissected from normal ovarian tissue. 
Matched primary and secondary metastatic serous ovarian adenocarcinoma 
specimens were verified histopathologically in five cases to comprise at least 70% 
tumour. A number of ovarian cancer genes previously identified by GEM were 
confirmed in this study e.g. CD24 [Welsh et al., 2001], HE4 [Schummer et al., 1999], 
PRAME [Ismail et al., 2000], B-factor (properdin) [Shridhar et al., 2001], and where 
the studies overlap, the data are highly consistent despite the difference in 
methodology.
Tumours rely very heavily on the surrounding stromal cells to participate in the 
production of growth factors and other products necessary for the cancer to become 
established (see section 1.5). Global analysis of tumour specimens will give 
information on the gene expression of all transcripts, but cannot differentiate which
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cell is contributing each transcript. Laser capture microdissection (LCM) [Simone et 
al., 1998] has been developed to obtain pure populations of cells from 
heterogeneous tissue. Individual cells can be selected and “captured” from cell 
aggregates or tissue. Frozen, formalin-fixed or paraffin-embedded tissue sections are 
processed, stained, and dehydrated, then scanned under an inverted microscope. 
Cells are visualized through a thermoplastic film which is attached to the bottom of 
an optically clear microfuge tube cap. A laser pulse, directed onto the cells of 
interest, melts the film and allows it to flow onto the targeted area where it cools and 
bonds with the underlying cell(s). The film along with the adhered cells or clusters is 
then lifted. Captured cells can then be used for microarray studies (see Figure 4.3).
Transfer Film p------
on Backing (____ Tissue Section
Laser Pulse 
Focally Activates 
Transfer Film
Cell{s) of Interest
Glass Slide
Transfer of 
•  J  Selected Cell(s)
Vacancy where Cells 
have been Selectively Procured
Figure 4.3. Laser capture microdissection.
A special thermoplastic film is coated onto to a small 
plastic cap that fits into a microfuge tube. The cap is 
then placed on the tissue to be microdissected, which 
becomes a part of the focal length of the microscope. 
When the targeted cells are identified, a low-power 
infrared laser pulse melts and anneals the film to the 
tissue. The cap is lifted and the tissue is captured 
for further analysis. An archival workstation allows 
photographic documentation of every step. This system 
ensures that biological molecules such as RNA and 
DNA, remain undamaged during the microdissection 
process. Figure taken from http://www.arctur.com.
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LCM is usually carried out on frozen sections when samples will be used for RNA 
isolation. This is because formalin fixation introduces crosslinks between nucleic 
acids and proteins, resulting in fragmentation of the RNA. Freezing avoids 
crosslinking but introduces a different problem. Endogenous nucleases are not 
irreversibly inactivated, and can become active during the tissue processing steps 
(fixation, staining, destaining, and dehydration) carried out after sectioning. Figure 
4.4 shows a summary of the microdissection process.
Heterogeneous
tissue population
ormal
epithelium
Tumour
Microdissected 
tumour cells
Normal
epithelium
Gene expression 
profiling
Figure 4.4. LCM on a heterogeneous tissue sample.
The heterogeneous tumour tissue is stained in order to identify the cancer cell subpopulation. 
LCM then captures normal cells and cancer cells separately, and these can then be processed 
for GEM analysis.
Analysis of cancer tissue by global survey and microdissection both have 
advantages and disadvantages. An advantage of the global survey approach include 
the use of a higher amount of starting material, and sufficient RNA can be extracted 
for microarray target preparation without the need for amplification. This method is 
also much less labour intensive. The disadvantage is that the actual percentage of 
the cancer cell population under study is unknown; if the percentage is low, then the 
signal from the cancer cell population may be obscured by the higher-abundance
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normal cell subpopulation. The advantage of microdissection is that clearly defined 
subpopulations can be directly compared. However, the disadvantages are due to 
the high level of expertise and resources that are required. Specialised training is 
required to use the LCM apparatus, and a trained pathologist must identify the cells 
to be extracted. Even though pure cell populations are obtained, only single cells are 
extracted so RNA invariably must be amplified. This technique is excellent for 
separating out normal, carcinoma in situ and invasive cancer cells from the same 
tissue. Sgroi et al [Sgroi et al., 1999] used LCM to isolate normal and invasive 
metastatic breast cancer cells from a single patient, and compared their gene 
expression profiles. Kitahara et al [Kitahara et al., 2001] also isolated normal and 
colorectal tumour populations and compared their expression profiles.
Applying this technique to ovarian cancer is more challenging. Although ovarian 
cancer can arise from any of the cell types found in the ovary, around 90% are 
derived from the ovarian surface epithelium. This epithelium covers the entire ovarian 
surface, and varies morphologically from simple squamous to cuboidal to low 
pseudostratified columnar. Although the ovarian surface is generally smooth early in 
life, the ovary becomes convoluted with age. Invaginations of the epithelium form 
crypts or gland-like structures that can become pinched off to form epithelial inclusion 
cysts within the underlying stroma. The incidence of inclusion cysts increases with 
age and are common in postmenopausal women. Epithelial ovarian cancers have a 
similar incidence. It has been hypothesised, but not proven, that these inclusion cysts 
are a potential origin of many epithelial cancers. The more frequent appearance of 
epithelial invaginations and inclusion cysts in women with hereditary risk of ovarian 
cancer has strengthened this hypothesis [Salazar et al., 1996]. In addition, some 
microscopic borderline and malignant tumours have been observed to arise directly 
within these sites, and they are often associated with dysplasia in inclusion cysts in 
the same or contralateral ovary [Deligdisch and Gil, 1989;Scully, 1995]. LCM studies 
would be invaluable in identifying GEM alterations in the cells from these structures.
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4.5 Ovarian Cancer Biomarkers
The early detection of ovarian cancer is vital for its ultimate control and prevention. 
The effectiveness of conventional therapeutics is limited once metastasis has 
occurred. Late-stage diagnosis of ovarian cancer can be attributed to the fact that the 
disease is relatively “asymptomatic” in its early stages, and that the symptoms of late 
stage disease, such as abdominal discomfort, weight loss, diarrhoea or constipation, 
vaginal bleeding and shortness of breath, are non-specific complaints. Consequently 
the overall 5 year survival is around 25%. To be effective, a clinically useful 
biomarker should be detectable in accessible body fluids such as blood, urine or 
saliva.
Molecular biomarkers are essential tools for detecting and monitoring cancer. The 
marker most extensively used in ovarian cancer is CA125, a high molecular weight 
glycoprotein which is expressed by tissues derived from the coelomic epithelium. The 
secreted levels are proportional to the tumour volume; hence only 50% of stage I 
tumours have elevated levels of CA125, which reduces its effectiveness as a 
screening marker [Jacobs and Bast, Jr., 1989]. An algorithm has been calculated 
[Skates et al., 1995] which takes into account sequential changes in CA125 levels 
over time, rather than a single reading. Other markers for ovarian cancer detection 
have been investigated, including Lysophosphatidic acid (LPA) [Xu et al., 1998], 
macrophage colony-stimulating factor (MCS-F) [Suzuki et al., 1995], ovarian 
carcinoma-associated antigen (OCA) [Knauf and Urbach, 1978] and tumour- 
associated trypsin inhibitor (TATI) [Medl et al., 1995]. However, none of these 
markers has proved superior to CA125.
This study has identified a potential new biomarker MGB2 which is significantly over­
expressed in primary and metastatic ovarian cancer compared to normal ovarian 
tissue. MGB2 is also increased in LMP and will therefore not be useful on its own as 
a tumour marker, but might still be helpful in combination with other markers. MGB2 
has not previously been described in ovarian cancer. This gene, located on 
chromosome 11 q13 is part of the uteroglobin family and was first sequenced by a 
group screening a human genomic library [Becker et al., 1998]. It has high sequence 
homology to mammaglobin 1 (MGB1) which is present in normal breast epithelia and
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frequently up-regulated in breast cancers [Watson and Fleming, 1996;Watson et al., 
1998]. MGB2 has been detected in axillary lymph node micrometastases of breast 
cancer patients [Ooka et al., 2000] and is over-expressed in endometrioid 
endometrial carcinomas compared to nonendometrioid cancers by cDNA microarray 
analysis [Moreno-Bueno et al., 2003]. Both endometrioid and breast cancers are 
oestrogen-dependent, and may explain a mechanism for the over-expression of 
MGB2. The link between ovarian cancer and oestrogen is less clear. The women’s 
health initiative (WHI) trial [Anderson et al., 2003;0oka et al., 2000] reported a non­
significant excess of ovarian cancer in women taking combined oestrogen and 
progesterone hormone replacement therapy compared to non-users. The belief is 
generally not held that ovarian cancer is directly influenced by oestrogen, indicating 
that MGB2 may be operating in a different manner in these cancers.
The qRT-PCR analysis of MGB2 confirmed the over-expression of MGB2 in primary 
and metastatic ovarian cancer in this study and showed that it also demonstrated 
high expression in LMP samples. LMP tumours are a distinct subtype of ovarian 
neoplasm which generally run a benign course with only 0.7% conversion to invasive 
disease. No biomarker to date is sufficiently specific for screening and monitoring 
disease progression in LMP tumours. Further studies are needed to test MGB2 as a 
biomarker for this cancer subgroup.
The only widely used ovarian cancer marker CA125 lacks specificity (CA125 or 
MUC16 is not present on the U95Av2 array). Within the panel of data available on 
other cancers, MGB2 appears to be a specific biomarker for ovarian tumours with 
low expression in most normal epithelial tissues and prostate and lung tumours. This 
survey was far from exhaustive relying on available published GEM data. The 
screening and selection of other candidates for serological study will benefit from 
more publicly available data, in particular, data on breast cancer. A combination of 
MGB2 and other biomarkers may give a more specific signature for epithelial ovarian 
carcinoma. This study demonstrates that GEM studies are a practical and 
economical prelude to streamline candidate genes for larger serological studies.
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4.6 The Future
I have investigated gene expression differences between normal ovary, primary and 
corresponding secondary omental serous adenocarcinoma in six patients. Although 
my findings have been replicated by other authors, ideally I would like to use more 
samples to make the work more substantive. Using more samples would enable me 
to correlate outcome with specific gene expression profiles. However, clearly, 
oligonucleotide arrays and the array experiments are costly which is why my study 
was limited. Any possible future work I describe here is meant if finances were not an 
issue.
Another way to take this work forwards is to compare the paired samples O and M 
used in this thesis to identify whether similarities exist between tumours which would 
contribute to the understanding of the pathogenesis of serous ovarian 
adenocarcinoma.
MGB2 is raised in both invasive cancers but also in LMP tumours. Investigating a 
larger series of both LMP and invasive cancers may identify whether MGB2 is raised 
in all LMP tumours or only in the small subset which become invasive.
Finally, I would like to test a panel of markers on serum samples from patients with 
ovarian cancer, benign gynaecological conditions, and other cancers and identify 
whether it is possible to define a fingerprint for serous ovarian cancer.
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Co nclusio n
Ovarian cancer has the highest mortality rate of all the gynaecological malignancies. 
The lack of specific signs and symptoms of early disease means more than 70% of 
women present at a late stage, where cytoreductive surgery and conventional 
chemotherapies have limited effect. Around 60% of women die of their disease. The 
current marker CA125 is not sufficiently sensitive to use as a mass screening tool in 
the general population, even when coupled with ultrasound scanning. There is an 
urgent need to discover a new strategy for ovarian cancer screening.
This study has used high density oligonucleotide arrays to compare the gene 
expression profiles of normal ovarian epithelium with primary serous 
adenocarcinoma and serous omental metastases from the same patients. The aims 
were to firstly identify genes involved in ovarian cancer progression and secondly 
identify new biomarkers which may be used as screening tools.
The main findings were the GEM profiles of primary and secondary cancers were 
more similar than dissimilar. Unlike Vogelstein’s model for colon cancer, no definite 
progression pathway was identified for ovarian cancer. This may imply that ovarian 
tumours, at an early stage, have the metastatic profile which will predestine them to 
metastasise even when the tumour is localised. There was a definite difference in 
GEM profiles between normal and cancer samples. The other main finding was one 
gene, not yet described in epithelial ovarian cancer, mammaglobin 2 (MGB2) was 
significantly over-expressed in primary and secondary disease compared to normal 
ovary. This gene meets the criteria for biomarkers, that is, it is secreted and is not 
expressed in other normal or cancer tissues at significant levels. Serum studies 
would show whether this marker has clinical usefulness, either alone, or as part of a 
panel of biomarkers.
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